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ABSTRACT

Background: The HPV vaccine is a primary prevention method available to reduce the burden
of HPV-related cancers and genital warts. The vaccine is currently approved for catch-up
vaccination among women 18 to 26 years of age. Despite this recommendation, the rate of
vaccine uptake among this group is considerably low (~34% uptake). One demographic
characteristic that is consistently reported as a risk factor for non-vaccination is relationship
status, specifically married or monogamous relationships. While the epidemiological data
confirm this association, there is a lack of understanding how this risk factor operates. By
elucidating the mechanism for this risk factor, HPV vaccine uptake among this consistently
unvaccinated group could be improved.
Purpose: The purpose of this study was to understand how young adult women’s relationship
status influence informational needs, motivations, and behavioral skills related to HPV
vaccination. This objective was achieved through the following specific aims: (1) assess how
relationship status affects primary reasons for non-vaccination among 18 to 26 year old women;
and (2) understand how relationship status frames HPV vaccine decision-making among 18 to 26
year old women.
Methods: To effectively achieve these specific aims, a concurrent mixed-methods study design
was conducted. In Phase I, a secondary data analysis using the 2010 National Health Interview
Survey was employed to determine if women in relationships are less likely to be interested in
vaccination and identify the primary reasons (e.g., misinformation, motivations, behavioral
skills) for non-vaccination among different relationship status categories. In Phase II, in-depth

ix

interviews were conducted with a sample (N=50) of 18 to 26 year old women at the University
of South Florida, stratified by relationship status and vaccination status. A comparative thematic
analysis was conducted to determine if there were differences in informational needs,
motivations, behavioral skills, and HPV vaccine decision-making between the groups.
Results: Using NHIS 2010 data, women who were living with a partner (PR 1.44 95%CI 1.071.87) and never married (PR 1.41 95%CI 1.12-1.73) were less likely to be interested in HPV
vaccination compared women who were married. Moreover, primary reasons for non-vaccination
differed significantly by relationship status group (p<0.01) Findings from the qualitative phase
from the study indicated that women’s risk perceptions for HPV were impacted by current
relationship status. Women in long-term relationships reported that monogamy and number of
sexual partners reduced their risk of HPV and perceived need of the HPV vaccine. Women in all
relationship status groups reported similar HPV knowledge levels (e.g., recognition that HPV is
sexually transmitted, less clarity on the outcomes associated with HPV), behavioral skills (e.g.,
procedural knowledge to get the HPV vaccine, perceived facilitators, perceived barriers), and
influential macro factors (e.g., anti-vaccination culture, television advertisement) related to HPV
vaccination.
Conclusion: This study found that relationship status impacts HPV vaccine decision-making
among young adult women. Specifically, it operates by modifying risk perceptions for HPV,
which serve as barriers to vaccination. Young adult women have the knowledge and behavioral
skills necessary to access and understand the importance of HPV vaccination; however, women
were unable to accurately perceive their risk for HPV, resulting in impaired motivation for
vaccination. A potential approach to address this issue is the use of health literacy. Future
research should integrate health literacy techniques with healthcare providers serving this

x

population to assist in the evaluation process for risk of HPV. This will facilitate shared
decision-making and patient-provider communication surrounding the HPV vaccine. This can
ultimately promote HPV vaccination among young adult women and reduce the morbidity and
mortality of HPV-related diseases.
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CHAPTER 1: INTRODUCTION

Background
Human papillomavirus (HPV) is the most incident and prevalent sexually transmitted
infection (STI) in the United States; it is estimated there are nearly 14 million new cases and a
total of 79 million cases a year (Satterwhite et al., 2013). The public health significance of this
STI is highlighted by the fact that HPV is a necessary cause for some cancers. There are two
grades of HPV infections: high-risk and low-risk. High-risk HPV, such as types 16 and 18, are
known to cause cancers, including cervical, vulvar, vaginal, penile, anal, and oropharyngeal
(Munoz et al., 2003; zur Hausen, 2002). While low-risk HPV, such as types 6 and 11, are known
to cause genital warts and recurrent respiratory papillomatosis (Lacey, Lowndes, & Shah, 2006).
HPV is transmitted primarily through genital sexual contact, but can also be transmitted via oral
to genital contact or skin to skin genital contact (Burchell, Winer, de Sanjose, & Franco, 2006).
As a primary prevention strategy for HPV, in 2006, the United States’ Advisory
Committee on Immunization Practices (ACIP) recommended routine vaccination for the 3-dose
quadrivalent HPV vaccine series for females 11 to 12 years of age (Markowitz et al., 2007).
Additionally, the quadrivalent vaccine, licensed as Gardasil ®, was approved for use in females
until age 26, if not previously vaccinated, as a “catch-up” group for vaccination. The
quadrivalent HPV vaccine (HPV4) protects against four strains of HPV; low risk types 6 and 11,
and high risk types 16 and 18 (Food and Drug Administration, 2014b). HPV4 serves as a primary
prevention method against genital warts and HPV-related cancers (Lacey et al., 2006; Munoz et
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al., 2003; zur Hausen, 2002). In 2009, this ACIP recommendation was expanded to include a
bivalent HPV vaccine (HPV2), licensed as Cervarix ®, that protects against HPV strains 16 and
18 (Centers for Disease Control and Prevention, 2010a; Food and Drug Administration, 2014a).
In 2015, the ACIP recommendation expanded to a third vaccine, Gardasil 9 ®, which protects
against the four strains in Gardasil and five additional strains (31, 33, 45, 52, and 58). The
recommendations were consistent with those currently in place for the Gardasil vaccine (Food
and Drug Administration, 2015; Petrosky et al., 2015).

Table 1: HPV Vaccine Rates among Females 18-26 Years
Year

HPV Vaccine Uptake*

11.6% (9.7, 13.6)
2008
19.0% (16.6, 21.4)
2009
21.5% (19.2, 23.8)
2010
29.7% (27.3, 32.2)
2011
34.1% (31.6, 36.7)
2012
*Uptake is having received at least one HPV vaccine dose; **NHIS 2008-2010 data source

Given the earlier approval of the HPV vaccine for females, national public health
priorities for HPV vaccination have focused primarily on females. Yet, current HPV vaccination
statistics in the United States reveal vaccine completion rates (16.6%) below the target of 80%
for females by the age of 13 to 15 years old (Healthy People 2020, 2015c). As a result,
unvaccinated adolescent females transition into the catch-up age range of 18 to 26 years, and are
consequently considered a priority population for vaccination. This time period is the last
opportunity for females to receive the vaccine; therefore, intervening during young adulthood is
essential for this primary preventive behavior and to ultimately decrease HPV-related disease.
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Unfortunately, rates in the catch-up age range among young adult women are also low.
Data from nationally-representative samples provide the most accurate and generalizable
representation of the HPV vaccination coverage among females 18 to 26 years old. The National
Health Interview Survey (NHIS) currently has data available from 2008 to 2012 for HPV vaccine
uptake (reported as: ever receiving at least one HPV vaccine dose). Rates have significantly
increased over time, and as of 2012 were at 34.1% (Table 1) (Schmidt & Parsons, 2014). The
latest NHIS 2013 data indicate 36.9% of women 19 to 26 years old received at least one dose of
the HPV vaccine; among these women, 27.6% received the first dose during this age range
(Williams et al., 2015). Despite these increases, these rates are dramatically low given that the
vaccine has been available for nine years.

Statement of Need
Young adulthood is a period for autonomous decision-making regarding sexual and
reproductive health choices. As such, it is necessary to understand the complex factors that may
contribute to these health decisions, such as receiving the HPV vaccine. Barriers and facilitators
to HPV vaccination among young adult (18 to 26 year olds) females have been widely reported
(e.g., low knowledge, perceived barriers, perceived benefits, self-efficacy, subjective norms,
healthcare provider recommendation and risk perception) (Allen et al., 2009; Bendik, Mayo, &
Parker, 2011; Bennett, Buchanan, & Adams, 2012; Bynum, Brandt, Sharpe, Williams, & Kerr,
2011; Daley, Vamos, et al., 2010; Dillard, 2011; Hodge, Itty, Cardoza, & Samuel-Nakamura,
2011; Joseph et al., 2014; Licht et al., 2010; Marchand, Glenn, & Bastani, 2012; Ratanasiripong,
Cheng, & Enriquez, 2013; Rosenthal et al., 2011; Schaefer Ziemer & Hoffman, 2013; Zimet,
Weiss, Rosenthal, Good, & Vichnin, 2010). Additionally, a limited number of interventions have
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been developed targeting this age group to improve HPV vaccination uptake and completion (Fu,
Bonhomme, Cooper, Joseph, & Zimet, 2014). One of the potential limitations with these studies
is that the entire group of female 18 to 26 years olds is being regarded as the same (i.e., there is a
lack of tailored health interventions or health research). This ignores the potential variability
within sub-groups of this population (e.g., different stages of readiness or demographic
characteristics) that may encounter different barriers or facilitators to vaccination. Thus, given
the minimal improvements in HPV vaccination among this age category nine years post-vaccine
licensure, research efforts should focus, not only on the broad population of 18 to 26 year olds,
but rather on sub-groups who are consistently less likely to be vaccinated over this time period.
One of these demographic characteristics that is consistently reported as a risk factor for
non-vaccination among young adult women is relationship status, specifically married or
monogamous relationships (Anhang Price, Tiro, Saraiya, Meissner, & Breen, 2011; Bernat,
Gerend, Chevallier, Zimmerman, & Bauermeister, 2013; Ford, 2011; Joseph et al., 2014; Laz,
Rahman, & Berenson, 2013; Liddon, Hood, & Leichliter, 2012; Liddon, Leichliter, &
Markowitz, 2012; Lindley, Elkind, Landi, & Brandt, 2013; Rahman, Laz, & Berenson, 2013;
Schmidt & Parsons, 2014; Wei, Moore, & Green, 2013; Williams et al., 2013; Zimet et al.,
2010). For example, according to 2010 NHIS data, unmarried or single women were
significantly more likely to be vaccinated compared to married women (OR=3.10, 95% CI 1.715.60) (Laz et al., 2013). Moreover, this is a risk factor for non-HPV vaccination that is specific to
female young adults, rather than young adult males (Bernat et al., 2013; Newman, Logie,
Doukas, & Asakura, 2013).
Thus far, no research has been conducted to understand why this is occurring and how to
remove this disparity. Women in long-term or monogamous relationships may be framing their
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perceived risk of HPV according to their current relationship status and as a result declining
vaccination. Interestingly, traditionally considered sexually high-risk women (e.g., more sexual
partners, history of HPV, lower age at sexual debut) were more likely to be vaccinated for HPV
compared to low-risk counterparts (Bednarczyk, Birkhead, Morse, Doleyres, & McNutt, 2011;
Bendik et al., 2011; Bernat et al., 2013; Gerend & Shepherd, 2011; Lindley et al., 2013; Manhart
et al., 2011; Mills, Vanderpool, & Crosby, 2011; Tiro et al., 2012). Moreover, healthcare
providers may also have biases toward evaluating risk for HPV and perceived vaccine need
based on relationship status of young adult women. Zimet et al., (2011) reported physicians
giving a lower priority to vaccinating female patients who were married or in monogamous
relationships compared to women who were single or dating. In contrast, these physicians
surveyed did not alter priority perceptions based on women’s sexual history (e.g., HPV infection,
abnormal Pap test) (Zimet et al., 2011). Gaining a deeper understanding of how this unique risk
factor, relationship status, operates will promote scientific advancement for HPV vaccination
among young adult women. Targeting the informational needs, motivations, and behavioral skills
required among women who are married or in long-term monogamous relationships through
interventions will ultimately promote HPV vaccination among this historically un-vaccinated
group.
While it is not disputed that monogamy is a protective factor for many sexual and
reproductive health outcomes (e.g., unintended pregnancy, HIV), risk for HPV still exists among
this group, even among persons engaging in serial monogamy (Burchell et al., 2006). Women
who have only one sexual partner of the opposite sex have an average lifetime risk of 85% for
HPV infection (Chesson, Dunne, Hariri, & Markowitz, 2014). Moreover, according to the
National Study of Family Growth, the average number of lifetime sexual partners for women is
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approximately 3.6 (Chandra, Mosher, & Copen, 2011). The average number of sexual
partnerships compounds the lifetime risk for HPV. These statistics regarding risk of HPV
transmission and sexual partnerships for women underscore the importance of HPV vaccination
regardless of sexual relationships; however, this may contradict common heuristic beliefs among
women that monogamous sex is safe sex. Furthermore, the ACIP guidelines do not provide any
conditions for vaccination based on relationship status or sexual activity for women (Centers for
Disease Control and Prevention, 2010a, 2010b, 2011). Therefore, being in a long-term,
monogamous relationship should not preclude HPV vaccination.
Disentangling this complicated health message for dissemination and implementation
into practice first requires a better understanding of the perspective of the target population to
recognize how relationship status influences HPV vaccination decision-making. This must be
considered within the context of other complex and evolving sexual and reproductive health
guidelines (e.g., recommendations for Pap tests) that are also targeted at this population.
Understanding why women may alter their risk perception for this particular health behavior will
inform the type of shared decision-making and patient-provider communication that should
occur surrounding this vaccine. Moreover, future interventions based on this research can tailor
health information and messages specific to the unvaccinated sub-groups of interest (i.e., women
in monogamous relationships) and reinforce messages to assist women in assessing risk for
acquiring HPV infection (Williams et al., 2013).

Public Health Significance
Thus, the next step in the research trajectory for HPV vaccination uptake in young adult
women is to understand how relationship status frames the HPV decision-making process. This

6

research is timely and innovative as it moves the current survey-based research forward to
understand why this disparity in HPV vaccination exists among young adult women in long-term
or monogamous relationships. This formative investigation will lay the groundwork for future
research and interventions to improve HPV vaccination rates among young adult women.
Furthermore, this research responds to a number of national research priorities. The
National Institutes of Health, Office of Research on Women’s Health (ORWH) 2020 Strategic
Plan recommended continued research to determine the best methods to improve adoption of
prevention behaviors during adolescence and young adulthood, including HPV vaccine
distribution (U.S. Department of Health and Human Services, Public Health Service, National
Institutes of Health, & Office of Research on Women’s Health, 2010). Moreover, the Centers for
Disease Control and Prevention (CDC) calls for additional research to increase HPV vaccine
coverage by engaging patients and providers to eliminate missed clinical opportunities
(Markowitz et al., 2014). Finally, the research’s long-term goals address multiple Healthy
People 2020 objectives, including (1) reduce the proportion of females with HPV; (2) reduce
invasive uterine cervical cancer cases; and (3) reduce the death rate from uterine cervical cancer
(Healthy People 2020, 2015a, 2015d). Therefore, the significance of this proposed research is
underscored by these national research goals.
Finally, this research is relevant to emerging technologies (e.g., 9-valent vaccine; secondgeneration HPV vaccines) and changing vaccine dosing schedules (i.e., changing from two
required doses rather than three required doses) (Markowitz et al., 2014). This evolution in HPV
vaccination practices will expand protection against new HPV types and eliminate barriers to
HPV vaccine completion (Joura et al., 2015). Therefore, it is critical to understand the sustained
barriers to HPV vaccination among the unvaccinated young adult female population as health
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messages surrounding the vaccine will become increasingly complicated with the evolving
science.

Specific Aims and Research Questions
The long-term goal is to increase HPV vaccination rates among young adult women 18 to
26 years of age, ultimately decreasing HPV-related disease (i.e., HPV-associated cancers, genital
warts). The purpose of this study was to understand how young adult women’s relationship
status influence informational needs, motivations, and behavioral skills related to HPV
vaccination. This objective was achieved through the following specific aims and mixed-methods
study design (Table 2).
To effectively achieve these specific aims, a concurrent mixed-methods study design was
conducted. In Phase I, a secondary data analysis using the 2010 National Health Interview
Survey was conducted to determine if women in relationships were less likely to be interested in
vaccination and identify the primary reasons (e.g., misinformation, motivations, behavioral
skills) for non-vaccination among different relationship status groups. In Phase II, in-depth
interviews were conducted with a sample (N=50) of 18 to 26 year old women at the University
of South Florida, stratified by relationship status and vaccination status. A comparative thematic
analysis was conducted to determine if there are differences in informational needs, motivations,
behavioral skills, and HPV vaccine decision-making attributed to relationship status.

Implications
This study used the Information, Motivation, and Behavioral Skills (IMB) Model
approach for study design by beginning with the elicitation phase, which is conducted prior to
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Table 2: Specific Aims of Dissertation Research
Specific Aims
Research Questions
Phase
1. Assess how relationship 1. Among unvaccinated 18 to 26 year old
1. Secondary data
status affects primary
women, are married women less likely
analysis of
reasons for nonto be interested in the HPV vaccine
NHIS 2010
vaccination among 18 to
compared to non-married women?
26 year old women.
2. Among 18 to 26 year old women who
are not interested in the HPV vaccine,
does relationship status impact the
primary reason for non-vaccination?
2. Understand how
3. How do HPV vaccine informational
2. In-depth
relationship status
needs, motivations, and behavioral skills
interviews with
frames HPV vaccine
differ among unvaccinated 18 to 26 year
college females
informational needs,
old women based on relationship
18 to 26 years
motivations, and
status?
old (N=50)
behavioral skills among 4. How do HPV vaccine informational
18 to 26 year old
needs, motivations, and behavioral skills
women.
differ among vaccinated 18 to 26 year
old women based on relationship
status?
5. How do HPV vaccine informational
needs, motivations, and behavioral skills
differ among women 18 to 26 years old
and in relationships (i.e., married, living
with a partner, or in a long-term
monogamous relationship) based on
vaccination status?
6. How do HPV vaccine informational
needs, motivations, and behavioral skills
differ among women 18 to 26 years old
and not in relationships (i.e., single or
single and dating) based on vaccination
status?

the intervention development and evaluation phases, to understand why young adult women are
not getting vaccinated at the catch-up age range (Fisher & Fisher, 2002). Findings from this
formative research will inform a quantitative survey utilizing the IMB Model to expand this
research to a larger sample of women and increase the generalizability. Moreover, it will inform
the types of health messages that should be tailored to different groups of young adult women
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based on relationship status, ultimately improving patient-provider communication concerning
actual risk for HPV and HPV vaccine shared decision-making. Future theory-based interventions
developed from these findings will utilize the IMB Model approach for intervention design and
intervention mapping methods (Bartholomew, Parcel, & Kok, 1998; Fisher & Fisher, 2002).
Moreover, future research should triangulate the findings from this study among young
adult females with healthcare providers who administer the HPV vaccine to young adult women.
While previous research indicates that these agents may have differential preferences for HPV
vaccination based on relationship (Zimet et al., 2011), an understanding of how this bias
operates, as well as the barriers that may need to be overcome is required.
This study has the potential to advance theoretical methodology and public health
practice. Fisher (2012) has proposed the use of the IMB Model to understand HPV vaccination;
however, no studies have used this theoretical model for HPV vaccination among young adult
females and a limited number have used this model among other populations for the HPV
vaccine (Fisher, 2012). Therefore, there is the potential to expand the utility and application of
the IMB Model to new health behaviors and target populations. This study is the first step in the
elicitation phase, while future research could expand upon these findings to develop and evaluate
an intervention targeting HPV vaccination among young adult women.
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Definition of Key Terms

HPV – Human papillomavirus

HPV4 – The quadrivalent HPV vaccine, which provides protection against HPV types 6,
11, 16, and 18. It is otherwise known and licensed as Gardasil ®.

HPV2 – The bivalent HPV vaccine, which provides protection against HPV types 16 and
18. It is otherwise known and licensed as Cervarix ®.

HPV9 – The 9-valent HPV vaccine, which provides protection against HPV types 6, 11,
16, 18, 31, 33, 45, 52, and 58. It is otherwise known and licensed as Gardasil 9 ®.

IMB Model – The Information, Motivation, and Behavioral Skills Model is a validated
approach for predicting and promoting health behavior.

NHIS – The National Health Interview Study is a nationally-representative annual crosssectional health survey in the United States.
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CHAPTER 2: LITERATURE REVIEW

Human Papillomavirus
Human papillomavirus (HPV) is the most incident and prevalent sexually transmitted
infection (STI) in the United States; it is estimated there are nearly 14 million incident cases and
79 million prevalent cases a year (Satterwhite et al., 2013). There are two grades of HPV
infections: high-risk and low-risk. High-risk HPV, such as types 16 and 18, are known to cause
cancers, including cervical, vulvar, vaginal, penile, anal, and oropharyngeal (Munoz et al., 2003;
zur Hausen, 2002). While low-risk HPV, such as types 6 and 11, are known to cause genital
warts and recurrent respiratory papillomatosis (Lacey et al., 2006). HPV is transmitted primarily
through genital sexual contact, but can also be transmitted via oral to genital contact and skin to
skin genital contact. Other routes of transmission exist, including nonsexual routes, such as
mother to child transmission and oral-digital infection, but are less common (Burchell et al.,
2006).

HPV Epidemiology
HPV infection prevalence varies based on study sample (e.g., population-based vs.
clinical sample). The National Health and Nutrition Examination Survey (NHANES) estimated
the prevalence of cervico-vaginal HPV among women in 2003-2006 to be 42.5% (95% CI 40.444.7%) and in 2007-2010 to be 39.8% (95% CI 37.7-42.0%). The prevalence was highest among
women 20 to 24 years of age. Women in this age category had a prevalence of 19.9% (95% CI
12

15.5-25.2%) for vaccine-type HPV1 and 16.2% (95% CI 12.2-21.4%) for high-risk vaccine-type
HPV2 (Markowitz et al., 2013). Among men, the prevalence of genital HPV was estimated to be
50%; the incidence of genital HPV was not associated with age among men (Giuliano et al.,
2011). Moreover, it is estimated that the average lifetime probability of acquiring HPV among
women with at least one male sexual partner is nearly 85% and among males with at least one
female sexual partner is 91% (Chesson, Dunne, et al., 2014).

Health Outcomes Associated with HPV
Cancer. HPV is a causal agent for many cancers, including cervical, vulvar, vaginal,
penile, anal, and oropharyngeal (Munoz et al., 2003; zur Hausen, 2002). Persistent HPV
infections are primarily responsible for progressing to precancerous or cancerous conditions
(Forman et al., 2012). According to the Centers for Disease Control and Prevention (CDC), an
analysis of the National Program of Cancer Registries and the Surveillance, Epidemiology, and

Table 3: HPV-Associated Cancer Rates per 100,000
Anatomic Site

Females

Males

Cervical

7.7

--

Vulvar

1.8

--

Vaginal

0.4

--

Penile

--

0.8

Anal

1.8

1.2

Oropharyngeal

1.4

6.2

*Data source: NPCR, SEER 2004-2008
1

Vaccine-type HPV refers to HPV types included in the vaccine; types 6, 11, 16 and 18
High risk vaccine-type refers to HPV types included in the vaccine and considered high-risk; types 16
and 18
2
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End Results program from 2004 to 2008 revealed an average of 33,369 HPV-associated cancer
cases were diagnosed annually—this is a rate of 10.8 per 100,000 population. The rate was
higher among females (13.2 per 100,000) compared to males (8.1 per 100,000) (Centers for
Disease Control and Prevention, 2012). The rates of HPV-associated cancers depend upon
anatomical site and sex (Table 3). HPV-associated cervical cancer has the highest rate (7.7 per
100,000), followed by oropharyngeal cancer in males (6.2 per 100,000). Additionally, cancers at
these sites are largely attributable to HPV, with nearly 96% of cervical cancer cases attributable
to HPV (Table 4) (Gillison, Chaturvedi, & Lowy, 2008). This translates to approximately 11,500
cervical cancer cases a year due to HPV (Centers for Disease Control and Prevention, 2012).

Table 4: Percentage and Number of Cases Attributable to HPV Annually
Anatomic Site

% (Range)

# (Range)

Cervical

96 (95-97)

11,500 (11,400-11,600)

Vulvar

51 (37-65)

1,600 (1,200-2,000)

Vaginal

64 (43-82)

500 (300-600)

Penile

36 (26-47)

400 (300-500)

Anal

93 (86-97)

2,900 (2,700-3,000) Females
1,600 (1,400-1,600) Males

Oropharyngeal

63 (50-75)

1,500 (1,200-1,800) Females
5,900 (4,700-7,000) Males

*Data source: NPCR, SEER 2004-2008, Gillison et al. (2008). Cancer, 113

There is also substantial mortality associated with these cancers. While data were not
available on the proportion of cancer deaths attributable to HPV, the overall mortality rates for
the cancers at the anatomical sites associated with HPV were available. For women, the age-
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adjusted mortality rates annually using 2007-2011 data are as follows: cervical 2.3 per 100,000
women, vulvar 0.5 per 100,000 women, anal 0.3 per 100,000 women, and oral cavity/pharynx
1.4 per 100,000 women (vaginal cancer data are not available). For men, the age-adjusted
mortality rates annually using 2007-2011 data are as follows: anal 0.2 per 100,000 men and oral
cavity/pharynx 3.8 per 100,00 men (penile cancer data are not available) (National Cancer
Institute, 2014).
Genital warts. HPV is also a cause of genital warts; HPV types 6 and 11 are associated
with over 90% of genital warts cases (Lacey et al., 2006). According to NHANES 1999-2004
data, 5.6% of adults age 18 to 59 years report ever being diagnosed with genital warts. The
proportion was higher for females (7.2%) compared to males (4.0%). Moreover, rates were
highest among females 25 to 34 years of age and males 35 to 44 years of age (Dinh, Sternberg,
Dunne, & Markowitz, 2008).
Recurrent respiratory papillomatosis. Recurrent respiratory papillomatosis is a rare
disease caused by HPV types 6 and 11. This condition produces benign warts in the upper
respiratory tract that can cause airway obstruction. This disease typically has a juvenile onset
prior to 18 years (Markowitz et al., 2014).

HPV Vaccination
Three vaccines have been developed and approved for use to prevent HPV and ultimately
reduce the impact of HPV-related health outcomes (i.e., cancer and genital warts). The
quadrivalent HPV vaccine (HPV4) was developed by Merck and Co, Inc. and prevents HPV
types 6, 11, 16, and 18 (Food and Drug Administration, 2014b). It has an efficacy rate of 98.2%
for HPV types 6, 11, 16, and 18 for clinical endpoints adenocarcinoma in situ and cervical
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intraepithelial neoplasia 2/3; 100.0% for HPV types 6, 11, 16, and 18 for clinical endpoints
vulvar intraepithelial neoplasia and vaginal intraepithelial neoplasia; and 98.9% for HPV types 6
and 11 for genital warts as a clinical endpoint (Kjaer et al., 2009). The bivalent HPV vaccine
(HPV2) was developed by GlaxoSmithKline and prevents HPV types 16 and 18 (Food and Drug
Administration, 2014a). It has an efficacy rate of 94.9% for HPV types 16 and 18 for clinical
endpoints adenocarcinoma in situ and cervical intraepithelial neoplasia 2/3 (Lehtinen et al.,
2012). The 9-valent HPV vaccine (HPV9) was developed by Merck and Co, Inc. and prevents
HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It has an efficacy rate of 96.7% for types HPV
31, 33, 45, 52, and 58 for clinical endpoints cervical intraepithelial neoplasia 2/3,
adenocarcinoma in situ, cervical cancer, vulvar intraepithelial neoplasia 2/3, vaginal
intraepithelial neoplasia 2/3, vulvar cancer, and vaginal cancer (Food and Drug Administration,
2015).
HPV Vaccination Guidelines
The Advisory Committee on Immunization Practices (ACIP) is responsible for setting
guidelines for immunizations in the United States. Table 5 describes the nine year timeline for
HPV vaccination recommendations from ACIP, starting with the first recommendation for HPV4
among females (Markowitz et al., 2007). As of 2015, the current recommendations for HPV
vaccination are: (1) HPV2, HPV4, and HPV9 for routine vaccination among females 11 to 12
years of age; (2) HPV2, HPV4, and HPV9 for catch-up vaccination among females 13 to 26
years of age; (3) HPV4 and HPV9 for routine vaccination among males 11 to 12 years of age; (4)
HPV4 and HPV9 for catch-up vaccination among males 13 to 21 years of age; and (5) HPV4 and
HPV9 for catch-up vaccination among male subpopulations until age 26, specifically men who
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have sex with men (MSM) or men who are immunocompromised (Centers for Disease Control
and Prevention, 2010a, 2010b, 2011; Petrosky et al., 2015).
HPV vaccination requires following a strict dosing schedule for vaccination completion.
For all vaccines, three doses are required. The vaccine should be administered at 0, 1-2 months,
and 6 months. Non-compliance with the schedule may offer limited immune response and
protection (Widdice, Bernstein, Leonard, Marsolo, & Kahn, 2011). However, current research is
dedicated to assessing the efficacy of only two doses of the vaccine in order to offer an
alternative dosing schedule (Markowitz et al., 2014).

Table 5: ACIP Recommendations for HPV Vaccination
Time

Target Group

Recommendation

2006

Females, 11-12 years

Routine HPV4 vaccination

Females, 13-26 years

Catch-up HPV4 vaccination

Females, 11-12 years

Routine HPV2 vaccination

Females, 13-26 years

Catch-up HPV2 vaccination

Males 9-26 years

May receive HPV4 vaccination;
not routine

Males, 11-12 years

Routine HPV4 vaccination

Males, 13-21 years

Catch-up HPV4 vaccination

Males, 21-26 years, MSM or
Immunocompromised

Catch-up HPV4 vaccination

Females, 11-12 years

Routine HPV9 vaccination

Females, 13-26 years

Catch-up HPV9 vaccination

Males, 11-12 years

Routine HPV9 vaccination

Males, 13-21 years

Catch-up HPV9 vaccination

Males, 21-26 years, MSM or
Immunocompromised

Catch-up HPV9 vaccination

2009

2011

2015
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Health Implications of the HPV Vaccine
HPV vaccination has the potential to significantly reduce the morbidity and mortality
associated with cancer. According to a population-based HPV model, HPV vaccination would
prevent 45,500 cervical cancer cases and 14,600 cervical cancer deaths at 30% vaccine coverage
among females 12 years and younger. These estimates increase dramatically for a 80% coverage
level (98,900 cervical cancer cases and 31,700 cervical cancer deaths) (Chesson, Markowitz, &
Dunne, 2014). While these models only incorporate cervical cancer, additional prevention can be
inferred for other HPV-associated cancers with higher HPV vaccination coverage. Moreover,
according to epidemiological cancer data of HPV-associated cancers, it is estimated that HPV
vaccination could prevent nearly 26,000 cancer cases a year (Centers for Disease Control and
Prevention, 2012).
Additionally, ecological trends of genital warts in a public family planning clinic in
California reveal decreases in genital warts rates among males and females since HPV vaccine
approval (Bauer, Wright, & Chow, 2012). Similarly, evidence from Australia indicates as
decrease in genital warts among young adult women attributable to the HPV vaccination
program (Donovan et al., 2011). HPV vaccination has the potential to impact morbidity rates of
genital warts; however, protection is only offered by the HPV4 and HPV9 vaccines that prevent
low-risk HPV types 6 and 11 (Food and Drug Administration, 2014b).

Economic Implications of the HPV Vaccine
In addition to the potential morbidity and mortality implications associated with the HPV
vaccine, economic evaluations are needed. The cost of the HPV vaccine series is estimated to be
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$500 (American Cancer Society, 2014a). The cost-effectiveness of the vaccine series must be
considered in relation to the potential economic costs associated with HPV-related outcomes.
The majority of early studies examining the cost-effectiveness of the HPV vaccine
examined female vaccination only. In these studies, HPV vaccination was considered costeffective compared to cervical cancer screening alone (Chesson, Ekwueme, Saraiya, Dunne, &
Markowitz, 2011; Kim & Goldie, 2008). One study compared coverage rates for female
vaccination at age 12 in the US. At 30% coverage, the cost of a quality-adjusted life year
(QALY)3 gained was $2,000 compared to no vaccination. In a comparison of 45% coverage to
the previously mentioned 30% coverage, the cost per QALY gained was $8,200. There is no
consensus regarding a threshold for “good value” for a QALY gained; however, $50,000 per
QALY is a commonly cited upper limit threshold (Eichler, Kong, Gerth, Mavros, & Jönsson,
2004; Kim & Goldie, 2008). Including males into this model increases the costs substantially,
especially when female vaccination coverage is higher. For example, compared to female
vaccine coverage of 45%, a model of male and female vaccination coverage at 30% was
estimated to cost $103,500 per QALY gained (Chesson et al., 2011). Furthermore, a systematic
review of 29 studies examining HPV vaccine cost-effectiveness revealed that overall routine
vaccination of females is cost-effective compared to traditional cervical cancer screening only;
however, the value of adding males to vaccination programs is less clear (Seto, Marra,
Raymakers, & Marra, 2012). This is likely due to the variability in estimate of female
vaccination coverage; lower female vaccine coverage improves the estimated cost-effectiveness
of including males in vaccine programs (Chesson & Markowitz, 2014). While the costeffectiveness of vaccinating the entire male population may not be optimal, one study has
3

QALY refers to the incremental cost per quality-adjusted life year gained by HPV vaccination. The
incremental cost per QALY is calculated as: (vaccination costs – medical costs averted from vaccination)
/ (number of QALYs gained by vaccination) (Chesson et al., 2011).
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evaluated the effectiveness of vaccinating the MSM population and found it to be a cost-effective
prevention method for anal cancer and genital warts (Kim, 2010).
An additional consideration that has been explored is extending the age limit for
vaccinating young women. Studies have consistently shown that HPV vaccination of young
women is less cost-effective as age increases compared to only vaccinating adolescents.4 Yet,
there is no consensus on a specific threshold where cost-effectiveness becomes futile (Chesson &
Markowitz, 2014; Kim & Goldie, 2008; Markowitz et al., 2014).
While these models currently provide the best estimates available for the costeffectiveness of HPV vaccination, the majority studies typically focus on direct health effects
and a limited range of cancer costs. This may significantly underestimate the cost-effectiveness
of the HPV vaccine as it can affect a wider range of economic outcomes. Marsh et al. (2014)
described the diversity of potential outcomes as extending beyond the individual, to family and
caregivers, government (e.g., treatment costs), and societal costs (e.g., improved health equality).
Moreover, the typically considered health-related costs exclude fertility impacts, out-of-pocket
costs, loss of productivity, other sequelae, and a larger range of HPV-associated cancers (Marsh,
Chapman, Baggaley, Largeron, & Bresse, 2014).
As HPV vaccination guidelines change (e.g., two doses) and other technologies evolve
(e.g., 9-valent vaccine), the estimated economic impact of the HPV vaccine will need to be
updated. Initial estimates of the cost-effectiveness for HPV9 indicate that the expanded vaccine
is more cost-saving compared to HPV4, especially for females (Brisson, 2014). The key
messages taken from the literature indicate that HPV vaccination is cost-effective for females and

4

As the age range is extended in the cost-effectiveness vaccination models, the incremental cost per
QALY gained increases to a level that may no longer be economically beneficial. For example, adding a
catchup program to 26 years old increased the cost per QALY to $152,700 compared to routine
vaccination at 12 years old (Kim & Goldie, 2008)
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the effectiveness declines with increasing age; however, no upper threshold has been established.
In addition, the cost-effectiveness of vaccinating males is less clear and further studies are
required to fully understand the economic implications.

HPV Vaccine Policies in the United States
While ACIP provides national guidelines for HPV vaccination in the United States, the
implementation of these guidelines vary by state. Given that there is a lack of standardization at
the national level, each state’s policy must be evaluated as it may be the result of policy from
state legislature or state executive branch (National Conference of State Legislatures, 2014).
Since 2006, 42 states and territories have introduced legislation to require the HPV
vaccine, fund vaccination, or educate the public or parents of school children on HPV
vaccination. Specifically, in the 2013-2014 legislative sessions, 10 states proposed legislation.
Educational policies have been enacted in Iowa, Colorado, North Carolina, Texas, and North
Dakota (Fernandez, Allen, Mistry, & Kahn, 2010). In 2007, Texas’ governor mandated the HPV
vaccination for school-aged children; however, this was overridden by the Texas legislature.
Only the District of Columbia and Virginia have enacted a legislative school vaccine
requirement with an opt-out policy for girls entering the sixth grade; both of which occurred in
2007 (Fernandez et al., 2010; National Conference of State Legislatures, 2014). As of 2014,
Rhode Island has created executive legislation through the State Health Department to require
the HPV vaccine for school entry for 7th grade starting in the 2015 school year (Gaito & North,
2014). No empirical evaluations have occurred to determine the effect of the Virginia and D.C.
school vaccine mandates; however, National Immunization Survey-Teen (NIS-Teen) 2013 data
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reveal that Virginia and D.C. are both below the national average for vaccine initiation and
completion among females (National Center for Immunization and Respiratory Diseases, 2013).
An examination of HPV vaccine related bills enacted in the US between 2006 and 2010
indicated that only 23% were actually enacted. Among the 32 bills enacted, 44% involved
policies, 25% provided education campaigns, 25% required insurance to cover vaccination, 13%
included voluntary vaccination, and 9% mandated vaccination for school entry (Laugesen et al.,
2014).
Other developed countries (e.g., United Kingdom, Australia, and Canada) have national
programs that publically fund HPV vaccination (Markowitz et al., 2012). In the United States,
this is not the case. Financing of the HPV vaccine is mainly the result of private insurance.
However, there are public financing options, such as the Vaccines for Children program,
Medicaid, or Children’s Health Insurance Program (Kaiser Family Foundation, 2014).
Alternatively, Merck and GlaxoSmithKline also offer assistance for vaccine payment (Kaiser
Family Foundation, 2014). Since cost and insurance coverage are often cited as barriers to HPV
vaccination in the United States by both target and catch-up age groups, consideration of
alternative strategies for funding the vaccine is needed.

HPV Vaccination Rates
Despite the primary prevention benefits of HPV vaccination, the rates of uptake and
completion remain low in the United States. As of 2013, using data from NIS-Teen, the rates of
vaccination initiation was 57.3% for females and 34.6% for males ages 13-17 (Table 6) (Stokley
et al., 2014). Fewer individuals received the second and third doses of the vaccine. In fact, the
completion rates of the HPV 3-dose series among initiators is 70.4% for females and 48.3% for
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Table 6: HPV Vaccination Rates Among 13-17 Year Olds
# Doses

Females

Males

≥1

57.3% ± 1.9%

34.6% ± 1.9%

≥2

47.7% ± 2.0%

23.5% ± 1.7%

≥3

37.6% ± 1.9%

13.9% ± 1.4%

*Data source: NIS-Teen 2013

males (Stokley et al., 2014). While these rates are increasing, the level of vaccination coverage is
lower than other adolescent vaccines, such as Tdap (Tetanus, diphtheria, pertussis) and
MenACWY (meningococcal). The Healthy People 2020 goals for teens 13 to 15 years in the US
include coverage of 80% for at least one dose of Tdap, at least one dose of MenACWY, and
three doses of HPV (males and females) (Healthy People 2020, 2015c). As of 2013, the goal was
met for Tdap (87.5%) and close for MenACWY (78.1%) indicating these goals are achievable
with current clinical encounters at this age range. However, HPV vaccination falls behind the
current target (Stokley et al., 2014). If the HPV vaccine were administered during healthcare
visits with other vaccine administration during this age range, then the rate of coverage for at
least one HPV vaccine dose could be 92.6% (Centers for Disease Control and Prevention, 2013).
The NIS-Teen does not capture vaccination rates for persons 18 and older; therefore,
other data sources are used for vaccination estimates. According to the National Health Interview
Survey (NHIS), uptake5 of the HPV vaccine has increased among women 18 to 26 years of age
from 11.6% (95% CI 9.7-13.6%) in 2008 to 34.1% (95% CI 31.6-36.7%) in 2012. Over the
2008-2012 timespan, overall 23.3% of women received at least one dose, 18.0% of women
received at least two doses, and 13.6% of women received at least three doses. Rates were
5

Participants asked if they ever received the HPV vaccine; uptake defined as having received at least 1
HPV vaccine dose.
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significantly higher for women 18 to 21 years of age (31.8%) compared to women 22 to 26 years
of age (16.9%) (Schmidt & Parsons, 2014). According to NHIS 2013 data, approximately 36.9%
of women 19 to 26 years old received at least one dose of the HPV vaccine; among these women
27.6% received the first dose during this age range (Williams et al., 2015).
Data regarding vaccination rates for young adult males are scarce. The latest data
available are from the 2011-2012 NHANES dataset. The HPV vaccine uptake rate was only
5.5% (95% CI 3.1-9.5%) and completion of the vaccine series was reported to be 59.1% (95% CI
37.2-77.6%) (Pierre-Victor, Mukherjee, Bahelah, & Madhivanan, 2014). Alternatively, the
National College Health Assessment (NCHA) data reported for the Fall 2013 survey, estimates
the male, college student vaccination rate (at least one dose) to be 28.6% (American College
Health Association, 2014). According to these data, the estimated proportion of college male
HPV vaccination has ranged from 13.1% to 24.6% between 2008 and 2012. Despite these higher
rates among college males, these rates are lower compared to college females (American College
Health Association, 2010, 2011, 2012, 2013).

Factors Influencing HPV Vaccination
Macro level factors. Among the environmental factors at the organizational level,
healthcare interaction and healthcare environment impact rates of vaccination (Tiro et al., 2012;
Wei et al., 2013; Williams et al., 2013). Moreover, at the highest level of influence, health
insurance, costs of vaccines, marketing of the vaccine, policies related to vaccination, and
feminization of HPV have all influenced the ability to access and receive the HPV vaccine in the
United States (Anhang Price et al., 2011; Daley, Buhi, Vamos, et al., 2012; Dempsey, Cohn,
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Dalton, & Ruffin, 2011; Ford, 2011; Hodge et al., 2011; Jain et al., 2009; Laz et al., 2013;
Lindley et al., 2013; Tiro et al., 2012; Wei et al., 2013; Zimet et al., 2010).
Provider recommendation. Key among all HPV vaccine target groups is the need for
provider recommendation. Therefore, understanding the factors influencing a provider
recommendation is necessary to consider. Characteristics of patients were a significant factor for
provider recommendation, specifically, recommendation depended upon age (Vadaparampil,
Murphy, Rodriguez, Malo, & Quinn, 2013), relationship status (Zimet et al., 2011), and gender
(females more than males) (Vadaparampil et al., 2013). Additionally, perceived barriers included
the anticipated parental response to the vaccine recommendation (Kahn et al., 2007), as well as
logistical concerns (e.g., reimbursement, cost of vaccine) (Ko, Missmer, & Johnson, 2010).
Practice environment also impacted providers; private practices and primary care practices were
more likely to recommend the vaccine (Ko et al., 2010; Vadaparampil et al., 2014). Finally,
practice guidelines are an external determinant to recommendation, especially given that the
guidelines have changed multiple times since the vaccine has been introduced (Vadaparampil et
al., 2013).
Factors among adolescents. Among adolescents, parents are the primary decisionmaking agents with regard to vaccination. As a result, the bulk of the literature has focused on
parents’ beliefs and attitudes toward HPV vaccination for their children (Fernandez et al., 2010).
In a systematic review of parental factors influencing HPV vaccination of children, lack of
knowledge or information, attitudes toward vaccination (e.g., vaccination in general, safety or
side effects of vaccine), provider recommendation, risk perceptions, and outcome expectations
with vaccination (e.g., belief child will engage in sexual activity) were reported as salient factors
among parents (Trim, Nagji, Elit, & Roy, 2012). Additionally, perceived barriers are reported,
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such as lack of insurance or funding for the vaccine (Donahue, Stupiansky, Alexander, & Zimet,
2014). Parental spousal agreement was also a predictor of intention to vaccinate (Rickert et al.,
2014).
Factors among young adult males. As for young adult males, awareness, knowledge,
perceived severity, perceived susceptibility, perceived barriers (e.g., cost, side effects), selfefficacy and provider recommendation were associated with HPV vaccination (Daley et al.,
2011; Fontenot, Fantasia, Charyk, & Sutherland, 2014; Katz, Kam, Krieger, & Roberto, 2012;
Newman et al., 2013). Additionally, rates of vaccination vary based on demographic
characteristics, such as, poverty, race/ethnicity and education (Daley et al., 2011; Lu et al., 2013;
Newman et al., 2013).

Factors Influencing HPV Vaccination among Young Adult Females
In order to assess the current state of HPV vaccination barriers and facilitators among
young adult women in the United States, a systematic review of the literature was conducted.
Articles were systematically selected from a search of PubMed and Web of Science databases,
during a date range of June 1, 2006 to May 1, 2015. Search terms were organized into general
categories of HPV (e.g., human papillomavirus, human papilloma virus, papillomavirus vaccines
[MeSH], HPV, papillomavirus), immunization (e.g., immuniz*, vaccin*), female (e.g., female,
women, woman, girl*), and young adult (e.g., college, catch-up, catch up, young adult). The
search strategy in each database used the Boolean term of ‘AND’ for inclusion of each general
category, and the Boolean term of ‘OR’ for inclusion of each search term within the category.
Inclusion criteria applied were: (1) empirically-based; (2) published in a peer-reviewed journal;
(3) reported stratified data for females 18 to 26 years of age; (4) referenced the HPV vaccine; (5)
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conducted post-vaccine licensure; and (6) conducted in the United States. Studies were excluded
if only a published abstract was available since not enough data would be available for
abstraction.

Figure 1: Search Results for Systematic Review
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Figure 1 presents the search process for this systematic review. The primary search of the
literature identified 1,892 records. After removing 181 duplicates, 1,711 articles remained.
Articles were then screened based on titles and relevance to the research topic; this removed
1,478 articles. Next, articles were assessed based on the abstract to determine the relevance to the
research topic; this resulted in 112 articles remaining. These remaining articles had the full-text
examined to determine eligibility based on the inclusion and exclusion criteria. The follow
articles were removed: 17 for not providing age-stratified results, 7 for not providing genderstratified results, 3 for not referencing the HPV vaccine, 4 for being outside of the United States,
2 for being before vaccine licensure, and 2 for only providing an abstract. As a result, 77 articles
remained.
The included observational studies had the following types of samples: 29 college (Allen
et al., 2009; Bednarczyk et al., 2011; Bendik et al., 2011; Bennett et al., 2012; Bynum et al.,
2012; Bynum, Brandt, Friedman, Annang, & Tanner, 2011; Bynum, Brandt, Sharpe, et al., 2011;
Cohen & Head, 2013; Daley, Vamos, et al., 2010; Dillard, 2011; Dillard & Spear, 2010; Gerend
& Shepherd, 2011; Harper, Alexander, et al., 2014; Harper, Irons, et al., 2014; Hodge et al.,
2011; Hopfer & Clippard, 2011; Krakow et al., 2015; Krieger, Kam, Katz, & Roberto, 2011;
Licht et al., 2010; Lindley et al., 2013; Marchand et al., 2012; Marchand, Glenn, & Bastani,
2013; Patel et al., 2013; Patel et al., 2012; Ratanasiripong, 2014; Ratanasiripong et al., 2013;
Roberts, Gerrard, Reimer, & Gibbons, 2010; Sandfort & Pleasant, 2009; Schaefer Ziemer &
Hoffman, 2013), 17 large national surveys (Anhang Price et al., 2011; Caskey, Lindau, &
Alexander, 2009; Ford, 2011; Gelman et al., 2013; Jain et al., 2009; Laz et al., 2013; Liddon,
Hood, et al., 2012; Liddon, Leichliter, et al., 2012; Pourat & Jones, 2012; Rahman, Islam, &
Berenson, 2015; Rahman et al., 2013; Schmidt & Parsons, 2014; Tiro et al., 2012; Vanderpool,
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Williams, Klawitter, & Eddens, 2014; Wei et al., 2013; Williams et al., 2015; Williams et al.,
2013), 8 insurance records or electronic health records (Chao, Velicer, Slezak, & Jacobsen,
2009, 2010; Cowburn et al., 2014; Hirth, Tan, Wilkinson, & Berenson, 2012; Kharbanda, Parker,
Nordin, Hedblom, & Rolnick, 2013; Rosenthal et al., 2011; Verdenius et al., 2013; Zimet et al.,
2010), 5 clinics (Dempsey et al., 2011; Joseph et al., 2014; Kennedy, Osgood, Rosenbloom,
Feinglass, & Simon, 2011; Klosky et al., 2015; Vanderpool, Casey, & Crosby, 2011), 3 minority
population (e.g., American Indians) (Casey, Crosby, Vanderpool, Dignan, & Bates, 2013; Head
& Cohen, 2012; Mills, Head, & Vanderpool, 2013), 2 combination of samples (e.g., clinic and
community) (Crosby, Casey, Vanderpool, Collins, & Moore, 2011; Mills et al., 2011), 2
community (Manhart et al., 2011; Vanderpool, Dressler, Stradtman, & Crosby, 2015) and 1 webbased (Bernat et al., 2013). Of the 77 studies, 9 were interventions (Gerend & Shepherd, 2012;
Gerend, Shepherd, & Lustria, 2013; Gerend, Shepherd, & Shepherd, 2013; Hopfer, 2012;
Juraskova et al., 2012; Krieger & Sarge, 2013; Paiva, Lipschitz, Fernandez, Redding, &
Prochaska, 2014; Patel et al., 2014; Vanderpool et al., 2013). Immunization rates, as well as,
barriers and facilitators to HPV vaccination among females 18 to 26 years of age were abstracted
from each article. These determinants were then stratified by levels of the Socioecological Model
(i.e., intrapersonal, interpersonal, organizational, community, and policy) (McLeroy, Bibeau,
Steckler, & Glanz, 1988). Pile sorting was used to assign a level and theme for each determinant
identified in each paper (Bernard & Ryan, 2010c).
This review summarizes the current state of HPV vaccination and the barriers and
facilitators of vaccination among women 18 to 26 years of age in the United States. It is evident
from this review of the literature that the majority of the research available has focused on the
intrapersonal level. Primarily, researchers have been interested in investigating the knowledge,
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attitudes, and beliefs regarding HPV, HPV-related outcomes, and HPV vaccination among this
age group.

Intrapersonal Barriers and Facilitators
Demographic characteristics. Given the recommendation for routine vaccination of
females 11 to 12 years of age, it is not surprising that HPV vaccination initiation and completion
is more likely among younger women (i.e., 18 to 21 year olds) in the 18 to 26 year old category
(Bendik et al., 2011; Bynum, Brandt, Sharpe, et al., 2011; Chao et al., 2010; Dempsey et al.,
2011; Hirth et al., 2012; Laz et al., 2013; Lindley et al., 2013; Rahman et al., 2015; Tiro et al.,
2012; Wei et al., 2013; Williams et al., 2015). Additionally, this age category is unique, in that
one barrier to vaccination is pregnancy or attempting to conceive (Verdenius et al., 2013; Zimet
et al., 2010). To date, the HPV vaccine is not recommended for use during pregnancy
(Markowitz et al., 2014).
Additionally, disparities exist with regard to sub-populations receiving the vaccine.
Racial and ethnic minorities tend to have lower uptake rates (Lindley et al., 2013; Williams et
al., 2015). African Americans are consistently less likely to initiate and complete the HPV
vaccine series compared to whites (Bednarczyk et al., 2011; Chao et al., 2010; Dempsey et al.,
2011; Ford, 2011; Kharbanda et al., 2013; Laz et al., 2013; Liddon, Leichliter, et al., 2012).
Asians also have lower uptake rates (Kharbanda et al., 2013). According to NHIS 2010 data,
Non-Hispanic whites were the most likely to be vaccinated (25.7%), followed by Non-Hispanic
Asians (22.9%), Non-Hispanic blacks (21.5%), Other (19.0%) and Hispanics (16.7%) (Williams
et al., 2013). In 2013, vaccination rates changed slightly for 19 to 26 year old women to whites
(43.1%), followed by blacks (30.6%), Hispanics (30.3%), and Asians (19.8%) (Williams et al.,
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2015). Yet, rates for HPV vaccine uptake have increased across all racial/ethnic groups,
according to NHIS 2008 to 2012 data (Schmidt & Parsons, 2014).
Having a low income or being below the federal poverty level was consistently associated
with non-vaccination (Chao et al., 2010; Jain et al., 2009; Laz et al., 2013; Rahman et al., 2013;
Wei et al., 2013). This is most likely connected to other social determinants of health (Healthy
People 2020, 2014), such as access to health care, which will be explored at the organizational
level. Additionally, a lower education level or not being in school was associated with nonvaccination and lower awareness of the vaccine (Chao et al., 2010; Ford, 2011; Gerend &
Shepherd, 2011; Manhart et al., 2011; Rahman et al., 2015; Rahman et al., 2013; Tiro et al.,
2012).
Knowledge. In the majority of behavioral health theories, it is recognized that a person
must have awareness or knowledge of the health behavior in order to successfully engage in it
(Brewer & Rimer, 2008). As a result, the bulk of the literature on HPV vaccination in females 18
to 26 year olds has focused on knowledge levels related to HPV and the vaccine. Unfortunately,
standard measures across studies do not exist; however, most studies conclude that limited
knowledge is associated with lower vaccine uptake (Bynum, Brandt, Sharpe, et al., 2011; Daley,
Vamos, et al., 2010; Hodge et al., 2011; Joseph et al., 2014). Many women cited needing more
information about the vaccine as a primary barrier to vaccination (Joseph et al., 2014;
Ratanasiripong et al., 2013; Zimet et al., 2010). Knowledge misperceptions include transmission
of HPV (e.g., oral sex, genital skin to skin contact, genetics) and likelihood of cervical cancer
(Cohen & Head, 2013; Sandfort & Pleasant, 2009). It must be noted that the majority of studies
assessing knowledge do so among college samples of women, who may have higher levels of
education. Therefore, this may overestimate HPV vaccine knowledge levels compared to the
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general public. To support this notion, one study found that knowledge about the HPV vaccine
was strongly associated with college educational attainment (Kennedy et al., 2011). Regardless,
the NHIS indicates that awareness of the HPV vaccine has increased across years, and is less
likely cited as a main reason for non-vaccination in 2010 compared to 2008 (Schmidt & Parsons,
2014).
Attitudes and beliefs. In addition to knowledge scales, many measures exist to assess
women’s attitudes toward the vaccine and beliefs about the vaccine. Given the novelty of the
vaccine, many early studies reported perceived barriers such as concern that the vaccine is too
new (Bednarczyk et al., 2011; Zimet et al., 2010), concern about side effects (Bednarczyk et al.,
2011; Hodge et al., 2011; Joseph et al., 2014; Ratanasiripong et al., 2013; Zimet et al., 2010), and
concern about efficacy (Cohen & Head, 2013). Moreover, women also reported an overall dislike
or fear toward needles, which was a primary barrier to uptake of the vaccine (Joseph et al., 2014;
Ratanasiripong et al., 2013). However, these barriers may be overcome with perceived benefits
of the vaccine. Women were more likely to be vaccinated or intend to be vaccinated with higher
perceived benefits (e.g., vaccination is preventing an HPV infection), higher perceived
importance of the vaccine, and a more positive attitude toward the vaccine (Bendik et al., 2011;
Bennett et al., 2012; Dillard, 2011; Ratanasiripong et al., 2013; Rosenthal et al., 2011; Schaefer
Ziemer & Hoffman, 2013).
Additionally, given that HPV is a sexually transmitted infection, stigma surrounding this
characteristic is apparent. Women have reported that the vaccine may endorse sexual behavior or
that they have heard of stigmatizing messages related to HPV (e.g., “people who have STDs are
careless and dirty,” “only sluts get HPV,” or “if you got HPV it means you weren’t smart about
who you were sleeping with”); and therefore are less inclined to be vaccinated (Hopfer &
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Clippard, 2011, p. 269; Joseph et al., 2014). Interestingly, little research has focused on the
concept that HPV is a sexually transmitted disease or associated with genital warts; rather the
focus has been on framing the vaccine as a method of cancer prevention. In fact, women were
more likely to be vaccinated when the vaccine was framed as cancer prevention (Hopfer &
Clippard, 2011). This corroborates the finding that vaccine uptake is more likely if women have
a higher perceived severity of cervical cancer, perceived likelihood of getting cervical cancer, or
higher worry about cervical cancer (Bendik et al., 2011; Krakow et al., 2015). Yet, having
fatalistic beliefs regarding cancer was associated with non-completion of the HPV vaccine series
(Vanderpool et al., 2015).
Control. As in many health behavior theories, confidence in one’s ability to perform the
behavior is integral to overcoming barriers to perform that behavior (Champion & Skinner, 2008;
Montano & Kasprzyk, 2008). As would be expected, women with higher perceived behavioral
control and self-efficacy were more likely to be vaccinated or intend to be vaccinated (Dillard,
2011; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). These barriers that
women overcome may not only be the barriers previously described at the intrapersonal level,
but may exist at higher levels.
Risk perception and risk reality. One of the largest barriers to vaccination among
females 18 to 26 years of age is a result of poor risk perception. Non-vaccinated women
consistently report a low perceived HPV risk attributed to a number of reasons, including not
being sexually active or using alternative HPV prevention methods (Anhang Price et al., 2011;
Cohen & Head, 2013; Gelman et al., 2013; Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph
et al., 2014; Laz et al., 2013; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013).
However, national recommendations state that the HPV vaccine is the best prevention method
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for HPV compared to condoms (e.g., inconsistent effectiveness) and monogamy or no current
sexual activity (e.g., the possibility of future sexual partners) (Markowitz et al., 2014).
This concept of poor risk perception as a barrier is contrasted by the risk reality of many
women who initiate the HPV vaccine. Interestingly, this is a health behavior that women who
participate in high-risk behaviors are more likely to uptake. With regards to sexual activity,
women who have a lower age of sexual debut, have more sexual partners, have vaginal sex, or
engage in mutual masturbation are more likely to be vaccinated (Bednarczyk et al., 2011; Bendik
et al., 2011; Bernat et al., 2013; Gerend & Shepherd, 2011; Lindley et al., 2013; Manhart et al.,
2011; Mills et al., 2011; Ratanasiripong, 2014; Tiro et al., 2012). Additionally, women who have
already been diagnosed with HPV, have had an abnormal Pap test, and have had no Pap test were
also more likely to initiate the HPV vaccination series (Anhang Price et al., 2011; Laz et al.,
2013; Ratanasiripong et al., 2013; Vanderpool et al., 2011). Finally, non-sexual risk behaviors
are also associated with vaccine uptake; these include cigarette smoking, illegal drug use, and
alcohol use (Manhart et al., 2011; Wei et al., 2013). As a result, it may be that these women who
are engaging in high-risk behaviors have a more accurate perception of their risk profile, and are
therefore more likely to be vaccinated. In contrast, other women may consider themselves
“protected” from HPV given their sexual health profile; thus, these women have a lower
perceived risk of HPV and are less likely to initiate the HPV vaccine series. This is especially
important to recognize as this catch-up age category for HPV vaccination is the only age group
where independent and autonomous decision-making can take place for the individual.

Interpersonal Barriers and Facilitators
Healthcare providers. A healthcare provider recommendation or offer for the HPV
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vaccination consistently increased initiation (Daley, Vamos, et al., 2010; Klosky et al., 2015;
Licht et al., 2010; Marchand et al., 2012; Rosenthal et al., 2011; Zimet et al., 2010). Women
cited not being offered the vaccine from their providers as a reason for not being vaccinated
(Anhang Price et al., 2011). Additionally, women reported a high level of trust in their providers,
as well as using the providers’ encouragement to overcome other barriers to vaccination (Dillard
& Spear, 2010; Joseph et al., 2014). Rosenthal et al. (2011) identified physician recommendation
as a moderating factor influencing HPV vaccination (OR=93.5, 95% CI 39.1-223.6), and as
result stratified the analysis to understand the effect more fully. Women who received a
physician recommendation were more likely to be vaccinated the stronger the recommendation
(OR=1.4, 95% CI 1.1-1.9) (Rosenthal et al., 2011). Characteristics of the healthcare provider also
influenced HPV vaccination; women with male providers were less likely to be vaccinated (Chao
et al., 2010). Similar to this is the specialization of the practitioner; women were more likely to
be vaccinated when visiting a family medicine or internal medicine physician (Chao et al., 2009,
2010). It is therefore apparent that healthcare providers have an integral role as agents to HPV
vaccination.
Subjective norms. Overall, when tested, subjective norms (i.e., perceived social pressure
to perform a behavior) were a significant predictor to HPV vaccination and intention (Allen et
al., 2009; Bennett et al., 2012; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013).
Subjective norms were strongest when considering “important people” as influential agents in
decision-making (Bennett et al., 2012). Additionally, women reported higher uptake when
encouraged by important others in their social network, such as sisters, sorority members,
friends, mothers, and healthcare providers (Cohen & Head, 2013). Women who perceived higher
social approval were also more likely to be vaccinated (Marchand et al., 2012). Thus, examining
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the social network of women is necessary in order to elicit who are these “important people” that
contribute to the decision-making process for the HPV vaccine. From the literature, three groups
of people emerged: family members, peers, and partners.
Family members. Receiving supportive messages or hearing about the vaccine from
family members increased the uptake of the vaccine (Hopfer & Clippard, 2011). Alternatively,
women who reported that their parents advised them not to obtain the vaccine or were against the
vaccine were less likely to be vaccinated (Ratanasiripong et al., 2013). Entangled in this issue is
the reported barrier to vaccination of fear of parental disclosure, which may be emphasized
among women who received negative messages about the vaccine from parents or family
members (Hopfer & Clippard, 2011). This fear of disclosure may also be exacerbated among
women who remain on family members’ insurance plans since evidence of HPV vaccination is
provided on insurance billing forms.
Among family members, one key agent among young adult women was mothers.
Mother-daughter communication and approval about the HPV vaccine positively impacted
daughters’ vaccine behavior (Krieger et al., 2011; Roberts et al., 2010). One reason that mothers
may appear to be influential agents compared to other family members is due to the design of
studies to assess only maternal influence; however, one study did examine the role of fathers in
HPV vaccination. In fact, among rural women, the perception that fathers wanted them to be
vaccinated was a significant predictor of HPV vaccination (Casey et al., 2013).
Peers. Women reported that peer descriptive norms (e.g., friends being vaccinated),
which reduced the stigma of HPV vaccination, were important to increasing the likelihood of
vaccination (Hopfer & Clippard, 2011). Additionally, peer approval (i.e., injunctive norms) was
reported as a facilitator for vaccine initiation (Manhart et al., 2011). Among a national survey of
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college students, women who reported being vaccinated were more likely to be a member of a
sorority, varsity athletics, or intramural/club sports (Lindley et al., 2013). Women in these groups
may experience more support from their peer social networks when participating in these
activities compared to women in non-formalized types of peer groups.
Partners. One of the most consistent findings in the literature was that married women
or women in a relationship were less likely to be vaccinated or intend to be vaccinated (Anhang
Price et al., 2011; Ford, 2011; Gelman et al., 2013; Jain et al., 2009; Joseph et al., 2014; Laz et
al., 2013; Liddon, Hood, et al., 2012; Liddon, Leichliter, et al., 2012; Rahman et al., 2013;
Schmidt & Parsons, 2014; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010).
Furthermore, in a national survey among college students, women who were not in a relationship
(OR=1.59, 95% CI 1.45-1.74) or in a relationship and not living with their partner (OR=1.31,
95% CI 1.20-1.43) were more likely to be vaccinated compared to women in a relationship and
living with their partner (Lindley et al., 2013). Hopfer and Clippard (2011) reported that women
may frame their perception of HPV susceptibility based upon their relationship status (Hopfer &
Clippard, 2011). Thus, partnership status, or rather monogamy, may be a key moderator to
uptake of the HPV vaccine among this age group of women. Additionally, women were more
likely to have a preference for male partners who were vaccinated, regardless of the woman’s
vaccination status. This preference was stronger among women with a higher perceived
vulnerability to HPV (Harper, Alexander, et al., 2014). Moreover, women were more likely to be
vaccinated when they perceived the vaccine as being beneficial to their partner (Patel et al.,
2013). Among all key change agents influencing HPV vaccination status, it appears that partners
are consistently reported in the quantitative, survey-based research, yet little examination has
occurred as to how these key agents are influential.
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Organizational Barriers and Facilitators
In this context, the organizational level includes the healthcare system organization,
specifically, access to healthcare, insurance coverage, and healthcare interactions.
Insurance coverage and cost. Women who are uninsured or publically insured were
consistently less likely to be vaccinated compared to women with private insurance (Anhang
Price et al., 2011; Dempsey et al., 2011; Ford, 2011; Hodge et al., 2011; Jain et al., 2009; Laz et
al., 2013; Lindley et al., 2013; Rahman et al., 2015; Tiro et al., 2012; Wei et al., 2013; Zimet et
al., 2010). Additionally, women with insurance were more aware of the availability of the HPV
vaccine compared to women without insurance (Ford, 2011; Pourat & Jones, 2012). Yet one
study found that insurance continuity (i.e., having insurance over a three year period) was not a
significant predictor of vaccine initiation (Cowburn et al., 2014). The issue of insurance coverage
may represent a more global barrier related to the cost of the vaccination series. Women without
insurance would need to pay out of pocket for the vaccine, which may cost approximately $140
to $170 per dose (American Cancer Society, 2014b; Planned Parenthood, 2014). This is
especially limiting since women (19 to 26 years) are no longer eligible for some programs that
can circumvent the cost, such as Vaccines for Children (American Cancer Society, 2014b). Cost
was repeatedly cited as a barrier to HPV vaccination among this target population (Head &
Cohen, 2012; Joseph et al., 2014; Zimet et al., 2010). Moreover, among women who were not
vaccinated and interested in obtaining the vaccine, one-third reported they would not receive the
vaccine if they had to pay full cost (Williams et al., 2013). While insurance coverage and cost of
the vaccine represent formidable barriers to vaccination, it must be recognized that these are not
the only barriers that must be removed. Two studies offered the vaccine for free to women in
rural areas of the United States. In these studies, despite the elimination of the main barrier, cost,
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women still faced additional barriers to being vaccinated, such as distance to the clinic and fear
of pain from the vaccine (Casey et al., 2013; Vanderpool et al., 2011).
Healthcare interaction. Women without a regular healthcare provider or without a visit
to a healthcare provider in the last year were less likely to be vaccinated (Tiro et al., 2012; Wei et
al., 2013; Williams et al., 2013). Given that women need to be seen by a medical provider in
order to receive the vaccine, a lack of interaction with a healthcare provider is a key barrier. In
order to assess this issue, many studies have used other types of health procedures or billing
codes (e.g., Pap test in past three years6) as surrogate measures for healthcare interaction.
Women who have not had a Pap test in the past three years or were not using hormonal birth
control (which requires a prescription from a healthcare provider), were less likely to be
vaccinated (Wei et al., 2013). Moreover, women who had sexually transmitted infection tests or
Pap tests were more likely to be vaccinated compared to women who did not (Chao et al., 2010;
Laz et al., 2013). Additionally, women who did not receive other types of vaccinations, such as
influenza or Hepatitis B, were also less likely to be vaccinated (Anhang Price et al., 2011; Jain et
al., 2009; Laz et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013).
However, there are some types of visits that reduce the likelihood of vaccination. Women with
an obstetric history (e.g., birth, pregnancy or abortion in medical record) or having one or more
pregnancies were less likely to be vaccinated (Chao et al., 2009, 2010; Verdenius et al., 2013).
Similarly, women with more emergency department visits were less likely to complete
vaccination; this may be the result of more serious health conditions that take priority to HPV
vaccination or a proxy measure of lack of insurance (Chao et al., 2009). In order to help facilitate

6

At the time of data collection (2010), Pap tests were recommended for women at the onset of sexual
activity every three years.
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HPV vaccination completion, utilization of immunization only appointments can increase rates
of completion, especially for second and third doses (Dempsey et al., 2011).

Community Barriers and Facilitators
Region. Women residing in the Northeast, West, or North Central/Midwest were more
likely to uptake the HPV vaccine compared to other United States’ regions, while controlling for
confounders, such as race and socioeconomic status (Lindley et al., 2013; Wei et al., 2013).
Additionally, women in the South were the least likely to be vaccinated; however, these women
reported the most interest in the vaccine (Rahman et al., 2013; Schmidt & Parsons, 2014). Thus,
women in the South may face barriers to receiving the vaccine despite an interest in uptake.
Accessibility. Not only is region of the United States a factor impacting HPV vaccination
among young adult females, but also level of urbanization. Women living in rural areas may
face more difficulties physically accessing the HPV vaccine and thus have lower rates of uptake
(Crosby et al., 2011; Hodge et al., 2011). Rural women reported wanting more accessible
community locations where they could receive the vaccine (Mills et al., 2013). Additionally,
accessibility may be impacted by a number of factors, including not knowing where to get the
vaccine, transportation barriers, and other responsibilities (e.g., childcare, work, or school) (Mills
et al., 2013). Confounding the issue of accessibility is the necessity for the three-dose vaccine,
meaning three separate visits, which serve as additional barriers (Head & Cohen, 2012).

Policy Barriers and Facilitators
No studies reported policy-related barriers or facilitators to HPV vaccination among this
specific age and gender group. However, this does not indicate there are none present.
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Interventions
There is a dearth of interventions implemented among this population in order to increase
HPV vaccination rates. Included in this review are nine studies that attempted to improve HPV
vaccination intention, uptake, or completion. The majority of these interventions implemented
educational techniques (e.g., tailored binder of information, education video, narrative message,
fact sheet, online information, or DVD) (Gerend & Shepherd, 2012; Gerend, Shepherd, &
Lustria, 2013; Hopfer, 2012; Juraskova et al., 2012; Krieger & Sarge, 2013; Paiva et al., 2014;
Vanderpool et al., 2013).
Among these studies, a tailored educational binder to perceived barriers improved HPV
vaccination intentions compared to a non-tailored message among unvaccinated college women.
One of these barriers was “I’m in a monogamous/committed relationship.” While overall the
intervention improved intention for vaccination, it is unknown the effect of each specific
message (Gerend, Shepherd, & Lustria, 2013). Additionally, a DVD intervention improved
completion of the HPV vaccination series compared to standard of care among a community
sample of women (Vanderpool et al., 2013). One randomized control trial compared the effect of
disease framing of HPV (either cervical cancer or genital warts) in a fact sheet among female
university students; there was no significant effect (Juraskova et al., 2012). Similar results were
found for a video that used loss-framing (i.e., emphasizing the costs of not getting vaccinated) or
gain-framing (i.e., emphasizing the benefits of getting vaccinated) for vaccination among
unvaccinated college women; there was no significant difference in vaccination between groups
(Gerend & Shepherd, 2012). In comparison, another study assessed disease message framing and
found framing HPV within the context of genital warts impacted intentions to talk to a healthcare
provider about the HPV vaccine among college-age females (Krieger & Sarge, 2013). One other
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study found a computer-based, tailored, education intervention to be feasible and acceptable
among a sample of college women (Paiva et al., 2014). A potential bias of the majority of these
educational interventions is that these were conducted among college/university students, who
may have higher knowledge levels than community-based samples of 18 to 26 year old women
(Kennedy et al., 2011), thus diminishing the effects of these interventions.
Patel et al. (2014) aimed to improve completion of the HPV vaccine series among women
in a community reproductive health center. The intervention used cues to action, specifically
automated reminder messages. These were delivered from the reproductive health center via
patient’s preferred method of communication. The reminder system did not successfully increase
completion rates (Patel et al., 2014).
Only one study emphasized the role of healthcare providers and peers in vaccination at a
university health center. In this randomized control trial, health messages included HPV
susceptibility, self-efficacy and safety. These messages were delivered by four types of agents:
peer only, medical expert only, combination or peer and medical expert, or neither. At the two
month follow-up, the peer-expert combination had the strongest effect (OR=2.01, 95% CI 1.054.10), while the other modes of delivery did not significantly impact HPV vaccination (Hopfer,
2012).

Application of Theory in Interventions
The majority of these studies utilized a theoretical framework to develop or evaluate the
intervention implemented. These theoretical frameworks included: the Health Belief Model
using only the perceived barriers construct for the study (Gerend, Shepherd, & Lustria, 2013;
Gerend, Shepherd, & Shepherd, 2013), the Culture-Centric Narrative Theory (Hopfer, 2012), the
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Theory of Planned Behavior (Juraskova et al., 2012; Vanderpool et al., 2013), the Extended
Parallel Process Model (Krieger & Sarge, 2013), the Transtheoretical Model (Paiva et al., 2014),
and a combination of the Theory of Planned Behavior and the Health Belief Model (Gerend &
Shepherd, 2012). Only one study did not use a theoretical framework in the intervention (Patel et
al., 2014).

Limitations of Current Research
The review of the literature revealed as plethora of barriers and facilitators to HPV
vaccination among young adult women. Despite the large amount of evidence describing these
multi-level factors, there are a limited number of interventions among women 18 to 26 years of
age. Among the nine interventions included in this review, only two included tailoring to specific
sub-sets of women (e.g., tailored to perceived barriers or stage of change) (Gerend, Shepherd, &
Lustria, 2013; Paiva et al., 2014). Yet, evidence supports the use of tailoring for health messages
(Kreuter & Wray, 2003), more specifically with HPV vaccine messages (Allen et al., 2009;
Gerend, Shepherd, & Lustria, 2013; Reiter, Brewer, Gottlieb, McRee, & Smith, 2009b).
Therefore, it is necessary to identify the types of characteristics among the target population that
require segmentation and tailored message framing in order to improve HPV vaccination.

Relationship Status and HPV Vaccination among Young Adult Women
According to the literature review, one of the most consistent predictors of HPV
vaccination is relationship status among young adult women. Specifically, women in long-term
or monogamous relationships are less likely to be vaccinated. The bulk of the available research
has focused on epidemiological risk factor associations regarding relationship status and HPV
vaccination using cross-sectional designs and large datasets or surveys. None of these studies
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have investigated how relationship status operates as a risk factor and how to intervene to
improve vaccination rates among young adult women.

Relationship Status is a Predictor of Vaccination – Quantitative Data
Among studies conducted within the 18 to 26 year old female target population, there are
14 studies supporting the association between relationship status and HPV vaccination (Anhang
Price et al., 2011; Bernat et al., 2013; Ford, 2011; Joseph et al., 2014; Laz et al., 2013; Liddon,
Hood, et al., 2012; Liddon, Leichliter, et al., 2012; Lindley et al., 2013; Rahman et al., 2013;
Schmidt & Parsons, 2014; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010). The
majority of these studies utilized nationally-representative surveys, including the National Health
Interview Survey (NHIS)7, the National Survey of Family Growth (NSFG)8, the Behavioral Risk
Factor Surveillance System (BRFSS)9 and the National College Health Assessment (NCHA)10
(Table 7).
Using data from NHIS surveys between 2008 and 2010, adjusted odds ratios reporting the
association between relationship status (reference group = married/in relationship) and HPV
vaccination uptake ranged between 2.4 to 4.1, all statistically significant (Anhang Price et al.,
2011; Laz et al., 2013; Wei et al., 2013; Williams et al., 2013). Similar findings were reported for
NHIS data examining interest in the HPV vaccine (Schmidt & Parsons, 2014). Analyses using
NSFG utilized different parameters for their populations and examined initiation of vaccination
and intention for vaccination; all analyses found statistically significant associations between

7

NHIS is used to monitor the health status of the U.S. population on a range of health topics.
NSFG is used to describe pregnancy, fertility, and contraception rates among U.S. men and women.
9
BRFSS is used to monitor prevalence of major behavioral risk factors among the U.S. population.
10
NCHA is used to monitor the health status and risk factors for participating U.S. universities.
8
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Table 7: Quantitative Studies Reporting Effect of Relationship Status on HPV Vaccine Uptake
Publication

Years

Dataset,
Sample Age

OR, 95% CI

Ford, 2011

2007-08

NSFG, 18-24

7.7, 1.8-33.3

Liddon, et
al., 2012

2007-08

NSFG, 20-24

2.7, 1.4-5.4

Rahman, et
al., 2013

2008-10

BRFSS, 18-26

1.4, 129-1.6

Anhang, et
al., 2011

2008

NHIS, 18-26

Lindley, et
al., 2013

2009

Laz, et al.,
2013

†

Comparison
Group

Referent
Group

Single

Married

Never
Married

Other

Never
Married

Other + Married

4.1, 1.9-8.6

Other

Married

NCHA, 18-24

1.6, 1.5-1.7

Not in a
relationship

In a relationship/
living together

2010

NHIS, 18-26

3.1, 1.7-5.6

Single

Married

Wei, et al.,
2013

2010

NHIS, 18-26

2.4, 1.4-4.2

Never
Married

Married or living
together

Williams, et
al., 2013

2010

NHIS, 18-26

2.4, 1.4-4.2

Other

Married

†

†

Inverse of the odds ratio calculated for consistency of referent group

these outcomes and relationship status (Ford, 2011; Liddon, Hood, et al., 2012; Liddon,
Leichliter, et al., 2012). One study used the BRFSS dataset for 2008 to 2010 and found that
women who were married, divorced, widowed, or separated were less likely to be vaccinated
than single, never married women (Rahman et al., 2013).
Overall, the survey-based, quantitative research supports the finding that young adult
women in relationships are less likely to receive or have interest in the HPV vaccine compared to
young adult women who are single. This consistent epidemiological support warrants further
investigation to how this risk factor may be moderating HPV vaccination uptake among the 18 to
26 year old female population.
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A Women’s Health Issue
While males (18 to 21 years old, and 21 to 26 years old for high risk populations) may
also make autonomous decisions regarding HPV vaccination in young adulthood, relationship
status does not appear to be a significant risk factor among this group. In a systematic review
examining HPV vaccine acceptability among males, relationship status was not a significant
demographic factor identified in the 29 included studies (Newman et al., 2013). Moreover, in a
web-based survey among young adult males and females, there were differences in factors
associated with vaccine uptake; in particular marital status was a predictor among females and
not a predictor among males (Bernat et al., 2013). This indicates the possibility of differences in
risk profile among males and females in this age category for HPV vaccination.

Hypothesized Mechanism
While the epidemiological data support the connection between relationship status and
HPV vaccination, these studies have not attempted to understand the mechanism for this
association. However, other quantitative findings investigating perceived risk or susceptibility
may connect this risk factor to HPV vaccination. Specifically, women who have lower HPV risk
perceptions are less likely to be vaccinated (Anhang Price et al., 2011; Cohen & Head, 2013;
Gelman et al., 2013; Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph et al., 2014; Laz et al.,
2013; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). Schaefer Ziemer and
Hoffman (2013) examined how Health Belief Model constructs differed between vaccinated and
unvaccinated women. Many unvaccinated women reported that they did not need the vaccine
since they did not perceive themselves as at risk, especially with monogamous partners. Thus,
these women were evaluating their proximal risk for HPV based on their current relationship or
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sexual partnership rather than considering their future risk for HPV. A similar evaluation of risk
occurs among women who report never having had sex and do not intend to be vaccinated; these
women are also altering their risk perceptions for HPV based on proximal factors, but based on
current sexual behavior (Liddon, Hood, et al., 2012). Schaefer Ziemer and Hoffman (2013)
suggest that future behavioral HPV vaccination research and interventions should emphasize that
future behavior and partner behavior affect HPV risk among women.
Similarly, Cohen and Head (2013) found that unvaccinated women reported an attitude of
low perceived risk for HPV, which was supported by the beliefs that HPV can be prevented
through monogamy and knowledge of their partners’ sexual history. To date, only one qualitative
study has investigated the narratives of HPV vaccinated and unvaccinated women as it relates to
sexual behavior (i.e., sexually active, not sexually active). Hopfer and Clippard (2011) reported
an emerging finding from this study that women framed their risk perceptions for HPV based on
relationship status. Again, false beliefs regarding risk for HPV were prominent among these
young adult women, including “I don’t feel personally vulnerable [to HPV] because I am in a
committed relationship where we are only seeing each other” (Hopfer & Clippard, 2011, p. 272).
Moreover, this discordance between risk perception and risk reality among women in this
age category is evident among traditionally sexually high-risk groups (e.g., multiple sexual
partners, previously diagnosed with HPV). In this case, many of the high-risk groups are getting
vaccinated compared to the perceived low risk counterparts (Anhang Price et al., 2011;
Bednarczyk et al., 2011; Bendik et al., 2011; Bernat et al., 2013; Gerend & Shepherd, 2011; Laz
et al., 2013; Lindley et al., 2013; Manhart et al., 2011; Mills et al., 2011; Ratanasiripong et al.,
2013; Tiro et al., 2012; Vanderpool et al., 2011). Overall, this concept is counterintuitive to
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typical health-related research, which focuses on high-risk groups not accessing healthcare
services.
Young adult women are not the only group with false beliefs regarding risk for HPV.
Healthcare providers may also be contributing to the low HPV vaccine uptake among women in
relationships. Zimet et al., (2011) reported physicians giving a lower priority to vaccinating
female patients who were married or in a monogamous relationship compared to women who
were single or dating. In contrast, these physicians surveyed did not alter priority perceptions
based on women’s sexual history (e.g., HPV infection, abnormal Pap test) (Zimet et al., 2011).
Thus, healthcare providers may suffer from the same risk perception bias as young adult women
regarding relationship status and HPV vaccination. This finding is concerning since
recommendation for vaccination from a healthcare provider was significantly associated with
HPV vaccine uptake among this population. Rosenthal et al. (2011) found that the strength of
physician recommendation was the strongest predictor of HPV vaccine uptake, and in fact
marital status was no longer a significant predictor. The authors suggested that despite married
women being less inclined to be vaccinated, a strong physician recommendation may increase
that likelihood (Rosenthal et al., 2011).

But isn’t, “Monogamous Sex, Safe Sex”?
While monogamy is considered a protective factor for many sexual and reproductive
health outcomes, it is not necessarily a guarantee to be protected from HPV throughout the
lifespan. In the United States, monogamy is often conflated with serial monogamy. Most people
are not lifetime monogamists with only one sexual partner (Conley, Ziegler, Moors, Matsick, &
Valentine, 2013). The average number of lifetime partners among women in the U.S. is 3.6,
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according to the National Survey of Family Growth 2006-2008 (Chandra et al., 2011). Evidence
supports that serial monogamy is considered a risk factor for acquiring HPV. Even if a woman’s
current sexual partner is monogamous, that does not circumvent the issue of that partner’s
previous sexual network, which is critical for HPV transmission (Burchell et al., 2006).
Additionally, recent research has evaluated the prevalence of HPV in recently formed
partnerships. The study found that heterosexual dyads in their “first relationship” with vaginal
sex had a prevalence of HPV that was approximately 17% (Burchell et al., 2014).
Moreover, if a woman has one sexual partner at the time for her vaccination decision, that
does not preclude her from exposure to HPV at the time of vaccination or in the future. The
prevalence of HPV is highest among females age 20 to 24 (59.8%, 95% CI 54.0-65.3%)
(Markowitz et al., 2013). Furthermore, it is estimated that the average lifetime probability of
acquiring HPV among women with at least one male partner is approximately 85% (Chesson,
Dunne, et al., 2014). In a study examining the incidence of HPV among heterosexual couples,
women in a heterosexual relationship had a 28% (95% CI 14%-40%) cumulative incidence of
any HPV type and 17% (95% CI 8%-26%) cumulative incidence of oncogenic HPV over a 12
month period. The 24 month prevalence of HPV among women in a heterosexual couple was
67.7% for any type of HPV and 46.5% for oncogenic HPV types (Nyitray et al., 2013). This
demonstrates that the risk for HPV among women in relationships or with lower sexual risk
profiles is not as low as perceived.
Despite this evidence supporting the risk for HPV with serial monogamy, heuristic
beliefs regarding the safety of monogamy overshadow the actual risk. Monogamy is perceived as
being “safe sex” and protecting individuals from STIs. However, serial monogamy without
additional protective behaviors (e.g., STI testing, waiting an amount of time for sexual behavior)
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does not necessarily protect against STIs. In fact, serial monogamy may produce added risk for
an individual who proceeds with sexual interaction with a partner without added precautions,
such as condom use (Conley et al., 2013).

Impact of Relationship Status on Other Health Behaviors
Other sexual and reproductive health behaviors are influenced by relationship status,
specifically condom use. A similar discrepancy occurs where persons in regular, long-term
relationships have less condom use compared to more transient or new relationships (Macaluso,
Demand, Artz, & Hook, 2000; Santelli et al., 1996). However, the differences between how
condom use and HPV vaccination relates to relationship status may be attributed to the proximity
of the behavior and outcome. Condom (non-)use and its associated outcomes, such as pregnancy
and STIs, is a proximal connection between behavior and outcome. In contrast, HPV vaccination
and its associated outcomes, such as future HPV infection or HPV-associated cancers, is a more
distal association between behavior and outcome. Thus, the connection of relationship status to
perceived risk of an outcome may be operating similarly among condom use and HPV
vaccination; however, it may differ based on the proximity of the outcome (e.g., short term STI
vs. long-term cervical cancer).

Theoretical Framework
The theoretical framework utilized for this study was the Information, Motivation, and
Behavioral Skills (IMB) Model to understand and promote HPV vaccination among young adult
women (Fisher & Fisher, 2002; Fisher, 2012). This study was supplemented with two constructs
from the Health Belief Model, perceived severity and perceived susceptibility, which were
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included within the Risk Perception sub-construct of the Motivation construct of IMB
(Champion & Skinner, 2008).

IMB Model Overview
The IMB Model was developed as a way to understand HIV risk and prevention in the
context of social-psychological conceptualizations (Fisher & Fisher, 2002). Not only does the
IMB Model provide a theoretical framework that can be applied to a range of preventive
behaviors, including condom use (Misovich, Fisher, & Fisher, 1997), but it also has a
methodological approach for designing theory-based interventions. Specifically, the approach
involves three steps: elicitation, intervention design and implementation, and evaluation of the
intervention (Fisher & Fisher, 1992). The IMB Model includes three overall determinants to
behavior: information, motivation, and behavioral skills (see Table 8 for the description of each
construct and an example application to HPV vaccination). There are sub-categories within the
motivation and behavioral skills constructs, which further delineate the determinants for
behavior. In addition to these constructs, the IMB Model also recognizes macro-level factors that
may work directly or indirectly to influence a behavior (Fisher, 2012).

IMB Model Application to Condom Use and Relationship Status
As previously stated, the IMB Model was initially developed as a behavioral framework
for preventing HIV. As such, one of the health behaviors of interest was condom use.
Interestingly, previous research has been conducted to evaluate the impact of relationship status
on condom use utilizing the IMB Model, and the finding may have some application to this
current research (Misovich et al., 1997).
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Table 8: IMB Model Constructs and Application to HPV Vaccination Examples
Construct

Definition

Application

Information

Information regarding preventive behavior

Information about risk for HPV and
potential protection from HPV
vaccination

Motivation
Personal
Social
Perceived
vulnerability

Attitudes toward practicing preventive acts
Perceptions of social support for
performing acts
Perceived vulnerability to the
disease/outcome

Distrust of vaccines
Physician recommendation
Perceived vulnerability to HPV

Behavioral Skills
Objective ability
Perceived selfefficacy

Ability to perform behavior
Confidence in ability to perform behavior

Schedule appointment
Confidence to discuss vaccine with
partner

Macro Factors

Factors that directly or indirectly impact
behavior

Insurance coverage and vaccine cost

Within this model, Misovich, Fisher & Fisher (1997) posit that distinctive Information,
Motivation, and Behavioral Skills exist among persons in a relationship and the use of condoms.
Regarding Information, people in relationships are more likely to rely on heuristic beliefs that
“monogamous sex is safe sex” and “known-partners-are-safe-partners.” These beliefs may
impede the individual from appropriately evaluating the risk of unprotected sex and the risk for
HIV. Moreover, there appear to be beliefs that limit the individual from evaluating their partner’s
risk for HIV, further elevating risk. For Motivation, personal motivation for condom use is
largely associated with trust in the relationship and of the partner. Especially if the individual
does not receive social support for condom use from their partner, they are less likely to engage
in the behavior. The most important motivating factor, which aligns with the issues described in
the information construct, is the low perceived vulnerability for HIV for themselves and partners.
These are largely formed by the false heuristic beliefs that inform the risk evaluation. Finally, the
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Behavioral Skills described are unique to the self-efficacy and ability to perform behaviors
related to condom use, specifically negotiating use with a partner and maintaining proper use
(Misovich et al., 1997).
The authors of this review emphasized the unique composition of the IMB Model
constructs for persons in relationships as it relates to condom use. The deficits in each of these
constructs should be targeted for prevention interventions in order to improve condom use
(Misovich et al., 1997). Moreover, the findings from this review have implications for this
research. Specifically, the Information and Motivation constructs report heuristic beliefs, partnerspecific influences, and perceived risk that translate for HPV vaccination among women in
relationships. Thus, these findings were applied in the in-depth interview guide instrument
development to recognize the potential issues that women may face for HPV vaccination
decisions in the context of the IMB Model.

IMB Model Application to Current Study
The IMB Model was used as the theoretical framework for guiding the study of
informational needs, motivations, and behavioral skills framed by relationship status impacting
HPV vaccination among young adult females (Figure 2). The study involved an assessment of
the four constructs (i.e., information, motivation, behavioral skills, and macro-level factors),
which may influence HPV vaccination behavior among four groups of women: (1) married or
living with a partner; (2) single, but in a long-term monogamous relationship; (3) single and
dating; and (4) single, but not in a relationship or dating (Zimet et al., 2011). These constructs
were also assessed across two groups of women based on vaccination status: (1) recently HPV
vaccinated; and (2) HPV unvaccinated.
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The first construct considered is Information. Traditionally, the IMB Model has described
this construct as cognitive processes that influence a behavior. However, given that women are
receiving information from a range of health information sources (e.g., Internet, peers, family,
partners, healthcare providers) (Daley, Vamos, et al., 2010; Sandfort & Pleasant, 2009), it is
necessary to include a measure of trustworthiness or value regarding these information sources.
The more valued the information source, the more likely the woman may be to prioritize that
information (Redmond, Baer, Clark, Lipsitz, & Hicks, 2010; Worsley, 1989). Additionally,
information about HPV and the HPV vaccine can influence motivation, behavioral skills, and

Figure 2: Application of IMB Model to HPV Vaccination in Young Women

vaccination. Many women cited needing more knowledge about the vaccine as a primary barrier
to vaccination, indicating how lack of information may impact motivations or behavioral skills to
vaccination (Joseph et al., 2014; Ratanasiripong et al., 2013; Zimet et al., 2010). Moreover, from
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the literature, there appear to be heuristic beliefs that monogamous sex is safe sex or that
condoms alone can prevent the transmission of HPV (Anhang Price et al., 2011; Cohen & Head,
2013; Gelman et al., 2013; Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph et al., 2014; Laz
et al., 2013; Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). These
informational beliefs may inform how women align their current sexual health behaviors and
relationships with the need for the HPV vaccine. Therefore, Phase II of the study included a
measure of women’s basic knowledge of HPV and the HPV vaccine, as well as assess the
information’s source trustworthiness, which may impact how likely that person is to act on that
information. Additionally, in Phase I of the study, some of the NHIS reasons for nonvaccination align with these false beliefs reported in the literature (e.g., don’t know enough about
the vaccine; not sexually active). How these differ based on relationship status is reported.
The second construct is HPV vaccine motivation. Fisher & Fisher have conceptualized
this construct to include three primary components: personal motivation, social motivation, and
perceptions of personal vulnerability to the disease (Fisher & Fisher, 2002). In this study,
personal motivation encompassed factors such as attitudes about vaccination and perceived
benefits and barriers to vaccination. Additionally, social motivation included perceived support
and social norms from significant others. From the review of the literature, important others
include: healthcare providers, partners, parents/family, and peers. Therefore, this study elicited
the injunctive norms of approval/disapproval from important others for HPV vaccination.
Perceptions of personal vulnerability to HPV will also be evaluated to determine if risk
perceptions regarding acquiring HPV differ based on relationship status and motivate the need
for HPV vaccination. The concept of personal vulnerability to HPV was operationalized utilizing
the Health Belief Model constructs of perceived susceptibility and perceived severity, which

55

together operate as perceived threat. Perceived susceptibility is one’s belief regarding the chance
of getting a condition, in this case HPV and HPV-related outcomes. Perceived severity is one’s
belief of the seriousness of the health condition (Champion & Skinner, 2008). The combination
of the Health Belief Model perceived threat construct with the IMB Model has been used and
evaluated previously (DeBate et al., 2013).
Behavioral skills is the third construct of the IMB Model. This concept is typically
ignored in other health behavior theories, which only emphasize perceived ability or control,
rather than actual skill or competence to perform the behavior. The skills considered integral to
HPV vaccination include: communication with important others (e.g., healthcare provider,
partner), funding the vaccine, accessing the vaccine, and complying with the three dose series
(Fisher, 2012). To help understand the skills required for vaccination, participants were asked to
describe how they would go about obtaining the HPV vaccine (unvaccinated) or how they went
about getting the vaccine (vaccinated) in order to elicit the procedural knowledge to obtain the
vaccine.
The final construct included the macro-level factors, which are higher-level determinants
that may directly or indirectly impact behavior. From the review of the literature, it was clear that
HPV vaccination is not only situated at an intrapersonal level; rather, higher levels of influence
impact this behavior. The review of the literature revealed barriers that extend beyond a
woman’s control, including cost of the vaccine, insurance coverage, and healthcare interaction
(Anhang Price et al., 2011; Dempsey et al., 2011; Ford, 2011; Head & Cohen, 2012; Hodge et
al., 2011; Jain et al., 2009; Joseph et al., 2014; Laz et al., 2013; Lindley et al., 2013; Tiro et al.,
2012; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010). It was important to take into
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consideration these potentially significant macro-level barriers that can impact a woman’s HPV
vaccination behavior.
This study has the potential to move the IMB Model field forward by demonstrating
application of the model to the HPV vaccination topic among young adult females. Fisher (2012)
emphasized the need for research using the IMB Model for this specific behavior, HPV
vaccination. Empirical evidence to support the framework in the elicitation phase will support
the justification that this robust theory has the ability to explain vaccination behavior in this
population. Moreover, the research findings from this study can inform the development of
validated instruments for using the IMB Model for HPV vaccination in quantitative research
studies. This can eventually assist in the development and evaluation of theory-based
interventions using the IMB Model.
In summary, the IMB Model is the most appropriate theoretical framework for guiding
the research to understand why and how informational needs, motivations, and behavioral skills
may be framed by relationship status for HPV vaccination among young adult females. This
robust framework comprises information, motivation, behavioral skills, and macro-level factors
constructs that can be applied to this focused area of research.
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CHAPTER 3: METHODS

Overview
The long-term goal of this research is to increase HPV vaccination rates among young
adult women 18 to 26 years of age, ultimately decreasing HPV-related disease (i.e., HPVassociated cancers, genital warts). The purpose of this study was to understand how young adult
women’s relationship status influences informational needs, motivations, and behavioral skills
related to HPV vaccination. This objective was achieved through the following specific aims and
mixed-methods study design:

1. Assess how relationship status affects primary reasons for non-vaccination
among 18 to 26 years old women.
A secondary data analysis using the 2010 National Health Interview Survey was
conducted to determine if women in relationships were less likely to be interested in
vaccination and identify the primary reasons (e.g., misinformation, motivations,
behavioral skills) for non-vaccination among different relationship status groups.

2. Understand how relationship status frames HPV vaccine informational needs,
motivations, and behavioral skills among 18 to 26 year old women.
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In-depth interviews were completed with a sample (N=50) of 18 to 26 year old
women at the University of South Florida, stratified by relationship status and HPV
vaccine status. A comparative thematic analysis was conducted to determine if there
were differences in informational needs, motivations, behavioral skills, and HPV
decision-making.

Timeline
Table 9: Timeline for Dissertation Research Study
Activity
Dissertation proposal

Feb

Mar

Apr

May

Jun

Jul

Aug

Sept

Oct

X

X

X

X

X

X

X

X
X

X

X

X

X
Phase I

IRB approval

X

Data cleaning

X

Data analysis

X

Report findings

X
X
Phase II

Develop instruments
Pilot interview guide
and recruiting materials

X
X

Finalize instruments

X

IRB approval

X

Recruitment

X

X

Data collection

X

X

Data analysis

X

Report findings
Dissertation defense

X
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Population
HPV vaccination is approved for use among adolescent females 11 to 12 years of age, but
also as catch-up vaccination until the age of 26 (Centers for Disease Control and Prevention,
2010a; Markowitz et al., 2007). The target population for this research study was women in the
18 to 26 year old age range. Two separate samples were used in this concurrent mixed-methods
study that included this target population. The first sample for Phase I was derived from a
nationally-representative cross-sectional survey and restricted to 18 to 26 year old females who
were HPV unvaccinated. The second sample for Phase II was recruited from the University of
South Florida and included 18 to 26 year old females based on relationship status and HPV
vaccination status.

Approach
This mixed-methods study design included two separate phases that both aligned with the
study objective to understand how young adult women’s relationship status influences
informational needs, motivations, and behavioral skills related to HPV vaccination. Phase I was a
quantitative analysis of a nationally-representative health survey and Phase II was a qualitative
analysis of in-depth interviews from a smaller sample of women.

Phase I: Quantitative, Secondary Data Analysis

Overview
The purpose of this research phase was to assess how relationship status affects the
primary reasons for non-vaccination among women 18 to 26 years old. To achieve this goal, a
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secondary data analysis was conducted using the National Health Interview Survey (NHIS) 2010
with supplemental cancer questions related to HPV vaccination. Previous studies using this
dataset have reported marital status as a significant factor for HPV vaccine uptake among this
population and reported the overall primary reasons for non-vaccination; however, there has not
been a specific investigation regarding the different categories of marital status (e.g., single,
married, divorced, separated, widowed) and vaccination interest, combined with reasons for nonvaccination among young adult women (Laz et al., 2013; Schmidt & Parsons, 2014; Wei et al.,
2013; Williams et al., 2013).

Subjects and Setting
The purpose of the NHIS is to monitor the health status of the United States’ population
among civilian noninstitutionalized persons. The survey has been conducted since 1957 and the
content of the survey is continuously updated. The NHIS is a cross-sectional household interview
survey with a multistage area probability design sampling plan that is representative of
households in the United States. The sampling plan is updated following each decennial census.
Moreover, the sampling procedure oversamples for Black, Asian and Hispanic persons. For the
2010 survey, within each household sampled, one civilian adult was randomly selected to
complete the Sample Adult questionnaire. Survey participation was completely voluntary.
Details regarding the complex sampling design for the NHIS can be found in Parsons et al.
(2014). The 2010 survey data were collected through a household interview by trained
interviewers from the U.S. Bureau of the Census. The questionnaire was completed using a
computer assisted personal interviewing device, where interviewers can directly impute the
participants’ responses.
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The 2010 survey included a final sample size of 27,157 for persons 18 years of age or
older that completed the Sample Adult component of the interview. The conditional response
rate for this component among eligible sample adults was 77.3%. However, the final response
rate for the Sample Adult was 60.8% considering the refusal household response rate (Division
of Health Interview Statistics & National Center for Health Statistics, 2011a)

Phase I: Research Question I
Research question. Among unvaccinated 18 to 26 year old women, were married
women less likely to be interested in HPV vaccination compared to non-married women? It was
hypothesized that women who were married (in a relationship) were less likely to be interested in
the HPV vaccine compared to non-married women.
Sample. The sample was restricted to NHIS Sample Adults (N=27,157) who were female
and between the ages of 18 to 26 years (N=2,011). The sample was further restricted to women
who responded to the HPV vaccine questions (N=1,892) and were not vaccinated with the HPV
vaccine (N=1,461) as these participants responded to the interest in the HPV vaccine questions.
Finally, cases were removed that had missing data for the primary analysis variables, including
HPV interest (N=1) and unknown marital status (N=3). This resulted in a final sample size of
1,457 women for Analysis 1 (Figure 3).
Data collection procedures. The datasets, formats, and codebooks were downloaded
from the NHIS website. These included information from the Person, Sample Adult, Cancer
Supplement, and Income Imputation datasets. The datasets were sorted by household and persons
ID numbers (HHX and FPX) and merged together in SAS 9.4. Only variables required for this
analysis were kept in the final dataset.
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Figure 3: NHIS Sampling Strategy

Instrumentation. The variables considered for this analysis were based on previous HPV
vaccine research among young adult women (Laz et al., 2013; Schmidt & Parsons, 2014; Wei et
al., 2013; Williams et al., 2013). Univariate analysis procedures, such as Proc Survey Freq and
Proc Survey Means, were used to examine the distribution of each variable. Additionally, NHIS
codebooks were consulted to identify any skip patterns in the dataset. Based on this review, the
variables for consideration in the final model were re-coded (Table 10).
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Table 10: Recoding of Variables for Phase 1 Research Question 1 Analysis
Description

Variable

Interest in
Vaccine

HPVINT

Relationship R_MARITL
Status

Had HPV

HPVHAD

Heard HPV
Vaccine

SHHPVHRD

Abnormal
Pap Test

PAPABN3

Regular
Healthcare
Provider

AMDLONG

OB/GYN

AHCSYR7

Question
Response Categories
Primary Variables
Would you be interested in 1 Yes
getting the HPV vaccine?
2 No or Don’t Know
Are you now married,
0 Married
widowed, divorced,
1 Widowed, Divorced, or Separated
separated, never married,
2 Living with Partner
or living with a partner?
3 Never married
Health-Related Variables
Have you ever been told
0 Yes
by a doctor or other
1 No or Don’t Know
healthcare professional
that you had HPV?
Two vaccines, or shots, to 0 Yes
prevent HPV infection are 1 No
available in the United
States. Both vaccines
prevent cervical cancer
and one also prevent
genital warts. The two
HPV vaccines are
sometimes called
CERVARIX ® or
GARDASIL ®. Before
this survey, have you ever
heard of HPV vaccines or
shots?
Have you had a Pap test in 0 Yes
the LAST 3 years where
1 No (includes women who did not have
the results were NOT
a Pap in the last 3 years)
normal?
About how long has it
0 In the last year
been since you saw or
1 More than a year
talked to a doctor or other
healthcare professional
about your own health?
During the past 12 months, 0 In the last year
have you seen or talk to
1 More than a year
any of the following
healthcare providers about
your own health? A doctor
who specializes in
women’s health?
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Table 10 (Continued)
General
Physician

AHSCY8_9

During the past 12 months,
have you seen or talk to
any of the following
healthcare providers about
your own health? A doctor
who treats a variety of
illnesses (a doctor in
general practice, family
medicine, or internal
medicine)?
During the past 12 months,
have you had a seasonal
flu shot?
Have you EVER received
the hepatitis B vaccine?

Flu Shot

SHTFLUYR

Hepatitis B
Shot

SHTHEPB

Region

REGION

Hispanic

ORIGIN_I

Race

RACERPI2

Age

AGE

NHIS – Recode

Education

EDUC

Health
Insurance

NOTCOV

What is the HIGHEST
level of education you
completed or the highest
degree you have received?
NHIS – Recode

Family
Income

POVRATI3

0 In the last year
1 More than a year

0 Yes
1 No
0 Yes
1 No

Demographic Variables
NHIS – Recode
0 Northeast
1 Midwest
2 South
3 West
Does person consider self
0 Yes
Hispanic/Latino?
1 No
NHIS – Recode
0 White only
1 Black/African American only
2 Other (AIAN, Asian, Other, Multiple
Race)

NHIS – Recode and
Multiple Imputation
Ratio of family income to
the federal poverty level
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0 18-21 years
1 22-26 years
0 Less than High School Diploma
1 GED or High School Diploma
2 More than High School
0 Not covered or Don’t know
1 Covered
0 200% +
1 100% < 200%
2 < 100%

The initial research plan intended to utilize personal reported income in the last year as a
measure of income for this analysis. However, upon examining the frequencies for this variable,
440 participants had missing data (due to skip pattern of being an unemployed adult), 106 did not
know, and 43 refused to answer. Due to the amount of missing data for the income variables in
the NHIS dataset, multiple imputation was utilized as an analysis tool to account for the missing
data. Five separate datasets were developed by the NHIS with the imputed values for family
income. These imputations were based upon a variety of demographic and health-related
variables. The imputed family income variable was transformed using the U.S. Census Bureau’s
poverty threshold to calculate the poverty ratio value (Division of Health Interview Statistics &
National Center for Health Statistics, 2011b).
For this analysis, the Income Imputation file was downloaded from the NHIS website and
the SAS code for multiple imputation was used to generate the 5 separate imputed datasets. Each
of these datasets was merged with the primary study dataset including the variables listed above.
Family poverty ratio was the only variable in this analysis that included imputed values. This
continuous variable was then transformed into a 3-level categorical variable (<100%, 100% <
200%, and 200% + of the federal poverty level).
Data analysis. All analysis procedures utilized survey-weighted SAS 9.4 procedures,
unless otherwise specified. These survey-weight procedures were weighted using primary
sampling units, strata and clustering variables (STRAT_P, PSU_P, and WFTA, respectively).
Univariate descriptive statistics were computed for each variable after re-categorization using
frequencies. Due to limitations in multiple imputation analysis using Proc Survey Freq, only the
first multiple imputation dataset was used to report poverty level frequencies. Bivariate
frequencies and Rao-Scott chi-square tests were then calculated to compare each independent
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variable to the outcome variable, interest in HPV vaccine. The Rao-Scott chi-squared test was
used since it is the default chi-square test for survey-weighted data. It uses a simple correction to
the Pearson chi-square test, which accounts for the complex sampling design of the survey that
limits the assumption of independent and identically distributed observations. This correction
considers the generalized design effect of the data (Rao & Scott, 1981).
Model building. Survey logistic regression was used to estimate the crude odds ratios and
95% confidence intervals between the outcome variable and each independent variable. This
provided the unadjusted effect for each variable on interest in the HPV vaccine. Interaction was
then assessed prior to evaluating potential confounding (Kleinbaum, Kupper, Nizam, &
Rosenberg, 2014). Since the primary purpose of this analysis was to describe the impact of
relationship status on HPV vaccine interest, the approach for assessing effect modification
examined only the primary predictor variable of interest (i.e., relationship status) with all other
independent variables. These models were hierarchically well-formulated, meaning it included
the interaction term (relationship status and the independent variable tested) and the two main
effects for these variables. None of the interaction models produced a significant interaction term
(p>0.10); therefore, it was determined that effect modification of the relationship status and HPV
vaccine interest association was not present.
Next, models were fitted to estimate the odds of interest in the HPV vaccine with
relationship status and each remaining predictor variable. The purpose of this exercise was to
screen for confounders to include in the final analysis model. Confounders were screened for
inclusion in the model if addition of that variable resulted in a change of the adjusted odds ratios
of more than 10% (Greenland & Rothman, 2008). However, no variables produced a 10%
change. Therefore, in order to develop the final model for analysis, crude odds ratios were
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examined for significance with the outcome variable and the literature was consulted for the
most salient confounding variables. This selection process produced the final model for
consideration to include the following variables: relationship status, Hispanic, race, region, age,
insurance coverage, poverty ratio, abnormal Pap test, heard of the HPV vaccine, flu shot in last
12 months and receipt of the hepatitis B vaccine.
Model diagnostics. Model assumptions for logistic regression were assessed; these
include: detecting outlying or influential points (Pearson residuals and DFBETAs), a test of
linearity for continuous predictors (not applicable), and model fit assessment (HosmerLemeshow Goodness of Fit Test) (Vittinghoff, Glidden, Shiboski, & McCulloch, 2005). Note
that the diagnostic procedures for the model did not utilize survey weights as SAS 9.4 does not
support these procedure options in survey-weighted models. The plots for the Pearson residuals
and DFBETAS did not identify any observations that would be considered outliers or influential.
The Hosmer-Lemeshow Goodness of Fit Test produced a chi-square value of 3.1330 and a pvalue of 0.9257. This non-significant value indicated no gross lack of fit with the model.
Additionally, the c-statistic for the model was 0.668.
The model was also assessed for multicollinearity. While the logistic regression function
in SAS 9.4 does not support the ability to assess multicollinearity, linear regression functions can
be used since these assessments do not rely on the outcome variable (IBM, 2014). A linear
regression model was fitted with the binary outcome variable and predictors. All categorical
predictors were re-coded as dummy variables for this analysis. This model produced the
tolerance and variance inflation factors used to assess multicollinearity. None of the predictor
variables had a tolerance level less than 0.2 or a variance inflation factor greater than 5,
indicating multicollinearity was not present in the model (Logan, 2011).
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This study was adequately powered to investigate the research question in Analysis 1,
which used logistic regression. According to a preliminary sample size analysis using G*Power,
the sample size of 1,457 was more than the minimum 849 required for 95% power (Faul,
Erdfelder, Lang, & Buchner, 2007). This power analysis was based on the following criteria: two
tailed test, odds ratio of 1.30, proportion of women interested in the vaccine who are in a
relationship 35%, alpha level 5%, and power level 95%. The parameter for the prevalence in the
unexposed is based on previous research: 35% proportion of women interested in the vaccine
who are in a relationship (Schmidt & Parsons, 2014). The hypothesized odds ratio represents a
small effect size (Chen, Cohen, & Chen, 2010).
Final model. Survey weighted logistic regression was used to produce crude and adjusted
odds ratios and 95% confidence intervals for the odds of interest in the HPV vaccine with the
following independent variables: relationship status, Hispanic, race, region, age, insurance
coverage, poverty ratio, abnormal Pap test, heard of the HPV vaccine, flu shot in last 12 months
and receipt of the hepatitis B vaccine. This model included the domain function to account for
the 5 imputed datasets for the poverty ratio variable. SAS multiple imputation analysis
procedures (PROC MIANALYZE) was used to estimate the model effects of the log odds ratios
and log odds 95% confidence interval for each variable. These were then exponentiated to
produce odds ratios and 95% confidence intervals, while accounting for the imputed data.
Prevalence ratios. The odds ratios and 95% confidence intervals produced by the logistic
regression models (crude and adjusted) were converted to prevalence ratios due to the high
prevalence of the outcome in this analysis (Zhang & Yu, 1998). The equation for conversion is:
RR = OR / (1 – PO) + (PO x OR). The prevalence of the outcome in each reference category was
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used to estimate the prevalence ratio. The prevalence ratios and 95% confidence interval were
reported.
Sensitivity analysis. Due to the small frequency of the Widowed, Separated, and
Divorced relationship status category (<5%), a sensitivity analysis was conducted to determine if
removing this group from the final model affected the measures of effect significantly. The same
procedures for multiple imputation, logistic regression, and prevalence ratio conversions were
used on a subset of the data excluding women in the “Widowed, Separated, and Divorced”
category (N=1,392). A threshold of 10% was used for each measure of effect to determine if
significant change had occurred between the final model and the sensitivity analysis model.

Phase I: Research Question II
Research question. Among unvaccinated 18 to 26 year old women, who are not
interested in the vaccine, is there an association between relationship status and the primary
reasons for non-vaccination? It was hypothesized that there were differences in primary reasons
for non-vaccination among relationship status group categories.
Sample. The sample was restricted to NHIS Sample Adults (N=27,157) who were female
and between the ages of 18 to 26 years (N=2,011). The sample was further restricted to women
who responded to the HPV vaccine questions (N=1,892), were not vaccinated with the HPV
vaccine or refused this question (N=1,479), and reported being not being interested in the HPV
vaccine or don’t know if interested in the HPV vaccine (N=988) as these participants responded
to the reasons for not interested in the HPV vaccine questions. Finally, cases were removed that
had missing data for the primary analysis variables, including unknown marital status (N=3) and
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refusing the primary reason for non-vaccination question (N=1). This resulted in a final sample
size of 984 women for Analysis 2.
Data collection procedures. The datasets, formats, and codebooks were downloaded
from the NHIS website. These included information from the Person, and Sample Adult, Cancer
Supplement datasets. The datasets were sorted by household and persons ID numbers (HHX and
FPX) and merged together in SAS 9.4. Only variables required for this analysis and descriptive
sample variables were kept in the final dataset.
Instrumentation. Two variables were of interest for this research question, specifically
primary reason for non-vaccination and relationship status. Univariate frequency analysis
procedures were used to examine the distribution of each variable. Based on this review, the
relationship status variable was re-coded (Table 11).

Table 11: Recoding of Variables for Phase 1 Research Question 2 Analysis
Description

Variable

Relationship R_MARITL
Status

Primary
Reason

HPVNOT

Question
Response Categories
Primary Variables
Are you now married,
0 Married
widowed, divorced,
1 Widowed, Divorced, or Separated
separated, never
2 Living with Partner
married, or living with a 3 Never married
partner?
What is the MAIN
01 Does not need vaccine
reason you would NOT 02 Not sexually active
want to get the vaccine? 03 Too expensive
04 Too old for vaccine
05 Doctor didn't recommend it
06 Worried about safety of vaccine
07 Don't know where to get vaccine
08 My spouse/family member is against it
09 Don't know enough about vaccine
10 Already have HPV
11 Other
99 Don't know
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Data analysis. Univariate survey-weighted frequencies were computed for the reasons
for non-vaccination variable and the relationship status variable. Next, a bivariate crosstabulation was calculated for these two variables, which revealed multiple cells with less than 5
observations. Due to the survey-weighting of these data and lack of exact tests available for these
survey procedures in SAS (SAS Institute Inc., 2015), data were transformed for the surveyweighted chi square test to determine if there was an association between relationship status and
reasons for non-vaccination. The cross-tabulations indicated the majority of the missing data was
in the Widowed, Separated, and Divorced relationship status category, therefore this was
removed from the final analysis (N=940). Additionally, the top four reasons for non-vaccination
were identified and the remaining reasons were combined into an “other” category to allow for
the chi-square test to be operational with the survey-weighted procedures. The top four reasons
were selected because remaining survey responses had cells with small numbers, which SAS
survey procedures are not equipped to handle (i.e., Fishers Exact test is not available with survey
procedures in SAS) (SAS Institute Inc., 2015).

Phase II: Qualitative Interviews, Young Adult Women

Overview
The purpose of Phase II was to understand how relationship status frames HPV vaccine
informational needs, motivations, and behavioral skills among 18 to 26 year old women. Indepth interviews with college women were conducted. Qualitative methods were preferred in this
instance since the research question aimed to understand and explain people’s views and
behaviors, ultimately using an interpretivist approach (Hennink, Hutter, & Bailey, 2011b).
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Additionally, this methodology was consistent with the IMB Model approach to study design
(Fisher & Fisher, 2002). The first step is the elicitation process to identify the existing
information, motivation, and behavioral skills for the health promotion behavior (Fisher &
Fisher, 2002).

Subjects and Setting
Phase II recruitment and data collection was conducted between March 2015 and April
2015. The target population for this research question was women between the ages 18 to 26
years at the University of South Florida. Women were recruited for participation through
multiple modalities in order to increase participation, which included: (1) course announcements
in multiple disciplines across campus (e.g., public health, anthropology, nursing), (2) on-campus
flyers at different locations (e.g., Education Building, Interdisciplinary Sciences Building,
College of Medicine, Morsani Center, Library, and Gym), (3) various USF
department/organization listserv announcements (e.g., Department of Civil and Environmental
Engineering, Department of Anthropology, USF Sororities), (4) handouts distributed through
Student Health Services healthcare providers at USF, and (5) a mass-informational email to all
USF-Tampa female students between the ages of 18 and 26 years. The combination of these
recruitment methods resulted in 1,113 people taking the recruitment eligibility survey (Appendix
A). Women who completed the survey and in-depth interview were provided an electronic $10
gift card to either Amazon or Starbucks.
Moreover, the study used quota sampling strategy (Bernard & Ryan, 2010e). There were
eight stratified sub-groups for which adequate sample sizes were aimed to reach. Participants
were stratified by relationship status (married or living with a partner; single but in a long-term
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monogamous relationship; single and dating; single but not in a relationship or dating) and HPV
vaccination status (vaccinated in the last six months or non-vaccinated). The categorization for
relationship status was based on previous research conducted by Zimet et al. (2011) regarding
healthcare providers’ preferences for HPV vaccination based on relationship status and sexual
history. This provided built in variability to the data to assess the impact of relationship status on
information, motivation, and behavioral skills related to the vaccine. According to Guest et al.
(2006) major themes and saturation can be achieved at a minimum of six interviews (Guest,
Bunce, & Johnson, 2006). The minimum number of women that were recruited for each stratum
was six with the option of adding additional participants to reach data saturation. This resulted in
a total of 50 participants; six per stratum, except for the long term monogamous relationship
status categories, which each had 7 participants in attempt to reach data saturation (Table 12).

Table 12: Phase II Samling Strategy
Unvaccinated

Vaccinated

Married or living with a
partner

N=6

N=6

Single, but in a long-term
monogamous relationship

N=7

N=7

Single and dating

N=6

N=6

Single, but not in a
relationship or dating

N=6

N=6

74

Women were eligible for the study if they met the following criteria: (1) student at the
University of South Florida, (2) between 18 and 26 years of age, (3) has not received any doses
of the HPV vaccine OR has received the first dose of the HPV vaccination series in the last 6
months; (4) speaks English, and (5) provides informed consent. Women were screened to
determine which stratified category for sampling they qualify. The only exclusion criterion was
if sampling was completed for a category.

Recruitment Challenges
The recruitment process for seven out of the eight strata was achieved in a two week
period in March and April 2015. However, only two women started the eligibility survey and fell
in the married/living with a partner and recently vaccinated category; one was interviewed and
one did not provide contact information. To help assist in the recruitment process for this group
of women, the recruitment handouts and announcements were revised to specify these specific
relationship status and vaccination criteria. These were then distributed through USF’s
organizations listserv. Through this second round of recruitment, an additional five women were
recruited and participated in the study.

Data Collection Procedures
The recruitment and sampling plan included multiple steps (Figure 4). Recruitment
announcements were distributed through the modalities previous described. Within these
recruitment materials was a link and/or QR code to a web-based survey to screen for eligibility
through Qualtrics (Qualtrics, 2013). Persons who were eligible to participate then completed an
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Figure 4: Phase II Procedures

informed consent document, demographic questions, knowledge questions and provided contact
information to schedule the in-depth interview (i.e., name, email, phone number). Among
persons who completed the baseline eligibility survey, selected participants scheduled a 20 to 25
minute in-depth interview via telephone or Skype (based on participant’s preference). Due to the
high volume of women responding to the eligibility survey and providing contact information in
some of the quota sampling strata, eligible participants were contacted on a first-come first-serve
basis, as well as with consideration for scheduling preferences. The eligibility survey was
initiated by 1,331 persons; 60% received the HPV vaccine, 31% never received the HPV
vaccine. Among the sample initiating the survey, 7% received the HPV vaccine in the last 6
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months. Among those persons, 388 were eligible, 375 consented, and 352 completed the entire
survey with contact information. Therefore the response rate among those considered eligible for
the study was 90.7%. The women selected for an in-depth interview were contacted via email
with multiple dates and times to schedule an interview based on the participant’s preferences.
All interviews were conducted over the telephone, which was the preference of all
participants rather than using video conferencing. During the interview administration, field
notes were written to allow the interviewer to reflect on important details of the interview, which
may not have been captured by reading transcripts in data analyses. All interviews were audiorecorded with two devices (one for back-up). Audio-recordings were then be transcribed
verbatim (11 were transcribed by the researcher and 39 were transcribed using professional
services – Verbalink). Transcriptions did not include participants’ names or any other type of
identifying information. Once transcriptions were completed, the audio files were destroyed to
protect participants’ confidentiality. A unique participant identifying number was used to link the
survey content to the interview transcript/audio file. Data from the surveys were downloaded
from USF Qualtrics (Qualtrics, 2013). The names and contact information from the participants
were only used for scheduling the interview. Once the interview was completed the names and
contact information were destroyed.

Instrumentation
Four sets of instruments were developed for Phase II data collection: (1) eligibility
questionnaire; (2) demographic questions; (3) knowledge questions; and (4) semi-structured
interview guide (Appendix B). These instruments were pre-tested with three individuals who
were similar to the target population of this study and who were not included in the final sample.
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This assisted in the quality of the instruments prior to implementation for data collection. The
primary purpose of the pilot tests was to assess content validity, feasibility, and acceptability of
the interview guide. The norm for qualitative interviews is to pilot test with a few interviews
among people with similar characteristics to the target population (Hennink, Hutter, & Bailey,
2011a).
Eligibility questionnaire. The eligibility questionnaire asked participants screening
questions based on inclusion criteria. These included sex (female), age (18 to 26), HPV
vaccination status (not-vaccinated or vaccinated within the last 6 months), and relationship
status. Persons who met the criteria continued with the demographic and knowledge questions.
Those persons who did not meet the criteria ended the survey.
Demographic questions. The participant demographic questions described the
respondent’s socio-demographics (e.g., race/ethnicity, insurance status, sexual orientation).
Knowledge questions. The knowledge questions were a true/false format and content
related to HPV transmission and the HPV vaccine. The knowledge test was the validated HPV
vaccine knowledge scale, previously administered to college females (Daley, Vamos, et al.,
2010). These close-ended questions objectively assessed the HPV and HPV vaccine knowledge
level among participants. Additionally, the respondents were asked to report information sources
for the HPV vaccine.
Interview guide. The interview was conducted using a semi-structured interview guide.
The interview guide was developed using the constructs from the IMB Model (i.e., Information,
Motivation, Behavioral Skills, and Macro Factors) and preliminary research related to condom
use and relationship status using the IMB Model (Fisher & Fisher, 2002; Fisher, 2012; Misovich
et al., 1997). Questions regarding perceived vulnerability/threat to HPV were developed based
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on constructs of perceived severity and perceived susceptibility in the Health Belief Model
(Champion & Skinner, 2008). All questions were open-ended with probing questions to allow for
more detail (Bernard & Ryan, 2010a). Moreover, the content validity of the interview guide was
examined by the IMB Model co-creator, William A. Fisher PhD, Distinguished Professor in the
Department of Psychology and the Department of Obstetrics and Gynecology at the University
of Western Ontario.
During the data collection process, an additional question was added to the information
section of the interview guide. Women reported on who they have heard about the HPV vaccine
from and who they trusted the most. However, to add detail on where they wished to receive
more information from, a question on information source preferences for the future was asked.
These modifications were added after pilot testing of the interview guide.

Pilot Testing
Pilot testing was conducted on March 12, 2015 with three subjects. Two were
unvaccinated, but one was “living with a partner” and the other was “single, but not dating.” One
was vaccinated and “living with a partner.” The length of the interviews was between 15 to 25
minutes. The pilot test entailed completing the online survey and the telephone interview. After
the survey and interview was completed, the pilot participants were asked their feedback on the
instruments and the process.
The primary area that required revisions was the beginning portion of the interview – the
information section and transition to the remaining part of the interview. Prior to conducting the
interview, the scores from the knowledge survey for each participant were reviewed to identify
three to four questions that the participants were unsure about or were incorrect. These were used
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to fill the stem, “People mention ________. What do you think about this statement? Why?”
Participants had a difficult time describing how they felt about the statement. Their responses
were either, “I don’t know” or “I don’t know a lot about HPV.” This important feedback
informed revisions of the interview instrument. Moreover, the revisions assisted in standardizing
this section of the interview guide. First, any similarities between the three pilot participants on
questions that were frequently missed on the knowledge scale were examined. Next, the survey
results from Daley et al. (2010), which was conducted among female college students, was
evaluated to determine the most frequently missed questions. These two processes elucidated
general categories of information that were frequently missed to HPV and the HPV vaccine. The
information questions were revised as follows:
1. What are some of the things you know about HPV?
a. Probe: Transmission
b. Probe: Outcomes – cancer, genital warts, herpes, HIV
c. Probe: Curability and length of infection
2. What are some of the things you know about the HPV vaccine?
a. Probe: Who can get it?
b. Probe: When should you get it?
c. Probe: Any negative effects associated with it?
The next area identified that required modifications was transitions. First, after the
participant was asked if the conversation can be audio-recorded, they were then ask, “So to start,
what do you think about the HPV vaccine?” This overlapped with some of the information
elicited in the information section. Therefore, this question was removed. Second, the interview
guide contained a script describing the HPV vaccine so that all participants move forward in the
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interview with basic knowledge about the vaccine. One of the pilot participants mentioned that
because she had low knowledge about the vaccine, she thought this was only being read to her
due to her low knowledge. She was reassured that this was not the case, and she recommended
including a statement prior to reading this script that this is read to all participants and is part of
the standard procedures for the interview. As a result, prior to reading the HPV vaccine
description, the interview guide included:
“I am going to read you a quick description of the HPV vaccine. I read this to all
participants in the interview that way we are all on the same page moving forward
with our conversation. Is that okay?”
Finally, I reflected as the interviewer on how the three pilot interviews went. I needed to be
cognizant of my affirmations and include a larger variety other than “okay.” I realized that I used
this throughout the interviews due to the fact that it is being conducted on the telephone. I want
the interviewee to know that I am paying attention to what they are saying by verbally
acknowledging it, since they cannot see my body cues. Additionally, I needed to be comfortable
with the interview guide in order to be flexible with the order of questions. Overall, the pilot
testing was a needed exercise to revise the instruments and practice the interviewing process.

Data Analysis
Qualitative data analysis is a cyclical and iterative process. First, a codebook was
developed with the a priori deductive codes based on the IMB Model. Each code contained a
code name, description, and examples. Open coding was conducted to apply these initial
deductive codes to the data. Additionally, during this process, emergent codes were identified
and added to the codebook (Bernard & Ryan, 2010d; Vamos, n.d.). These emergent codes
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included anti-vaccine movement and personal decision. The constant comparative method was
used to assist in categorizing codes (Bernard & Ryan, 2010c). Once all the codes were applied to
the transcripts, themes and relationships among codes were identified through axial coding.
Summaries of major themes were written, and representative quotes were selected. A final read
through of the data was conducted using selective coding to validate the relationships between
categories (Bernard & Ryan, 2010d; Vamos, n.d.). Throughout the coding process, memos were
written to document emerging ideas, insights, or thoughts related to the data analysis. Data
analysis was conducted using Atlas.ti 7 data management software (Atlas.ti Scientific Software
Development, 2012).
Because stratified groups of women were sampled for this study, a comparative thematic
analysis was used to compare and contrast information, motivation, behavioral skills, and macro
factors among the groups (Bernard & Ryan, 2010c; Guest, MacQueen, & Namey, 2012).
Specifically, matrices were developed to quantitatively and qualitatively compare the content of
the codes across interviews within stratified groups. Four group comparisons occurred during
data analysis (Figure 5). These included: (1) comparing the IMB themes across the four different
relationship status categories among unvaccinated women; (2) comparing the IMB themes across
the four different relationship status categories among vaccinated women; (3) comparing the
IMB themes across vaccination status among women single and single and dating; and (4)
comparing the IMB themes across vaccination status among women in married or living with a
partner and single, but in a long-term monogamous relationship.
Within each of these groups, data saturation was assessed. Saturation is reached once
information is no longer being added with each additional interview (Glaser & Strauss, 2009).
The study design of including at least six participants per group was based on empirical evidence
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that data saturation can be reached at this level (Guest et al., 2006). While composing summary
statements for each group among major themes for this analysis, saturation was assessed by

Figure 5: Phase II Analysis Strategy

reviewing the homogeneity of the participant responses. The two groups for long-term
monogamous relationship status required additional interviews to reach data saturation due to
outlier cases in the sample. As a result, one interview was added to each of these two groups.
One method to improve the objectivity of results was to assess the reliability of the data
analysis process. Inter-rater reliability is a methodology used to compare the coding process
between one or more individuals (Bernard & Ryan, 2010b). The purpose was to confirm that the
coding process was systematic and reproducible. To determine the reliability of the coding
process and codebook, an additional researcher coded 10% of the transcripts to produce an interrater reliability measure. Once the primary researcher (Thompson) coded all of the transcripts
(N=50), a second researcher then coded 10% sample of the transcripts (N=5) independently
using the developed codebook. Any discrepancies in the codes were discussed between coders
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and a final decision on the appropriate approach to proceed was determined. A threshold of a
Cohen’s kappa of 80% was used to indicate “almost perfect agreement” among coders (Bernard
& Ryan, 2010b; Landis & Koch, 1977). The inter-rater reliability coding process for this study
produced a Cohen’s kappa of 88% indicating almost perfect agreement.

Triangulation
The findings from Phases I and II meaningfully informed the interpretation of the overall
results. Phase I quantitatively reported the differences in the primary reason for non-vaccination
by relationship status among young adult women using a nationally representative sample. Phase
II elicited the knowledge and perceptions of young adult women to explain why these reasons
may exist. Together this provided an overall picture of the disparities for HPV vaccination as it
relates to relationship status among young adult women with generalizability and depth.

Protection of Human Subjects
This project aimed to protect the human subjects involved. The project received two
separate Institutional Review Board (IRB) approvals prior to commencement of each phase of
the research study. This project was non-invasive and presented minimal risk to human subjects.
Subjects were women between the ages of 18 and 26 years old. There were two aims, each of
which had different human subjects, risks and benefits, and data monitoring plans.

Phase I
To achieve the specific aim of Phase I, a secondary data analysis of NHIS 2010 was
conducted. This is a publically available dataset distributed by the National Center for Health
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Statistics. The data are de-identified, thus protecting the anonymity and confidentiality of
participants. Therefore, this phase was categorized as Exempt Review of Human Subjects
Research, Category Four according the University of South Florida IRB. Data were downloaded
from the CDC website and stored on a personal hard drive. All results were reported in aggregate
numbers and cells less than five were not reported.

Phase II
Human subjects. To achieve the specific aim of Phase II, in-depth interviews were
conducted with young adult 18 to 26 year old women attending the University of South Florida.
Women were recruited through announcement, handouts, and flyers at the University of South
Florida. Fifty were recruited and invited to participate in a scheduled interview. Women were
eligible for the study if they meet the following criteria: (1) student at the University of South
Florida, (2) between 18 and 26 years of age, (3) has not received any doses of the HPV vaccine
OR received the first HPV vaccine within the last 6 months; (4) speaks English, and (5) provides
informed consent. Women were provided an informed consent form electronically during the
eligibility screening questionnaire, which required a check box to consent prior to proceeding
with the survey. Women who consented were asked to provide contact information to schedule
an in-depth interview that would last approximately 30 to 45 minutes. The interview was
conducted via telephone. An in-depth interview guide was used to lead the interview and was
based on the IMB Model constructs. The interview was audio-record and transcribed. All
identifiers were removed and the data de-identified. Additionally, participants completed the
eligibility questionnaire, as well as a knowledge survey scale. These were collected using
Qualtrics. All data were de-identified and only linked to using a unique participant code. The
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unique participant code was only linked to a participant’s name and contact information (phone
and email) to schedule and contact for the follow-up interview. Once a contact and interview was
conducted, the identifying information was destroyed. No identifiers were included in any report
or dissemination product following this research. All electronic files were stored on a password
protected computer.
This study followed all guidelines designated by the USF IRB, including informed
consent and voluntary participation/withdrawal from the study.
Risks and benefits. The following risks were reasonable in relation to the benefits of this
study. This research was considered to be minimal risk. There were no known additional risks
for participating in this study. While name and contact information data were collected, these
were not linked to any participant data from the surveys or interviews. No personally identifying
information was used in any dissemination products.
There were limited benefits to participating in this study. All participants contributed to
formative research for future HPV vaccination interventions that will benefit the larger public.
Moreover, participants were offered $10 for their time and participation.
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CHAPTER 4: RESULTS

Overview
The goal of this study was to understand the information, motivation, and behavioral
skills related to HPV vaccination among young adult women. The results of this dissertation are
presented in two sections. First, the quantitative analysis of the National Health Interview Survey
2010 is presented, which examined the association between relationship status and interest in
HPV vaccination among unvaccinated women. Second, the results of the qualitative analysis of
information, motivation, and behavioral skill decision-making factors for HPV vaccination
among a sample of college women interviewed are presented.

Phase I: Quantitative Analysis
The quantitative analysis for Phase I comprised two separate research questions used to
examine the National Health Interview Survey 2010.

Phase I Research Question I – Interest in HPV Vaccination
Description of sample. The final analytic sample from the NHIS 2010 dataset comprised
1,457 women (Table 13). The majority of women had no interest in receiving the HPV vaccine
(69%). With regard to relationship status, over half were never married (59%), and the remaining
were married (22%), living with a partner (14%), or widowed, divorced, or separated (4%).
Demographic characteristics revealed the majority of the sample was non-Hispanic, White, from
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the South, between the ages of 22 and 26, had insurance coverage, and 200% above the poverty
ratio. Nearly 70% of women had heard of the HPV vaccine in the past. Within the sample, only
11% had a previous abnormal Pap test and 11% had a flu shot in the past 12 months. Over half of
participants received the Hepatitis B vaccine previously.
Bivariate analyses. Each predictor variable was examined with the outcome variable,
interest in the HPV vaccine. Significant associations were found for all variables, except for race,
age, and insurance coverage (Table 13). Crude prevalence ratios estimated the effect size for the
association between the predictor variable and outcome variable. Women who were living with a
partner (PR=1.50, 95%CI 1.13-1.92) or never married (PR=1.41, 95%CI 1.14-1.71) were
significantly more likely to be interested in the HPV vaccine compared to married women. There
were no significant differences between women who were married and women who were
widowed, divorced, or separated. Additionally, women who were Hispanic, <100% below the
poverty ratio, had a history of an abnormal Pap test, heard of the HPV vaccine, had a flu shot in
the last 12 months, and received the Hepatitis B vaccine were more likely to be interested in the
HPV vaccine. Women living in the Midwest were less likely to be interested than women living
in the South.
Final model. The final regression model examining the effect of relationship status on
interest in HPV vaccination adjusted for Hispanic ethnicity, race, region, age, insurance
coverage, family poverty ratio, abnormal Pap history, heard of the HPV vaccine, flu shot in the
last 12 months, and ever received the Hepatitis B vaccine (Table 14). Compared to crude effects,
the adjusted model had attenuated effects for living with a partner (PR=1.50; aPR=1.44), region
(Midwest: PR=0.73, aPR=0.71), abnormal Pap (PR=1.79, aPR=1.75), and Hepatitis B vaccine
(PR=1.37, aPR=1.30), while having an augmented effect for Hispanic (PR=1.25, aPR=1.39),

88

<100% of the poverty level (PR=1.24, aPR=1.27), heard of the HPV vaccine (PR=1.53,
aPR=1.58), and had a flu shot (PR=1.41, aPR=1.49).
Women who were living with a partner (PR=1.44, 95% CI 1.07-1.87) or never married
(PR=1.41, 95% CI 1.12-1.73) were more likely than married women to be interested in the HPV
vaccine. There were no significant differences between women who were married or widowed,
divorced, or separated. Hispanic women were more likely to be interested in the vaccine
compared to non-Hispanic women (PR=1.39, 95% CI 1.15-1.64). Other significant demographic
factors include women living in the Midwest being less likely to be interested in the vaccine
compared to women living in the South. Additionally, women below 100% of the poverty level
compared to women 200% or more above the poverty level were more likely to be interested.
Other health indicators also significantly increased likelihood of interest in the HPV vaccine,
including having an abnormal Pap test, having a flu shot, and having the Hepatitis B vaccine.
Finally, women who have heard of the HPV vaccine were 58% more likely to be interested in the
vaccine compared to women who had not heard of the vaccine.
Sensitivity analysis. Among the sample of 1,457 women for this analysis, 0.3% were
widowed, 1.8% were divorced, and 2.3% were separated. Due to the low frequencies of these
groups, and as a combined group, a sensitivity analysis was conducted, which examined the full
model while excluding these records (N=1,392). Comparing the adjusted prevalence ratios of the
full model with the adjusted prevalence ratios of the sensitivity analysis did not identify any
changes greater than 10% in the measures of effect (Table 15). Therefore, this group did not
significantly alter the prior analysis.
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Table 13. Frequencies of Demographic and Health Characteristics by Interest in the HPV
Vaccine among the NHIS 2010 Sample of Women 18-26 Years (N=1,457)
Variable
HPV Interest
Yes
No
Relationship Status
Married
Widowed, Div, Sep
Living with Partner
Never Married
Hispanic
Yes
No
Race
White
Black
Other
Region
South
Northeast
Midwest
West
Age
18-21 years
22-26 years
Insurance Coverage
Yes
No
Poverty Ratio
200% +
100 < 200%
< 100%
Abnormal Pap Test
Yes
No
Heard of the Vaccine
Yes
No
Flu Shot last 12 mo
Yes
No
Hepatitis B Vaccine
Yes
No

N Total

% Total

483
974

31.5%
68.5%

313
65
211
868

22.1%
4.3%
14.2%
59.4%

N Yes

% Yes

85
21
77
300

23.7%
30.9%
35.6%
33.4%

P-value

<0.01

<0.01
366
1091

14.6%
85.4%

138
345

38.0%
30.4%
0.28

998
296
163

74.4%
17.0%
8.6%

320
107
56

30.6%
35.4%
31.6%

563
188
325
381

39.3%
14.2%
25.7%
20.8%

209
56
84
134

34.6%
28.7%
25.1%
35.5%

463
994

31.6%
68.4%

150
333

31.1%
31.6%

1043
414

73.3%
26.7%

342
141

31.6%
31.2%

566
363
528

41.9%
24.2%
33.9%

172
120
191

27.9%
32.8%
35.0%

161
1296

11.1%
88.9%

84
399

51.8%
28.9%

954
503

70.4%
29.6%

358
125

35.1%
22.9%

159
1298

11.3%
88.7%

68
415

42.3%
30.0%

<0.01

0.85

0.90

0.03

<0.01
<0.01

<0.01

<0.01
805
652

57.4%
42.6%

90

315
168

35.5%
26.0%

Table 14. Crude and Adjusted Converted Prevalence Ratios for Interest in the HPV Vaccine
among the NHIS 2010 Sample of Women 18-26 Years (N=1,457)
Variable
Relationship Status
Married
Widowed, Div, Sep
Living with Partner
Never Married
Hispanic
Yes
No
Race
White
Black
Other
Region
South
Northeast
Midwest
West
Age
18-21 years
22-26 years
Insurance Coverage
Yes
No
Poverty Ratio
200% +
100 < 200%
< 100%
Abnormal Pap Test
Yes
No
Heard of the Vaccine
Yes
No
Flu Shot last 12 mo
Yes
No
Hepatitis B Vaccine
Yes
No
†OR = odds ratio

%Interest

Crude OR†
(95% CI) ††

Crude PR†††
(95% CI)

Adjusted OR
(95% CI)

Adjusted PR
(95% CI)

23.7%
30.9%
35.6%
33.4%

Referent
1.44(0.78, 2.66)
1.78(1.18, 2.69)
1.62(1.19, 2.19)

Referent
1.30(0.82, 1.91)
1.50(1.13, 1.92)
1.41(1.14, 1.71)

Referent
1.36(0.73, 2.54)
1.67(1.09, 2.56)
1.62(1.17, 2.24)

Referent
1.26(0.78, 1.86)
1.44(1.07, 1.87)
1.41(1.12, 1.73)

38.0%
30.4%

1.41(1.09, 1.82)
Referent

1.25(1.06, 1.46)
Referent

1.68(1.24, 2.27)
Referent

1.39(1.15, 1.64)
Referent

30.6%
35.4%
31.6%

Referent
1.24(0.95, 1.63)
1.05(0.73, 1.51)

Referent
1.16(0.96, 1.37)
1.03(0.79, 1.31)

Referent
1.23(0.90, 1.69)
1.19(0.81, 1.74)

Referent
1.15(0.93, 1.40)
1.12(0.86, 1.42)

34.6%
28.7%
25.1%
35.5%

Referent
0.76(0.57, 1.02)
0.63(0.48, 0.84)
1.04(0.79, 1.37)

Referent
0.83(0.67, 1.01)
0.73(0.58, 0.89)
1.03(0.85, 1.21)

Referent
0.75(0.53, 1.05)
0.61(0.45, 0.82)
1.05(0.78, 1.42)

Referent
0.82(0.64, 1.03)
0.71(0.56, 0.88)
1.03(0.84, 1.24)

31.1%
31.6%

Referent
1.02(0.80, 1.31)

Referent
1.02(0.85, 1.20)

Referent
1.02(0.78, 1.35)

Referent
1.02(0.84, 1.22)

31.6%
31.2%

Referent
0.99(0.76, 1.27)

Referent
0.99(0.83, 1.17)

Referent
0.97(0.74, 1.27)

Referent
0.98(0.81, 1.17)

27.9%
32.8%
35.0%

Referent
1.27(0.96, 1.68)
1.37(1.07, 1.77)

Referent
1.18(0.97, 1.41)
1.24(1.05, 1.46)

Referent
1.26(0.91, 1.73)
1.42(1.06, 1.89)

Referent
1.17(0.94, 1.44)
1.27(1.04, 1.52)

51.8%
28.9%

2.65(1.91, 3.67)
Referent

1.79(1.51, 2.07)
Referent

2.53(1.79, 3.57)
Referent

1.75(1.46, 2.05)
Referent

35.1%
22.9%

1.81(1.44, 2.28)
Referent

1.53(1.31, 1.76)
Referent

1.91(1.48, 2.46)
Referent

1.58(1.34, 1.84)
Referent

42.3%
30.0%

1.70(1.21, 2.40)
Referent

1.41(1.14, 1.69)
Referent

1.88(1.28, 2.75)
Referent

1.49(1.18, 1.8)
Referent

35.5%
26.0%

1.57(1.27, 1.94)
Referent

1.37(1.18, 1.56)
Referent

1.44(1.15, 1.81)
Referent

1.30(1.11, 1.49)
Referent

†† 95%CI = 95% confidence interval
†††PR = prevalence ratio
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Table 15. Sensitivity Analysis for Adjusted Converted Prevalence Ratios for Interest in the HPV
Vaccine among the NHIS 2010 Sample of Women 18-26 Years (N=1,392)
Variable
Relationship Status
Married
Living with Partner
Never Married
Hispanic
Yes
No
Race
White
Black
Other
Region
South
Northeast
Midwest
West
Age
18-21 years
22-26 years
Insurance Coverage
Yes
No
Poverty Ratio
200% +
100 < 200%
< 100%
Abnormal Pap Test
Yes
No
Heard of the Vaccine
Yes
No
Flu Shot last 12 mo
Yes
No
Hepatitis B Vaccine
Yes
No

%Interest Adjusted PR
(95% CI) †
23.5%

30.4%
30.3%

34.2%

31.3%

31.6%

27.6%

Referent
1.44(1.07, 1.87)
1.40(1.11, 1.71)
1.40(1.16, 1.65)
Referent

% Change

0%
0%
1%

Referent
1.20(0.97, 1.45)
1.17(0.90, 1.46)

4%
4%

Referent
0.84(0.65, 1.07)
0.73(0.59, 0.90)
1.05(0.85, 1.28)

2%
3%
2%

Referent
1.01(0.83, 1.21)

1%

Referent
0.99(0.80, 1.19)

1%

Referent
1.21(0.97, 1.46)
1.29(1.07, 1.53)

3%
2%

1.74(1.44, 2.05)
Referent

1%

28.9%

4%

22.5%

1.65(1.38, 1.93)
Referent

9%

41.4%

1.36(1.13, 1.58)
Referent
1.27(1.08, 1.47)
Referent

2%

26.3%

†Prevalence ratio and 95% confidence interval
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Phase I Research Question II – Reason for Non-Interest in HPV Vaccine
Description of sample. The second sample from the NHIS 2010 dataset comprised 984
women who provided a reason for non-interest in the HPV vaccine (Table 16). Due to skip
patterns in the dataset, this sample contained a different subset of women compared to the
analytic sample one in Table 13. The majority of women were never married (58%), followed by
married (25%), living with a partner (13%) and widowed, divorced or separated (4%). Most
women were non-Hispanic, White, from the South, between the ages 22 and 26 years, and had
insurance coverage. Additionally, most women had not had an abnormal Pap test and had heard
of the HPV vaccine. Approximately half of participants received the Hepatitis B vaccine and less
than 10% received the flu shot in the last 12 months.
Primary reasons for non-vaccination. The percentage of each primary reason among
each relationship status category is reported since the percentages are adjusted for survey
weighting (Tables 17 and Figure 6). Within each relationship status category, the most common
reason for non-vaccination and non-interest was reported as “does not need vaccine” (40%
overall). The second most common reason for women who were married (14%); widowed,
divorced, or separated (18%); and never married (13%) was “doesn’t know enough about
vaccine,” while women who were living with a partner had “worried about safety of the vaccine”
(15%). Overall, more than 70% of responses among all relationship status categories were “does
not need vaccine,” “doesn’t know enough about vaccine,” “worried about vaccine safety,” and
“doctor didn’t recommend.” Very few participants reported the remaining available factors as
reasons for non-vaccination. The only exception being that women who were never married were
more likely to list “not sexually active” compared to other relationship status categories (11%).
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Table 16. Description of NHIS 2010 Sample of Women 18 to 26 Years who were Not Interested
in the HPV Vaccine (N=984)
Variable
Relationship Status
Married
Widowed, Div, Sep
Living with Partner
Never Married
Hispanic
Yes
No
Race
White
Black
Other
Region
South
Northeast
Midwest
West
Age
18-21 years
22-26 years
Insurance Coverage
Yes
No
Abnormal Pap Test
Yes
No
Heard of the Vaccine
Yes
No
Flu Shot last 12 mo
Yes
No
Hepatitis B Vaccine
Yes
No

N Total

% Total

231
44
135
574

24.7%
4.3%
13.2%
57.8%

231
753

13.2%
86.8%

683
192
109

75.3%
16.1%
8.6%

357
132
244
251

37.5%
14.7%
28.1%
19.8%

317
667

31.8%
68.2%

707
277

73.1%
26.9%

79
905

8.0%
92.0%

601
381

66.4%
33.3%

92
892

9.6%
90.4%

498
483

54.2%
45.8%
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Table 17. Primary Reason for Non-Interest and Non-Vaccination by Relationship Status among
NHIS 2010 Women 18 to 26 Years (N=984)
Married

Does Not Need Vaccine
Doesn’t Know Enough About Vaccine
Worried About Safety of the Vaccine
Doctor Didn’t Recommend
Not Sexually Active
Too Expensive
Too Old for Vaccine
Don’t Know Where to Get Vaccine
My Spouse/Family Member is Against It
Already Have HPV
Other
Don’t Know

Widowed,
Divorced,
Separated
51.8%
18.4%
10.0%
<2%
<2%
3.8%
2.2%
0
0
3.6%
5.1%
3.3%

47.6%
14.4%
3.9%
10.4%
<2%
2.2%
2.1%
<2%
<2%
3.3%
13.0%
<2%

Living
with
Partner
40.9%
8.3%
15.2%
7.8%
<2%
2.1%
4.8%
<2%
0
5.4%
13.2%
<2%

Never
Married

Total

34.7%
12.7%
14.9%
6.3%
11.1%
2.8%
3.1%
<2%
<2%
2.2%
9.4%
2.0%

39.5%
12.8%
12.0%
7.3%
6.8%
2.6%
3.1%
<2%
<2%
2.9%
10.6%
<2%

Figure 6. Percentages of Main Reason for Non-Vaccination by Relationship Status
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Due to the limited number of responses in many categories, these were combined to
reflect an “other” reason for non-vaccination and non-interest. Additionally, the widowed,
divorced, and separated group was removed from the analysis due to low frequencies (N=44).
The resulting 940 participants’ primary reason for non-vaccination is provided in Table 18.
Using a Wald chi-square test, an association between relationship status and primary reason for
non-vaccination was present (χ2 = 63.77, p-value < 0.0001). Women who were married were
more likely than other relationship status categories to believe that they did not need the vaccine,
while women living with a partner were more concerned about the safety of the vaccine. In
contrast, never married women were the most likely to report an “other” reason for nonvaccination, which may be attributed to the large percentage indicating not being sexually active.

Table 18. Primary Reason (condensed) Non-Interest and Non-Vaccination by Relationship
Status among NHIS 2010 Women 18 to 26 Years (N=940)
Married
Does Not Need Vaccine
Doesn’t Know Enough About Vaccine
Worried About Safety of the Vaccine
Doctor Didn’t Recommend
Other

47.6%
14.4%
3.9%
10.4%
23.6%

Living with
Partner
40.9%
8.3%
15.2%
7.8%
27.9%

Never
Married
34.7%
12.7%
14.9%
6.3%
31.6%

Total
38.9%
12.5%
12.1%
7.6%
28.9%

This research study involved two phases, a quantitative and qualitative phase. To assist in
the comparison of the quantitative results in this phase to the interview results in Phase II, the
two relationship status categories Married and Living with a Partner were combined in order to
compare these to the Never Married group (Table 19). Similar sampling stratifications were used
in Phase II. Using a Wald chi-square test, an association between relationship status and primary
reason for non-vaccination was present (χ2 = 25.57, p-value < 0.0001). More women in the
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relationship groups believed they did not need the vaccine compared to the never married group.
In contrast, more women in the relationship status group did not receive a doctor
recommendation for the vaccine compared to the never married group. More women in the
never married group cited safety concerns as a reason for non-interest in the HPV vaccine.

Table 19. Primary Reason (condensed) Non-Interest and Non-Vaccination by Combined
Relationship Status among NHIS 2010 Women 18 to 26 Years (N=940)

Does Not Need Vaccine
Doesn’t Know Enough About Vaccine
Worried About Safety of the Vaccine
Doctor Didn’t Recommend
Other

Married or
Living with
Partner
45.3%
12.3%
7.9%
9.5%
25.1%

Never
Married

Total

34.7%
12.7%
14.9%
6.3%
31.6%

38.9%
12.5%
12.1%
7.6%
28.9%

Phase II: Qualitative Analysis
Descriptive characteristics of the eligible sample and interviewed sample are reviewed.
Additionally, key themes from the in-depth interviews by IMB construct are described.

Descriptive Characteristics of Sample
Description of eligible sample. A total of 352 women completed the eligibility
questionnaire, informed consent, and provided contact information for the in-depth interviews.
The majority of women who were eligible for the study did not receive the HPV vaccine (85%)
(Table 20). Approximately a third of the sample were either single or in a long term
monogamous relationship, respectively. The smallest category was women who were married or
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living with a partner (13%). The average age of respondents was 21 years (range 18-26).
Regarding race and ethnicity, 19% were Hispanic, 9% were international students, and 52% were
White. The majority of women self-identified as heterosexual (87%). The primary mode of
insurance was through private insurance (63%), while 9% reported being uninsured. Most
women had heard of the HPV vaccine from a healthcare provider (68%) and the average
knowledge scale score was 15.3 out of a possible 23 (higher score indicating higher knowledge).
Description of interview sample. The final interview sample comprised 50 women from
the eligible 352. The relationship status and vaccination status frequencies reflect the quota
sampling technique employed for conducting interviews. All groups had 6 participants, with the
exception of women in the long term monogamous relationship categories, each of which had 7
participants. Descriptive characteristics were relatively similar when comparing the eligible
sample to the interview sample (Table 20).
Moreover, characteristics were similar across the eight quota categories (Table 21). The
knowledge scale score was the highest for women who were vaccinated and married or living
with a partner, and lowest for women who were unvaccinated and single and dating (this is
attributed to one participant listing unsure for every knowledge item resulting in a zero score).
This study’s sampling design was stratified by relationship status: married/living with a
partner; long-term monogamous relationship; single and dating; and single. Women were asked
to self-identify their relationship status on the eligibility questionnaire and then described their
relationship status in more detail during the interview. Women who were unvaccinated described
their relationship at the present time and women who were vaccinated were asked to recall their
relationship at the time of vaccination. Descriptions of these relationship status groups are
presented in Table 22.
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Table 20. Descriptive Demographic Characteristics of Eligible Sample and Interviewed Sample

HPV Vaccination
Never
Last 6 months
Relationship Status
Married or Living with Partner
Long Term Monogamous
Single and Dating
Single
Age
Hispanic
International Student
Race
American Indian/Alaskan Native
Asian
Native Hawaiian/Pacific Islander
Black
White
Other
Multiracial
Sexual Orientation
Bisexual
Homosexual
Heterosexual
Unsure
Other
Insurance Status
Private
School
Medicaid
Other
Uninsured
Not Sure
Knowledge Scale Score
Heard of HPV From….
Healthcare Provider
Family
Partner
Friends
Radio
TV
Internet
Other
Never

Eligible Sample (N=352)

Interview Sample (N=50)

299 (84.9%)
53 (15.1%)

25 (50.0%)
25 (50.0%)

46 (13.1%)
116 (33.0%)
79 (22.4%)
111 (31.5%)
21.1 (2.0) years
68 (19.3%)
32 (9.1%)

12 (24.0%)
14 (28.0%)
12 (24.0%)
12 (24.0%)
21.3 (2.1) years
12 (24.0%)
2 (4.0%)

3 (0.9%)
50 (14.2%)
1 (0.3%)
67 (19.0%)
188 (53.4%)
23 (6.5%)
20 (5.7%)

1 (2.0%)
8 (16.0%)
0 (0%)
8 (16.0%)
24 (48.0%)
4 (8.0%)
5 (10.0%)

23 (6.5%)
12 (3.4%)
305 (86.7%)
7 (2.0%)
5 (1.4%)

4 (8.0%)
0 (0%)
45 (90.0%)
1 (2.0%)
0 (0%)

220 (62.5%)
23 (6.5%)
24 (6.8%)
44 (12.5%)
32 (9.1%)
9 (2.6%)
15.3 (4.1)

29 (58.0%)
4 (8.0%)
8 (16.0%)
3 (6.0%)
6 (12.0%)
0 (0%)
15.3 (3.9)

238 (67.6%)
112 (31.8%)
9 (2.6%)
128 (36.4%)
25 (7.1%)
147 (41.8%)
109 (31.0%)
34 (9.7%)
29 (8.2%)

38 (76.0%)
17 (34.0%)
2 (4.0%)
21 (42.0%)
5 (10.0%)
17 (34.0%)
18 (36.0%)
3 (6.0%)
0 (0%)
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Table 21. Descriptive Demographic Characteristics of Interviewed Sample by Stratifications
(N=50)
Vaccination Status
Relationship Status
N
Age
Hispanic
International Student
Race
American Indian/Alask. Native
Asian
Native Hawaiian/Pacific Island.
Black
White
Other
Multiracial
Sexual Orientation
Bisexual
Homosexual
Heterosexual
Unsure
Other
Insurance Status
Private
School
Medicaid
Other
Uninsured
Not Sure
Knowledge Scale Score
Heard of HPV From….
Healthcare Provider
Family
Partner
Friends
Radio
TV
Internet
Other

Unvaccinated
M/LP LTM SD
6
7
6
22.8
21.9 21.3
(1.5) (2.7) (2.4)
1
2
2
0
0
0

S
6
21.5
(1.9)
1
1

Vaccinated
M/LP LTM SD
6
7
6
22.0
20.1 19.5
(1.1) (2.0) (1.6)
1
3
1
1
0
0

S
6
21.5
(1.9)
1
0

0
0
0
0
5
0
1

0
2
0
0
3
2
0

0
1
0
1
3
1
0

0
2
0
2
1
1
0

1
1
0
0
4
0
0

0
0
0
3
3
0
1

0
0
0
1
3
0
2

0
2
0
1
2
0
1

1
0
5
0
0

1
0
6
0
0

0
0
6
0
0

0
0
6
0
0

0
0
6
0
0

1
0
5
1
0

1
0
5
0
0

0
0
6
0
0

3
1
0
0
2
0
15.0
(3.8)

5
1
0
1
0
0
15.3
(3.9)

4
1
0
0
1
0
13.5
(7.0)

2
0
3
0
1
0
14.0
(3.2)

5
1
0
0
0
0
18.2
(2.8)

3
0
3
0
1
0
15.6
(3.4)

2
0
1
2
1
0
16.0
(2.5)

5
0
1
0
0
0
14.5
(4.0)

3
2
0
1
1
5
2
1

5
3
0
5
1
3
3
0

6
3
0
4
1
2
3
0

3
1
0
2
1
2
2
0

6
2
2
1
0
0
1
0

6
3
0
3
0
2
1
1

3
1
0
3
0
2
3
1

6
2
0
2
1
1
3
0
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Table 22. Description of Relationship Status by Sampling Group
Vaccination Relationship
Description
Unvaccinated Married/Living All women mutually monogamous with current partner.
with Partner
All women stated they saw a future with this partner.
One married, the rest living with a partner.
Length of relationship range 1 year – 7 years
Long-Term
Five women mutually monogamous with current partner and
Monogamous
two women not sexually active with current partner.
All women stated they saw a future with this partner.
Length of relationship range 1 year – 6 years
Single and
Four women mutually monogamous with current partner;
Dating
length of relationship range 2 months – less than a year.
Two women dating; one was not sexually active at the time and
the other was sexually active with her partner.
Single
All women were not sexually active or in any type of
partnership at the time of interview.
Vaccinated
Married/Living All women mutually monogamous with partner at the time of
with Partner
vaccination.
All women stated they saw a future with this partner.
One married, the rest living with a partner at the time of
vaccination. One woman was no longer living with her partner,
but they were still in a relationship at the time of interview.
Length of relationship range 2 years – 4 years.
Long-Term
Six women were mutually monogamous with partner at the
Monogamous
time of vaccination; one woman was not sexually active at the
time.
All women stated they saw a future with this partner at the
time; one of the women is no longer in that relationship.
Length of relationship range 5 months – 3 years.
Single and
All but one woman had been sexually active at the time of the
Dating
vaccination or prior to vaccination.
Two women described their relationships as “on-and-off
again.”
Two women said they were currently sexually active and
monogamous in the partnership.
Single
Only one woman was never sexually active.
The remaining five women were currently single, but had
sexual partners in the past or currently (not monogamous).
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IMB Model Factors Influencing HPV Vaccination
Information – HPV and HPV vaccine. Women’s knowledge about HPV and the HPV
vaccine were assessed through two modalities, the closed-ended survey and the open-ended
interview. The percent correct for each knowledge survey question was compared to findings
from the qualitative interviews (Table 23).
Overall, there were no major differences in knowledge about HPV or the vaccine by
vaccination status or relationship status. When asked generally about HPV in the interviews,
some women stated that it is the human papillomavirus and described differences in HPV
presentation/transmission between sexes. However, the majority of women needed to be probed
on the topic. In the survey, the majority of women correctly knew that there were many types of
HPV (78%), men and women would get HPV (96% and 78%), and you can have HPV without
knowing it for you and your partner (96%). Less than half of the sample knew that HPV was not
a bacterial infection, while over 90% reported that HPV is a virus.
With regard to the curability of HPV, most women in the interview reported that people
have HPV for life and that it cannot go away (N=20). However, the majority of these statements
included the context of uncertainty by qualifying the statement with “I don’t know” or “I’m
unsure.” This limited knowledge on the curability of HPV in the interviews agrees with the lower
frequencies of similar questions correct on the knowledge scale. This was especially true for only
12% getting the statement correct for “Most HPV infections clear up within a short time.”
The survey only focused on two prevention methods for HPV: condoms (78%) and the
vaccine (98%). The majority of participants answered these questions correctly. Similar answers
were reported in the interviews; however, additional prevention methods were cited, including
abstinence and sex with known partners.
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Table 23. Comparison of Quantitative and Qualitative Assessment of Knowledge about HPV

General Info
Cure

Antibiotics can cure HPV (58%)*
HPV can be cured (40%)*
Most HPV infections clear up within a short
time (12%)

Most women stated you have HPV for life
or that it does not go away (N=20); others
were uncertain
Uncertainty regarding curability of HPV

Using a condom decreases the chance of HPV
transmission (78%)
There is a vaccine for women that prevents
certain types of HPV (98%)

Women reported varies prevention
modalities: vaccine (N=21), condoms or
barrier methods (N=18), abstinence (N=8),
sex with known partners (N=2)

HPV is spread on toilet seats (56%)*
Transmission of HPV can occur through sexual
contact with another person (88%)
HPV is a sexually transmitted infection (68%)
HPV can be passed to a newborn at birth (52%)
Even if you do not see a wart, you can transmit
HPV (76%)

Most women knew that HPV was sexually
transmitted (N=38); however there was
uncertainty regarding exact routes of
transmission (e.g., skin to skin, oral,
vaginal-penile, bodily fluids, kissing)

Some types of HPV cause cervical cancer
(94%)
HPV can cause HIV/AIDS (56%)*
HPV can cause abnormal Pap smears in women
(74%)
HPV can cause herpes (30%)*
HPV can cause genital warts (60%)
HPV can affect a woman’s ability to get
pregnant (6%)*

The most frequently reported outcome
associated with HPV was cervical cancer
(N=24)
Other outcomes included: genital warts
(N=13), cancer unspecified (N=5),
reproductive cancers (N=2), vaginal cancer
(N=1), uterine cancer (N=1), ovarian
cancer (N=4), penile cancer (N=1), rectal
cancer (N=1), anal cancer (N=2),
orolaryngeal cancer (N=1), infertility
(N=2)

Outcomes

There are many types of HPV (78%)
Only men can get HPV (96%)*
You can have HPV without knowing it (96%)
You can always tell when someone else has
HPV (96%)
HPV is a virus (92%)
Only women can get HPV (78%)*
HPV is a bacterial infection (44%)*

Prevent

Themes from Qualitative Knowledge
Interview
HPV stands for human papillomavirus
Awareness that females and males could
get HPV, but uncertainty regarding if males
are affected or just carriers
Limited knowledge regarding types of
HPV

Transmission

Quantitative Knowledge Survey (% correct)

*False statement; % reflects the proportion of participants who were correct
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Most women in the interview knew that HPV was transmitted sexually (N=38); however,
some were uncertain when stating this. Similarly 68% and 88%, respectively, of the interviewed
sample correctly reported on the knowledge scale that “HPV is a sexually transmitted infection”
and that “transmission of HPV can occur through sexual contact with another person.”
Moreover, while women knew the sexually transmitted nature of the virus, they were unsure of
specific routes, such as penile-vaginal sex, oral sex, or skin to skin contact.
Women were more likely to know that HPV causes cervical cancer in both the survey and
interview. Fewer women were aware that HPV could cause genital warts, abnormal pap smears,
and other types of cancers (e.g., anal, vaginal, oral). Additionally, women often conflated genital
warts with herpes in their description of the outcomes related to HPV. Of particular concern is
that approximately half of the participants believed that HPV causes HIV/AIDS and the majority
of women believe HPV affects fertility.
During the interview, women were asked to share everything that they knew about the
HPV vaccine. There was confusion as to whether males could also receive the HPV vaccine. Yet
more than half of the women were aware that both sexes could receive the HPV vaccine (N=28).
Moreover, there were a variety of age ranges reported for when people should receive the HPV
vaccine. For the most part, the ranges were between teens and twenties; however, some women
reported that people should get the vaccine after becoming sexually active (N=7). Some of the
participants mentioned that there are side effects associated with the HPV vaccine; however, this
was usually a nebulous statement. Only four women, who had received the HPV vaccine, were
able to accurately describe what these side effects entailed (e.g., pain, fainting).
Information – Trusted and preferred sources. The majority of women in the interview
sample reported they had heard of HPV from a healthcare provider (76%). During the interview,
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the interviewer listed the information sources each woman had marked on the survey and then
asked her to describe which source she trusted the most. The majority of women said that they
trusted a healthcare provider the most as the source for HPV information (N=31 out of 38 who
listed it). This was attributed to them knowing the individual’s medical history, having training
in the field, and having their best interests in mind.

“I feel like I trusted them a lot. They reassured me about the vaccine, told me not
a lot about it. But I mean enough that I felt safe enough to take it. And they gave
me a packet explaining what it was. I didn't actually read a lot of it. In all of my
honesty, but yeah.” (P9, Vaccinated, Long-term Monogamous).

“Because they are medical professionals and you know they take the oath so I
assume that they have my best interests at heart.” (P10, Unvaccinated,
Married/Living with Partner)

“Because, um, they're like, my doctor, and I feel like they would be like – I guess,
more objective view, versus like, your friends and stuff. Um, I don't know, 'cause
they're a doctor, I guess. They're paid to know what they're talking about.” (P36,
Vaccinated, Single)

“Normally they [doctors] are very informative and they had more experience
dealing with certain fields than I have so I would trust them to give me the right
advice when it comes to certain things like vaccines, what you should have done,
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um the types of care that would be best for you, stuff like that. I know this isn't
always going to be the case but you just you kind of have to have faith in your
doctor and hope that they will.” (P45, Vaccinated, Married/Living with Partner)

Other trusted sources of information included: parents, friends, or Internet. Women were
asked where they would prefer to receive additional information about the HPV vaccine during
the interview. The two primary modes of information were a healthcare provider or the Internet.
When the Internet was mentioned, women said they would prefer reputable sources, such as
WebMD or scientific reports.
Motivation – Attitudes about vaccines in general. Similar to the information theme,
there were no major group differences in attitudes about vaccines generally. Most women had
favorable opinions about vaccines (N=44) stating that they were valuable for personal and
population health since these could prevent diseases.

“I think – well, because they protect a lot of people from, you know, it’s kind of
like a tier one preventative measure that can be taken so that like widespread, you
know, diseases and stuff or to prevent the disease from becoming really
widespread.” (P8, Unvaccinated, Single and Dating)

A few women even mentioned the benefit of herd immunity, and the importance of
getting vaccinated since certain groups cannot get vaccinated (N=4).
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And, I think vaccines are important because you're not just protecting, like,
yourself; you're protecting others who may not necessarily be able to get the
vaccine, or people who have like, weaker immune systems and are more
susceptible to it.” (P36, Vaccinated, Single)

“I think there's more benefits than risk and I'm a strong advocate of herd
immunity as well for those who can't get vaccinated. And a lot of people think that
because certain diseases aren’t prevalent in America anymore they are still
prevalent in other countries and because of all the international travel there is it's
important that everyone remains - continues to get vaccinated.” (P50,
Vaccinated, Married/Living with Partner)

However, there were women across all subgroups who were more weary of vaccines
(N=10). Reasons for concern included: too many vaccines, needing different dosing schedules,
favored natural medicine, unsure of efficacy, distrust in the FDA and clinical trials, wanting to be
aware of what is in the body, wanting to be more informed, fear of bad reactions, and that their
attitude depends on the vaccine.

“I'm not a proponent. Um, I never get a flu shot. I don’t really believe in
vaccines. I think it just puts a lot of unnecessary stuff in your body and, you
know, with the flu shot they only – like they pick the seven most common strains
they're predicting for that year and give it to you, so you could still end up with
the flu. I think it's not a guaranteed thing. So I wouldn't say that I'm pro-vaccine.
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Um, I mean I think – I mean I'm not one of those people that believes that like
vaccines cause autism. I think we should all get vaccinated for chicken pox and
measles and what-have-you, but I don’t really believe in taking anything
additionally.” (P15, Vaccinated, Married/Living with Partner)

One emergent theme during the discussion of vaccines was the polarization of this topic.
A few women reported being “pro-vaccine” when asked how they feel about vaccines in general
(N=3). Women then elaborated on the anti-vaccine movement resulting in people not vaccinating
their children, which has invaded the culture in the United States. General attitudes about the
anti-vaccine movement were that it was not evidence-based, it was causing more harm than
good, and influenced by celebrity figures.
Motivation – Attitudes about HPV vaccine. Women were then asked to describe their
attitudes specifically about the HPV vaccine. There were significant group differences, with the
unvaccinated groups having more mixed feelings about the HPV vaccine and the vaccinated
group having more favorable attitudes about the HPV vaccine.
Most unvaccinated women had favorable opinions about the HPV vaccine (N=13), which
was attributed to disease prevention. A couple even questioned why they had not received the
vaccine yet given the positive attributes (N=2). However, negative attitudes about the HPV
vaccine were apparent, including: negative side effects (N=3), unsure of the intended audience
(e.g., sexually active only) (N=2), newness (N=2), is for people more at risk of HPV (e.g., more
sexual partners) (N=2), and promotes sexual activity (N=1). Others were generally unware about
the HPV vaccine (N=6). In contrast, vaccinated women had more favorable opinions (N=23),
similar to the unvaccinated women citing that it was important due to its potential for disease
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prevention. A few women even stated that they believed everyone should get the HPV vaccine
(N=3).
Overall there was a sentiment that the HPV vaccine was a different type of vaccine
compared to required (e.g., MMR) or optional vaccines (e.g., flu) currently available. As one
participant summarized,

Interviewer: “Do you see the HPV vaccine as being an important vaccine?”
Interviewee: “Um, yeah. I would see that as more important than, like, a flu
shot.”
Interviewer: “Okay, but maybe how about compared to the vaccines that are
required?”
Interviewee: “Hmm. Um, probably not as important.”(P13, Unvaccinated, Longterm Monogamous)

In contrast, some participants echoed this concept of the HPV vaccine being in its own
class of vaccines. Women had a difficult time placing it as either a required or optional
vaccine for the public.

Interviewer: “In terms of comparing it to other vaccines, do you think it should be
a required vaccine, or is it something that's more optional?”
Interviewee: “I think it's definitely more optional. Um, I'm not sure if it should be
required 'cause I feel like everybody should have that type of choice. But I know
the HPV vaccine when they were like trying to give it to younger girls, there was
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like an issue about like basically, ‘Is that promoting younger girls to have sex?’
which it's not. It's just preventing if I ever do decide to have sex, you know, that
they'll have that protection. Um, but, yeah, I think it should be optional, and I
think, you know, people should decide like the steps or the choices you should
make on that.” (P25, Vaccinated, Long-term Monogamous)

Despite the differences in attitudes about the HPV vaccine between vaccinated and
unvaccinated women, there were generally four key messages about the good things about the
HPV vaccine across all groups. These themes included: (1) prevents diseases (e.g., HPV, genital
warts, cervical cancer, cancer) (N=43); (2) keeps you safe and protected (N=8); (3) reduces
spread of HPV and/or protects partners (N=8); and (4) not having to worry about HPV or some
of its outcomes (N=7).

“Good things, um, well one thing, even if you are not sure about your partner you
know that even if that person he or she has something, if you got HPV vaccinated,
you will be safe. You will not have to worry about it. And most importantly it can
lead to cervical cancer and I think you are protected against that.” (P5,
Unvaccinated, Single)

“It will make me safer in the future ‘cause I won’t, you know, spread – if I don’t
already have it, HPV, which I don’t, then if I, you know, I have intercourse with
more people then I won’t spread it to them if I am protected against it.” (P35,
Unvaccinated, Single and Dating)
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Similarly there were no major differences in bad attributes of the HPV vaccine. These
included (1) side effects (N=20); (2) the fact that it was a shot or a vaccine (N=8); and (3) the
cost (N=5). There were a quarter of participants who could not list any negative attributes about
the vaccine—seven vaccinated and six unvaccinated. Cost was mentioned in the context of it is
an expensive vaccine for women who do not have insurance, but not necessarily a personal
barrier.

“…maybe cost? For some people. I'm not sure. Uh, I mean I don't know if HPV
[vaccine] is covered under all people's insurance or sometimes if the vaccine is
not required, it's not necessarily covered for people.” (P1, Unvaccinated,
Married/Living with Partner)

Additionally, women had fear of shots or needles, which translated in the vaccine being less
favorable due to the administration method.

“For me, I just don't like shots, so for me it'd be like having to go get a shot that
would probably the worst to me.” (P21, Unvaccinated, Single and Dating)

Side effects were again cited as a bad feature of the vaccine; however, participants continued to
have difficulties describing these side effects. Six vaccinated women and three unvaccinated
were able to describe the side effects, which were primarily pain, nausea, and rash. One woman
described weighing the costs and benefits, essentially her risk for HPV against the potential side
effects.
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“So I think the bad thing would be if there was any side effects, whatever that
would come along with. You know, if it goes cause like some sort of – maybe like
some discomfort, like uncomfortable sex or something like that. And if I’m not
sexually active or if my partner later on is not – doesn’t have HPV, then why
would I get the vaccine if I know I’m not gonna get it?” (P6, Unvaccinated,
Single)

Motivation – Social influences. Women were asked who in their life influenced their
decision for vaccination or non-vaccination. For unvaccinated women, these influential agents
impacted their decision not to get the vaccine or would be influential if they decided to get the
vaccine. All were probed for key groups identified in the literature, which include healthcare
providers, parents, peers, and partners. Again, there were no major differences observed by
sampling group. More than half of participants reported that their healthcare provider’s
recommendation influenced or would influence (for unvaccinated women) their decision to get
the HPV vaccine (N=33). This was attributed to providers being familiar with their health
history, being able to explain their risk for HPV, and reassuring the participant that it was a good
vaccine to get.

“Like my doctor probably. But only 'cause she's pretty like trustworthy. I feel
like, um, if she is really, um – uh, what's the word I'm looking for – like
sympathetic. Like I don't feel like she's like the kind of – like not try to get this
over, and over and get in, get out, "Tell me what your complaints are." So if she
recommended something, I would feel like it was because she's trying to do
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something good rather than just like trying to make money.” (P23, Unvaccinated,
Long-term Monogamous)

“It made me worry a little less, so I, like I said, I trust my doctor. He’s been my
doctor since – you know, my pediatrician since birth. So, he wouldn’t do
anything – he wouldn’t make me do anything stupid.” (P27, Vaccinated, Single
and Dating)

The second key agent to HPV vaccine decision-making was a parental figure, specifically the
mother (N=23). Some mothers’ negative opinions about the HPV vaccine or medicine in general
influenced women’s decisions about the vaccine. However, mothers were seen as important
because they ensured health and healthcare throughout childhood.

“Um, well, 'cause she's always been very like adamant about like making sure
that my health needs are provided for, and making sure that, um, I have the
proper vaccinations…”(P23, Unvaccinated, Long-term Monogamous)

Additionally, some women reported that mothers’ personal experiences with HPV or cervical
cancer were also influential (N=2). Other family members were mentioned as being important
figures, but not as frequently as mothers. These were fathers, sisters, and grandparents.
Less influential figures were peers and partners. Friends were seen as important figures in
the HPV vaccine decision-making process when they could share their experience with the
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vaccine (N=18). These narratives of getting the vaccine reassured women that the vaccine was
safe and a good option for them.

“Um, I guess friends, too, like a couple other friends have had it, like I haven't,
like, gone into detailed conversations with them about it, but just seeing, like, like
the majority of my friends, like, have it or get it done, I guess that would persuade
me more to get it, like I feel like, "Okay," like, "This is safe. If this person did it,
then I'll be fine."” (P11, Unvaccinated, Single and Dating)

Across all relationship status groups, partners were rarely mentioned as influential for
getting the HPV vaccine (N=11). Women reported they discussed the vaccine with their partner
and that it was dismissed or the partner had no opinion. This was illustrated by this participant’s
description of her boyfriend,

“Him [boyfriend] personally, he didn't really have an opinion on it [HPV
vaccine] which was weird because I wanted to talk to him, I wanted to get his
opinion. He's not really opinionated on stuff like that so, he didn't really give me
it.” (P48, Vaccinated, Married/Living with Partner)

Others mentioned they thought their partner should look into the vaccine too. However, only a
few of these comments reported that the partner had a major influence on the individual’s
decision-making.
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One emergent theme during this interview process was the idea that HPV vaccine
decision-making was a personal decision, rather than dependent upon others. Approximately a
quarter of the women reported that getting the HPV vaccine was a personal decision (N=12).
However, most of these women also mentioned influential others described above. Therefore, for
this group of women while others in the social environment may influence HPV vaccine
decision-making, the ultimate decision rested with the individual to decide if the vaccine is right
for her.
Motivation – Reasons for (non-)vaccination. To gain context to the HPV vaccine
decision-making process, participants were asked the primary reason they did not receive the
HPV vaccine when they were an adolescent. Three primary reasons emerged across all sampling
groups. The first was that the vaccine was never brought up by a healthcare provider or any other
agent (N=21). In other words, the participant never heard of the HPV vaccine during
adolescence. The second reason for non-vaccination was a maternal figure deciding that the
adolescent female did not need the HPV vaccine (N=14). This is similar to the comment from the
social motivation that mothers were the primary caretakers for health-related needs during
childhood and adolescence. Mothers did not want the female adolescent to get the vaccine out of
fear of increased sexual activity, the newness of the vaccine, the side effects, or not seeing their
daughter at risk.

“My mom said it wasn't important, and this was in high school, because my
doctor offered it to me, and I was 16 – I think I was 16 or 17, and my mom was
just like, "Oh, you don't need that," and especially since, I mean, I don't know why
she said that. Probably because I wasn't having sex then, but that's really why I
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never got the vaccine, and I wasn't offered it again, you know, like out of sight,
out of mind.” (P12, Unvaccinated, Long-term Monogamous)

Finally, many women mentioned that they did not receive the HPV vaccine as an adolescent
because they were not sexually active at the time (N=11). This corroborates the misperception
that the HPV vaccine is only for persons who have initiated sexual activity and at higher risk of
HPV. As one participant stated, “I wasn’t having sex so I didn’t see a need for it.” (P49,
Vaccinated, Long-term Monogamous). It was not only the individual participant who believed
that they did not need the vaccine due to sexual inactivity, but it was also perceived that parents
and healthcare providers agreed with this belief.
While there was consistency across groups regarding the reasoning for not getting a
vaccine at a younger age, there was more variability for HPV vaccine decisions in young
adulthood. Unvaccinated women in relationships (long-term monogamous or married/living with
a partner) described four primary reasons: (1) monogamy or perceived low risk (N=5); (2) not
offered or recommended by a healthcare provider (N=4); (3) time and/or money (N=2); and (4)
use of other preventive measures (e.g., Pap test) or belief in natural medicine (N=2).
Unvaccinated women who were single and dating were more unsure of the reasons why they
have not received the HPV vaccine as a young adult (N=3). Women who were unvaccinated and
single only also stated two primary reasons for non-vaccination. The first was a lack of
awareness about the vaccine (N=2), and the second was they perceived themselves not at risk for
HPV due to sexual inactivity (N=3). Cost was also a reason for two participants in the single and
dating, and single groups. Overall in the unvaccinated groups, it was clear that lack of awareness
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of the HPV vaccine served as a primary obstacle to vaccination, as well as perceptions of low
risk of HPV.
In contrast, there were many more factors that contributed to the decision-making process
among women in the vaccinated groups. Women who were vaccinated and in relationships had a
variety of cues that influenced their decision to get the vaccine. These included a family history
of cancer (N=3), a history of HPV or an abnormal Pap (N=2), becoming sexually activity (N=2),
needed follow-up shots (N=2), getting insurance (N=1), vaccine was free until age 19 (N=1),
living with a partner (N=1), became aware of the vaccine recently (N=1), belief that the vaccine
was required for college (N=1) and parents recommending (N=1). Women who were vaccinated
and single and dating or single only stated that they received the vaccine now because a
doctor/friend/mother recommended the vaccine (N=7), they just became aware of the vaccine
and wanted the added protection (N=2), belief it was required for school (N=2) or it was
convenient (N=1). While doctor recommendation was a factor for women not in relationships, it
was not listed as a reason for women in relationships.
Motivation – Relationship status and HPV vaccine decision-making. Participants
were asked how they thought their relationship status impacted their decision to get the HPV
vaccine. The summaries are presented by relationship status category in Table 24. Note that
women in married/living with a partner and long-term monogamous categories were
consolidated into one group due to similar findings. It was the original intention to consolidate
single and dating and single only into one category as well; however, these groups had distinct
responses that are presented individually.
There was variability observed for how relationship status impacted HPV vaccine
decision-making. Unvaccinated women who were either in a relationship or single only stated
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that their current relationship status was reasoning for not getting the vaccine now, this was
attributed to monogamy or number of partners and sexual inactivity. Women in both of these
groups said they would be more likely to get the vaccine if their relationship were to change. In
contrast, women who were single and dating reported that their relationship status did not impact
their decision not to get the HPV vaccine. If their relationship changed to a long-term
relationship, they reported they would be less inclined to get vaccinated. Across all groups of
vaccinated women, relationship status was less influential on their decision to get the vaccine;
rather the women reported wanting the security of protection.
Motivation – Risk perceptions – Perceived susceptibility. Participants’ perceived
susceptibility to HPV was evaluated by asking what they thought their risk of HPV was with and
without the vaccine. The summaries are presented by relationship status category in Table 25.
Risk perceptions for HPV differed primarily across relationship statuses, rather than
vaccination status. This is likely attributed to the questioning of the perceptions of risk qualified
by with or without the vaccine. Women in relationships stated that their perceived risk of HPV
was low, which was attributed to monogamy and number of sexual partners. These women said
their risk would minimally decline with the vaccine. The perception of risk was more variable for
single and dating women, who attributed their risk to similar factors, but also unprotected sex,
annual exams, distance to partner, and sexual activity. All women in these groups said their risk
would decrease with the vaccine. Finally, women who were single said that their risk for HPV
was low and that their risk would decline or remain the same with the vaccine. A larger
proportion of unvaccinated women who were single were sexually inactive compared to women
who were vaccinated.
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Table 24. Comparison of Relationship Status’ Impact on HPV Vaccine Decision-Making by
Sampling Group

In a
Relationship
(Includes
Married/Living
with Partner
and Long-term
Monogamous)

Unvaccinated
Because they were in monogamous
relationship and/or had few partners
they did not need the HPV vaccine.

Vaccinated
Some women (N=5) said they
wanted the vaccine for the protection
in their relationship at that time.

“Because, I know that it is a sexually
transmitted infection and I believe
that if I'm in a monogamous
relationship that the likelihood that I
get it is less than. I know that people
aren't perfect, things happen. But I
genuinely believe that we are going
to be mutually exclusive, long-term.”
(P10)

“Yes, it’s – it’s really wanting
protection as well, just not myself
but also him, I didn’t want him to
accidently get it from me if I
somehow got it.” (P41)

If relationship status changed, they
would consider getting the vaccine
because they need protection from
the uncertain risk.

Single &
Dating

“So if he had had more sexual
partners or if I was interested in
having more sexual partners, I
would definitely go out and get the
vaccine just because I don't know
where like his partners would have
been coming from, or wouldn't have
known where my future partners are
coming from.” (P23)
Relationship did not have a major
influence on decision, but there was
a concern of needing it for future
partners.
“Right now, since I’m not sleeping
with anyone, I’m like, ugh, I don’t
need to get it yet, but then at the
same time I’m like, well, I might
sometime soon so I probably should
be protected and that’s where I’m at
with that.” (P35)
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The majority of women (N=8) said
that it was a personal decision only
to get the vaccine and their
relationship had no influence.
“…it was more for my own personal
health.” (P9)
If relationship status changed to
single, it would be even more
important to get the vaccine.
“So I feel like if I wasn't in a
monogamous relationship I probably
would've been more concerned,
'cause I would've felt like there's
more chance of contracting it.”
(P15)
Half women said they wanted to get
the vaccine because of the
uncertainty of their current/future
sexual partners’ history.
“Yes, only because like we were
sexually active, and I was like any
kind of like extra protection I was
game for. He – he had been with
other people before, and I'm like you
can't really tell when somebody has
HPV; he might not even know.”
(P19)

Table 24 (Continued)
Single &
Dating

Women said they would be less
inclined to get the vaccine if they
became monogamous or entered a
long-term relationship.
“I feel like if I, like, was with this
person, like long-term and that's it,
like I probably wouldn't be as
inclined to do it.” (P11)

Single Only

Women said they did not need the
vaccine due to lack of sexual
activity.
“Yeah, in – in a sense it does ‘cause
as I mentioned before, I – my
lifestyle is to be abstinent ‘til
marriage so the fact that I’m not
married just means that I’m not
going to – I’m not going to need the
vaccine. So in a sense, like if I got
marriage and my partner ended up
being – ended up having HPV or
something, then I would get the
vaccine.” (P6)
If relationship status changed to a
serious relationship or if they were
to get married, they would consider
getting vaccinated.
“Interviewer: Let's say
hypothetically if your relationship
status changed in the future, maybe
you found a partner, would this
change your decision about the
vaccine?
Interviewee: Yes it would. I would
go and get the vaccine.” (P5)
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Half women said it was a personal
decision only to get the vaccine and
their relationship had no influence.
“I don’t remember thinking about
the relationship when I got the
vaccine. I thought more, um, I guess
in the future. I thought about, like,
um, more up, like, later on in life,
you know, as you would want to be,
you know, protected against
that….Like, I didn’t want to
eventually be married and have that,
you know, worry in my mind about
HPV.” (P27)
Women in this group said that their
relationship status did not impact
their decision to get the HPV
vaccine.
“I don't think it [relationship status
– single] really impacted it. Like, I
think even if I hadn't been seeing
anyone I probably would've gotten it
anyway because my doctor
recommended it. So, I don't think it
really had a major impact on my
decision.” (P36)

Table 25. Comparison of Perceived Risk of HPV With and Without the Vaccine by Sampling
Group

In a
Relationship
(Includes
Married/Living
with Partner
and Long-term
Monogamous)

Unvaccinated
Without Vaccine: Low risk for HPV
attributed to monogamy and number of
sexual partners.
“I have this thing – like this – this, uh,
association, "Oh, we've been together.
We don’t have it. We're fine," though I
know that's not always the case that,
you know.” (P16)
With Vaccine: Risk would decline
slightly or stay the same because it is
already low.
“I feel like if I were in – I don't know
like single or perhaps in like a nonexclusive relationship, it’s something
that I would think about a little bit
more. But as – yeah, I’m just like – it –
it hasn’t really felt as relevant for me,
but I definitely think that there’s like a
lot of benefits to it.” (P7)

Single &
Dating

Without Vaccine: Varied risk among
women, ranging from low, medium,
high, and unsure. Risk for HPV was
attributed to monogamy, unprotected
sex, and annual checkups.
“I don't know. I don’t think it’s – I
don’t think it’s very high. But you
don’t know. I mean I – ‘cause it’s not
my choice. Like I don’t – you know, I
don’t have a lot of sexual partners and
I haven’t in the past and I only have
one ever. So like - but still, it only
takes one person to get it so I don't
know. I don't think in the high risk
group, but maybe I am.” (P35)
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Vaccinated
Without Vaccine: Low risk for HPV
attributed to monogamy and number of
sexual partners; however, some (N=5)
women stated it was high because of
uncertainty or “you never know.”
“I'd probably say it is low… Um, just
that I'm only with one person at one
time. So it's like I don't have multiple
partners.” (P49)
“I feel like it's high, but I'm also the
same person that, like, you know, when
you hear like 1 in 4 people have an
STD, I find that to be extremely high.
In my mind it feels high.” (P15)
With Vaccine: Risk would decrease
minimally because already low.
“Um, of course, now it's [risk for
HPV] definitely much, much lower.
There's still a risk because the vaccine
doesn't work 100 percent.” (P46)
Without Vaccine: Varied risk among
women, ranging from low, medium, to
high. Risk was attributed to current
sexual activity (e.g., distance partner,
not sexually active, on-and-off again
partner).
“Um, honestly, I know that the, like,
amount of people that have this [HPV]
is high. So, um, I honestly don’t date a
lot. I haven’t had, like, a lot of
boyfriends and stuff that are sexual
relationships with people, so my
chances are fairly low, but I know
there are a lot of people out there. So I
would say, you know, still the risk is, is
high.” (P27)

Table 25 (Continued)
Single &
Dating

Single Only

With Vaccine: All women said risk
would decline with the vaccine.

With Vaccine: All women said risk
would decline with the vaccine.

“Yeah, whatever risk I may have had,
yes, it will definitely decline with the
vaccine.” (P37)

“Yes, I think that – I mean I’m not a
100 percent protected from it but a lot
less prone to the infection or the virus
I mean.” (P40)
Without Vaccine: Four said low risk
attributed to sexual history and two
said high because of either their
partner’s sexual history or because
HPV is common.

Without Vaccine: Zero risk because
not sexually active.
“Personally, I think it’s probably like a
.01 percent. Again, because of the
abstinence policy that I abide by and
again, if I had a marriage – when –
when I get married I – it’s – it’s sort of
like a trust thing, you know? You
should know if your –if your partner
has HPV.” (P6)
With Vaccine: Half of women said
there would be no change in risk
because they are not at risk to begin
with, while the other half said the risk
could decrease.
“No, my risk wouldn’t change ‘cause
although like I would understand
getting the vaccine would change my
mindset, it still wouldn’t change my
lifestyle, like just because – just
because I wear a seatbelt in the car
doesn’t mean that I’m gonna drive
faster.” (P6)

“If you're sexually active, then
probably a high risk. If you're not
sexually active, then I guess you're
kind of okay. I think I'm a low risk. I'm
not sexually active.” (P30)
With Vaccine: All but one said the
risk would decline; the one who said
no change stated her risk was already
low to begin with.
“I think it's lower than it was before I
got the vaccine.” (P36)
“Yeah, I mean, I still think I'm at low
risk because I have the vaccine. It's
an extra safety net for me.” (P3)

Motivation – Risk perceptions – Perceived severity. Perceived severity of outcomes
associated with HPV was assessed by questioning participants about how they perceived the
consequences of HPV. There were no salient group differences among sampling groups, rather

122

three primary consequences emerged. The first outcome focused on by participants was cervical
cancer, or more generally cancer (N=45). This was seen as the most severe outcome associated
with HPV attributed to the fact that it is life-threatening, serious, has significant treatment costs,
and fatal.

“I would say, well if it was, if it was as bad as cervical cancer, I would say the
consequences would be awful. Um, potentially life threatening, would be the best
way I could put that.” (P48, Vaccinated, Married/Living with Partner)

Some women even drew on experiences of knowing others who suffered through cancer to
emphasize the severity of this disease. Others mentioned that cervical cancer would ultimately
affect their fertility and potential to have children in the future.
The second outcome described was genital warts; however, sometimes this was referred
to as just warts or conflated it with herpes (N=40). The general sentiment was, “…genital warts,
I've seen pictures and it does not look very pleasant.” (P17, Unvaccinated, Married/Living with
Partner) In comparison to cancer, women reported that it was not as serious as cervical cancer,
but still serious due to it being uncomfortable, cosmetically displeasing, and painful. “Well, I
mean to me the scariest one is cervical cancer, and plus I don’t know anyone that wants warts.”
(P15, Vaccinated, Married/Living with Partner) Others mentioned that they would not have to
want to disclose having genital warts to a partner and that it would affect their sex life.

“I mean I guess especially it's not appealing if you're trying to engage in any type
of sexual activity with anybody. But if you would be self-conscious and you would
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feel not clean with yourself, you know. It's not a good thing to feel like you have.
It's not something that you would wanna advertise or anything like that.” (P25,
Vaccinated, Long-term Monogamous)

Finally, some participants described the emotional responses of having HPV (N=9).
Psychosocial reactions included loss of trust in partners, the stigma of having a sexually
transmitted infection, and being self-conscious. These emotional responses were primarily a
reflection of how others, specifically future or current sexual partners, would perceive them with
an HPV diagnosis.

“…you know, diagnosed some psychological or emotional I guess turmoil of
sorts; and so have to deal with, "Oh, I have an STD," and not seeing it's pretty,
uh, negative in our culture.” (P23, Unvaccinated, Long-term Monogamous)

A comment made by one participant put into context how some women may perceive
HPV in the realm of sexually transmitted infections. She stated,

“I feel like it's, it's – in a way, I just feel like it's HIV's little sister. Like it's just,
it's just you can get – you can get it so many times until you actually get the HIV.
So it's definitely – it's like a chance. You can a chance to like get yourself
together; and it's just a red flag. Like, "Hey, you have to protect yourself. You
have HPV, now you have to protect yourself, you know, right before you, you
know, things can get out of hand.” (P26, Vaccinated, Single and Dating)
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This indicates that HPV may be a surrogate for sexual behavior that may place a woman at more
risk for other, perceived more serious, sexually transmitted infections.
Behavioral skills – Procedural knowledge. In order to elicit the behavioral skills
needed to get the HPV vaccine series, participants were asked to describe the steps for getting it.
For unvaccinated women, this was a hypothetical situation of what they thought would be
involved. For vaccinated women, they recalled the process. Overall the groups were similar in
displaying procedural knowledge for getting the HPV vaccine. For the vaccinated women,
approximately half of participants said they went to a regularly scheduled annual exam or other
healthcare appointment where the HPV vaccine was discussed. It was at these visits that the
women decided to get the vaccine then based on conversations with healthcare providers or other
staff. In contrast, the other half made specific appointments to get the HPV vaccine; however,
this was usually the result of another cue to action for getting the vaccine. Most women
described speaking to their healthcare provider about the vaccine prior to initiating the series.

“I went to my healthcare provider because, in order to go to college, I had to get
a couple more vaccines. And he said that there was another vaccine that was
available for me to have in case I became sexually active or already was. And, he
told me a little bit about it. He told me about what it prevents, such as, you know,
cancers, genital warts. I told him to give me the need-to-know information and
all the cons, and I remember he said auto-immune disease was a con. And, I
decided it's better safe than sorry, and because I do believe in vaccines, I decided
to go ahead with it.” (P3, Vaccinated, Single)
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The majority stated they used insurance coverage to pay for the vaccine; only three said they
received the vaccine for free and another said her mother covered the payment.
Women who were vaccinated were in different stages of getting the follow-up shots. Of
the women who reported completing the vaccine series (N=16), these women made follow-up
appointments in advance and typically had an immunization-only appointment. Unvaccinated
women mentioned that in order to successfully complete the vaccine series, they would need to
schedule follow-up appointment in advance.
In comparison, women who were unvaccinated reflected on the steps they would need to
take if they hypothetically decided to get the HPV vaccine. Women said they would go to a
scheduled annual exam or schedule a specific visit for the vaccine, then ask for more information
from their healthcare provider to clarify that the vaccine was right for them.

“So I would go to the gynecologist and then I would be talking with them at my
appointment and then one of us would say, ‘Hey, do you want to get – you can get
a HPV vaccine?’ Or if they didn’t ask me this time I would bring it up because
I’ve been thinking about it a lot and then I would say, ‘Should I get the vaccine?’
Or actually I’d say something I want ‘cause it sounds like I probably do really
want it and so I’d say, ‘I want to get the vaccine. Should I now – is it good for
me?’ And then I would ask them like how we would go about doing this, like
when will I get the first shot or what – and then I’d ask what maybe the
complications are, like people’s side effects they’ve had from the vaccine. And
that would be – that would be it. I either get it or I wouldn’t.” (P35,
Unvaccinated, Single and Dating)
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Most women said their insurance would cover the vaccine, but there were seven women who
said they would need to figure out their finances to cover the expense. Finally, they stated they
would need to schedule follow-up visits for the additional shots. These steps were essentially the
same as the vaccinated group indicating that the unvaccinated have the procedural knowledge to
get the HPV vaccine.
Behavioral skills – Facilitators. Women were asked to describe factors that would make
the vaccination process easier for them, considering the steps needed to get the vaccine (Figure
7). For vaccinated women, this involved reflection on events that had occurred, while
unvaccinated women described what they believe would facilitate the process. Interestingly,
women in the unvaccinated group were able to describe more facilitators compared to the
vaccinated group, 39 and 30, respectively. This may be due to women in the unvaccinated group
describing hypothetical scenarios for themselves and women generally, whereas the vaccinated
women reflected on their individual experiences.
All groups of women described logistics and convenience as the primary facilitator for
HPV vaccination (N=19). This included items such as time off of work, distance to the
provider’s office, easy scheduling, vaccine only appointments, and efficiency of the office.
Additionally low cost of the vaccine or insurance coverage was also a facilitator (N=23). Women
in the unvaccinated group were more interested in the cost aspect compared to vaccinated
women.
All groups of women emphasized that a trusting relationship or reassurance from a
healthcare provider would help/helped the decision-making process (N=13). These women
described an evaluation process to determine if the vaccine was right for them and a reliance on a
healthcare provider’s judgement. As one participant stated, “Just the reassurance from talking to
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the doctor” (P4, Vaccinated, Long-term Monogamous) made the process easier. Additionally,
women also described having a regularly seen healthcare provider or a provider they could trust
as a facilitator. Support from influential others agreeing with the decision for the vaccine was
also reported (N=4); these influential others included parents and partners.
Since unvaccinated women were still undecided or decided against getting the HPV
vaccine, when describing facilitators for vaccination, some women mentioned the desire to have
more information or awareness about the vaccine (N=5). This is another opportunity for a
healthcare provider to have a role in the decision-making process.
There were a few facilitators that were described that were unrealistic. Women stated
they would rather the shot be in a pill format or that there were fewer shots (N=5). This is similar
to the negative attributes described about the HPV vaccine.
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Figure 7. Frequency of Facilitators for HPV Vaccination by Vaccination Status
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Behavioral skills – Barriers. Similar to the facilitators for the HPV vaccination process,
women were asked to also describe perceived barriers (hypothetical or actual). Unvaccinated
women had 33 accounts of describing barriers compared to vaccinated women at 19 (Figure 8).
This is largely attributed to 40% of the vaccinated women stating that there were no barriers to
vaccination, which may be due to the recall of the process.
Logistics continued to be of prime importance to the young adult women across
vaccination status (N=15). Again, this included factors such as time, convenience, and
accessibility. However, in this scenario 15 unvaccinated women described insurance or cost as a
potential barrier, while only one vaccinated woman described the insurance process. Again, this
is likely due to the fact that vaccinated women were able to overcome this obstacle and no longer
see it as a barrier, while unvaccinated women were describing what they perceive to be future
obstacles.
Lack of healthcare provider support or recommendation was not seen as a significant
barrier (N=3); rather healthcare provider input appears to be more of a positive factor. Lack of
support from influential others was also seen as a barrier (N=4); these important others included
parents and partners. Only one vaccinated woman described wanting to receive more information
prior to getting the vaccine as a factor that made the process difficult. Finally, many of the
barriers described were opposite of the facilitators listed; however, there were a few new items,
including fear of needles (N=6) and fear of side effects (N=5).
Macro factors – Healthcare interaction. Women were asked how many times they
visited a healthcare provider in the last year. Almost all women (N=41) reported seeing at least
one physician in the past year, typically a gynecologist or general practitioner for an annual
appointment. Women who did not see a doctor in the last year mentioned that they only see a
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Figure 8. Frequency of Barriers for HPV Vaccination by Vaccination Status

doctor when they are sick. Among this group of women with low healthcare interaction (N=9), a
third was women who were unvaccinated and single only. These women reported not being
currently sexually active, which may contribute to their low utilization of healthcare services
from a gynecologist.
Macro factors – Health insurance. According to the survey administered prior to the
interview, a total of six participants did not have insurance at the time of the interview. There
were two vaccinated participants without health insurance, and four unvaccinated participants
without health insurance. The majority of participants, 58%, had some form of private insurance
(N=29). The remaining had Medicaid (N=8), school-sponsored (N=4), and other (N=3).
Macro factors – Social and cultural factors. Finally, participants were asked to share
any social or cultural factors that influenced their decision or opinion about the HPV vaccine.
This concept was difficult for women to articulate, and as result they were probed about
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government involvement, vaccine discussions in our culture, and media messages. There were no
group differences in these factors; in fact, the items listed by women were very individualized.
Only eight women could not list any social or cultural factors that influenced their opinion about
the HPV vaccine (N=3 unvaccinated and N=5 vaccinated).
Societal norms regarding views on medicine and vaccines in the United States were
discussed. Women reported having a distrust in the American medical system and/or a focus on
natural and holistic medicine (N=8). Many of the women’s preferences for holistic and natural
remedy stemmed from their culture or upbringing. Similarly, a couple of women reported the
skepticism they had for new medicine and lack of information on long-term outcomes (N=2).

“Just that I come from a family that’s more into like holistic remedies and cures
for things. We don’t really go to the doctor or take a whole lot of medicine, um,
things like that, so I’m always leery of vaccines and vaccinations.” (P15,
Vaccinated, Married/Living with Partner)

Yet despite these preferences for natural medicine, women still recognized the importance of the
HPV vaccine for prevention of disease.

“I think, I think definitely I've, I've carried it on [traditional medicine] in the
sense like I don't, I don't take over-the-counter stuff when I'm sick or, you know,
things like that. But definitely things that are more out of my control like, you
know, getting an STI, or like if, if I can prevent something like that, then I'll
definitely try to because it's like, it's like my life being in somebody else's hands,
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it's not really my life in my own hands.” (P25, Vaccinated, Long-term
Monogamous)

Additionally, there were HPV vaccine specific societal attitudes that impacted the
participants’ opinions about the HPV vaccine. These HPV vaccine factors included (1)
connection of the vaccine to sex, abstinence, and stigma (N=4); (2) lack of awareness in society
of this vaccine (N=2); (3) non-required vaccine indicating its lack of importance (N=2); and (4)
negative reputation of the vaccine (N=1).
The most prominent theme discussed by women was the anti-vaccination movement
(N=11). These women reported not agreeing with the movement, but recognized that it
contributes to negative views of the HPV vaccine. As one woman stated, there are polarizing
opinions on vaccination in our society,

“Society’s view of vaccinations, like I just think it’s like half and half, like half of
them say it’s very good, half of them say it’s super bad.” (P11, Unvaccinated,
Single and Dating).

Finally, women described media messages they had viewed about the HPV vaccine and
vaccines generally. Among these messages, there were negative (N=6), positive (N=4), and
mixed or incomplete messages (N=2). Two specific media campaigns/advertisements were
described, these included “One Less” and “Tell Someone.” One participant also mentioned an
episode of the HBO television show, Girls, mentioning HPV and its relation to sexual activity.
Most women reported a level of skepticism of the mass media messages that were presented.
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“I haven’t seen many – like a lot of media promoting HPV except here in like the
- and with pamphlets and like the - student health services that’s advocating for it.
But I’ve seen a lot of like stuff against it saying that it causes autism in kids and
stuff like that since that has been disproven.” (P41, Vaccinated, Long-term
Monogamous)

Summary of IMB Factors for HPV Vaccine Decision-Making
The research questions for this phase aimed to compare informational needs, motivations,
and behavioral skills for HPV vaccination across vaccination status (i.e., vaccinated and
unvaccinated) and relationship statuses (i.e., married/living with partner, long-term
monogamous, single and dating, and single). During these comparisons, it was clear that there
were no significant differences across these groups for the following constructs: Information:
Knowledge, Preferences, and Trust; Motivation: Attitudes about Vaccines, Social Motivation,
Reasons for Non-Vaccination at a Younger Age, and Perceived Severity; Behavioral Skills:
Procedural Knowledge; and Macro Factors: Healthcare Interaction, Insurance, and
Social/Cultural Factors (Figure 9).
When comparing across vaccination status, there were differences between vaccinated
and unvaccinated women for Motivation: Attitudes about HPV Vaccine, Motivation: Reason for
(Non-)Vaccination Now, and Behavioral Skills: Facilitators and Barriers. Finally, differences
were observed across relationship status categories (i.e., In a relationship; Single and Dating; and
Single Only) for Motivation: Perceived Risk of HPV and Motivation: Reason for (Non-)
Vaccination Now.
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Figure 9: IMB Model for HPV Vaccination among Young Women
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Chapter 5: Discussion

Overview
HPV vaccination has been available for the prevention of HPV-related disease among
females since 2006 (Markowitz et al., 2007). While targeted toward young adolescents aged 11
and 12 years, the rate of uptake among this group continues to be below optimal (Healthy People
2020, 2015c; Stokley et al., 2014). As a result, unvaccinated young adult women continue to fall
in the catch-up age range of 18 to 26 years for HPV vaccination. Unfortunately, approximately
only a third of 18 to 26 year old women have received the HPV vaccine resulting in a large
proportion of women who cannot benefit from this type of prevention for HPV-related disease
(Schmidt & Parsons, 2014).
In order to improve HPV vaccine rates among this catch-up range of women, it is
necessary to examine groups who continue to have low rates. Repeatedly in the literature,
married women or women in relationships are identified as having lower HPV vaccine uptake
rates compared to women who are single (Anhang Price et al., 2011; Bernat et al., 2013; Ford,
2011; Joseph et al., 2014; Laz et al., 2013; Liddon, Hood, et al., 2012; Liddon, Leichliter, et al.,
2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013;
Williams et al., 2013; Zimet et al., 2010). However, until now, it was unknown the particular
reasons for this disparity.
This study aimed to understand the information, motivation, and behavioral skills
influenced by relationship status for HPV vaccine decision-making among young adult women.

135

This was achieved through a two phase, mixed methods research study. Phase I comprised a
quantitative analysis of a nationally representative dataset to examine how interest in HPV
vaccination and primary reasons for no interest in HPV vaccination differed by relationship
status among young adult women. Phase II expanded upon this premise, by conducting in-depth
interviews with young adult women to understand their HPV vaccine decision-making process,
specifically their informational needs, motivations, behavioral skills and the influential macro
factors. Women were stratified by relationship status and vaccination status to allow for
qualitative comparisons between groups.

Relationship Status and HPV Vaccination

Phase I – Reasons for Non-Interest in HPV Vaccination
Using data from the National Health Interview Survey, this study found that married
women were approximately 40% less likely to be interested in HPV vaccination compared to
never married women and women living with a partner. This confirmed the hypothesis that
women who were married would be less likely to be interested in HPV vaccination compared to
other relationship status groups. These findings are similar to other studies examining marital
status and HPV vaccination interest using epidemiological data (Anhang Price et al., 2011;
Bernat et al., 2013; Ford, 2011; Joseph et al., 2014; Laz et al., 2013; Liddon, Hood, et al., 2012;
Liddon, Leichliter, et al., 2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & Parsons,
2014; Wei et al., 2013; Williams et al., 2013; Zimet et al., 2010); however, this study utilized
more specific categorizations of relationship status, specifically dividing non-married to never
married and living with a partner. No significant differences were observed when comparing
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married and widowed, divorced, or separated relationship status groups. This may be due to the
latter group once being in a marital relationship.
Moreover, while previous research examined how relationship status (i.e., married, not
married) was associated with interest in the HPV vaccine, it did not evaluate the reasons for noninterest in vaccination (Schmidt & Parsons, 2014). Using the NHIS dataset, differences in
primary reasons for non-vaccination were observed by relationship status category, confirming
the study’s hypothesis. Belief that they did not need the HPV vaccine was the primary reason for
non-vaccination among all relationship status groups, yet it was highest among the married
women (48%). This may be attributed belief that they are perceived not at risk for HPV in this
relationship status, and therefore do not need the HPV vaccine (Schmidt & Parsons, 2014).
Additionally, married women were more likely to cite lack of doctor recommendation as
a primary reason for non-vaccination compared to other relationship status groups. Previous
research has indicated that healthcare providers may have a bias that reduces their
recommendation for HPV vaccination to young adult female patients in relationships (Zimet et
al., 2011). While lack of doctor recommendation and perceived lack of need of the HPV vaccine
were key factors for married women, other relationship status groups were more likely to list
worried about the safety of the vaccine; 15.2% and 14.9%, respectively compared to 3.9%.

Phase II –Relationship Status, Risk Perception, and HPV Vaccine Decision-Making
The primary purpose of conducting Phase II was to elucidate the connection between
relationship status and HPV vaccination decision-making. Women in long-term relationships
reported that their current relationship status impacted their decisions not to receive the HPV
vaccine. Women attributed their decision not to receive the vaccine to current monogamy and
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few sexual partners. Moreover, these women described their perceived risk for HPV as low and
indicated that their risk for HPV would not significantly change with the vaccine due to it
already being quite low. This connects to what is seen in the quantitative literature that women in
relationships are less likely to receive the HPV vaccine, and how previous researchers
hypothesized this was attributed to risk perceptions (Anhang Price et al., 2011; Laz et al., 2013;
Lindley et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013).
Similarly, women in this sample who were in relationships and vaccinated stated that
their risk for HPV was low for comparable reasons. However, these women were less likely to
state that their relationship status impacted their decision for vaccination, rather reasons for
vaccination varied widely for this group. One of the primary themes among these cues to action
for HPV vaccination was a realization of high risk for HPV or HPV-related outcomes, which was
in the form of being diagnosed for HPV or an abnormal Pap, having a family history of cancer,
or changing relationship or sexual status (e.g., becoming sexually active or moving in with
partner). This indicates that while relationship status serves as a primary barrier to HPV
vaccination for women in relationships, significant cues to action that permit women to realize
actual risk for HPV can facilitate the vaccination process. As of yet, no interventions have been
developed for this population to address this specific barrier.
Unvaccinated women who were single and dating reported that their relationship status
did not impact their decision for non-vaccination. In fact, these women had more accurate
perceptions of their risk for HPV compared to women in relationships who were unvaccinated.
Women who were single and dating were more likely to question why they had not yet received
the HPV vaccine. Similarly, women who were single and dating and vaccinated reported a more
accurate risk perception for HPV and that their decision for the vaccine was not based on their
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relationship status. Both groups of women acknowledged the advantage of getting the HPV
vaccine was the uncertainty of future sexual partners. Women who were single and dating were
more heterogeneous than the other relationship status categories. This particular group’s
variability is often overlooked in other study designs since they are lumped into the “single” or
“never married” category (Anhang Price et al., 2011; Ford, 2011; Laz et al., 2013; Liddon, Hood,
et al., 2012; Liddon, Leichliter, et al., 2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt &
Parsons, 2014; Wei et al., 2013; Williams et al., 2013).
In contrast, women who were unvaccinated and single only perceived themselves at zero
risk for HPV, which was attributed to lack of sexual activity. Most of these women recognized
their potential risk for HPV once commencing a relationship or sexual activity; however, stated
they would wait until that point to receive the vaccine. Cohen and Head (2013) reported a similar
argument from young adult women who were not sexually active. While these women stated that
their current relationship status did not impact their decision to get the HPV vaccine, the fact that
they were single and not sexually active was their primary reason for not getting the vaccine
now. Thus, in a sense, these women’s relationship statuses were the primary barrier for not
getting the HPV vaccine, much like women who were in relationships and unvaccinated. Gerend,
Shepherd, and Shepherd (2013) evaluated the multidimensional nature of perceived barriers to
HPV vaccination among young adult women. This study found one of the barrier dimensions
was perceived lack of need, which included the clustering of not sexually active and
monogamous relationship. In contrast, women who were single and vaccinated stated that their
relationship status did not impact their decision for vaccination, but much like women in
relationships and vaccinated, they had a variety of cues to action for getting the vaccine,
including recommendations from providers and parents.
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These findings suggest that among unvaccinated young adult women, women were
framing their risk for HPV and perceived need for the HPV vaccine based on their current
relationship statuses. Yet, there was some discussion of the potential need or lack of need if
relationship statuses were to change in the future among unvaccinated women. For example,
women in relationship said that the vaccine would be more important if they were no longer in a
monogamous partnership. In contrast, women who were single and dating said the vaccine would
be less important if they did enter a long-term monogamous relationship. While these women
were cognizant of the potential change in risk for HPV based on changing relationships, these
were not motivating factors when the women evaluated their potential risk for HPV. In other
words, women were evaluating their current risk for HPV, rather than recognizing the potential
for that risk to change in the future. The low risk perceptions of women in relationships due to
monogamy observed in this study are similar to the HIV risk perceptions among women in close
relationships. The concept of knowing their partner and engaging in monogamy supersede any
other risk behaviors the couple may be engaging in, for example, sex without condoms
(Misovich et al., 1997). These findings should be considered in the context of the potential
lifetime risk for HPV among a woman, which underscores the need for HPV vaccination. The
average lifetime risk of HPV among women with one opposite sex partner is 85% (Chesson,
Dunne, et al., 2014). Recent evidence suggests the prevalence of HPV is approximately 17%
among heterosexual couples who did not have any other sexual partners (Burchell et al., 2014).

Triangulation
The findings from Phases I and II were complementary and both confirmed the
hypothesis the relationship status is influential to HPV vaccination among young adult women.
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The findings from Phase I described differences in reasons for non-interest in HPV vaccination
based on relationship status groups using a nationally generalizable and large sample. While this
suggested that differences do exist by relationships status, this survey was limited by not
expanding upon the reasons for non-interest and non-vaccination. Phase II’s qualitative
methodology permitted an in-depth understanding of reasons for not receiving the HPV vaccine
among a smaller sample of young adult women. To assist in the comparison between phases, the
relationship status categories from Phase I were redefined to be Married or Living with a Partner
and Never Married to mirror the relationship status categories from Phase II (see Table 19, Page
97).
The quantitative data indicated that more women who were Married or Living with a
Partner reported “does not need vaccine” compared to Never Married women (45.3% and 34.7%,
respectively). This is similar to the findings among unvaccinated women in Phase II that women
who were married or living with a partner reported not needing the vaccine due to monogamy or
other protective sexual practices in their relationship. In contrast, women who were single and
dating were more likely to state that they were unaware of the vaccine as a reason for nonvaccination.
Another key difference observed between the relationship status groups from the survey
data were women who were Married or Living with a Partner reported a lack of doctor
recommendation more often compared to Never Married women (9.5% and 6.3%, respectively).
In the interview sample, vaccinated young adult women were asked their reasons for receiving
the HPV vaccine as a young adult. Women who were single and dating or single only were more
likely to report a doctor recommendation as a cue to vaccination, whereas women in
relationships did not cite this as a reason.
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These results provide evidence of the importance of mixed methodology for public health
research, especially for a complicated topic, such as HPV vaccination. The qualitative data
supplemented the quantitative results by expanding upon the reasons for non-vaccination with
narratives from the target population. Furthermore, these narratives were not constricted to
closed-ended questions, but based on the diverse perspectives of the participants. Moreover,
while the quantitative and qualitative painted a picture of the barriers to HPV vaccination, the
qualitative data enriched these findings by also evaluating the facilitators to vaccination among
already vaccinated women. However, there are limitations to these comparisons due to
differences in samples and recruiting methods, as well as categorizations of relationship status.
The quantitative data were more restricted in relationship status types for an 18 to 26 year old
population, whereas the interview sampling disentangled the “Never Married” group into three
distinct strata (i.e., Long-term Monogamous, Single and Dating, and Single Only), which was
found to have significant variability in responses.

Informational Needs
Knowledge about a health behavior is often recognized as a key step in the behavior
change process (Brewer & Rimer, 2008). Awareness about the HPV vaccine was found to be a
significant predictor of interest in HPV vaccination among young adult women in the NHIS
sample (PR = 1.58, 95% CI 1.46-2.05). In examining the primary reasons for non-interest in
vaccination, not knowing enough about the vaccine was only reported by 13% of sample.
Women in the Phase II sample had adequate knowledge about HPV and the HPV vaccine.
Compared to a 2008 sample of college women using the same knowledge scale, the 2015 sample
had higher scores, 14.1 and 15.3, respectively (Daley, Vamos, et al., 2010). This coincides with
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other literature indicating that awareness about the HPV vaccine have increased over time
(Schmidt & Parsons, 2014).
In the Phase II sample, women demonstrated a surface level awareness and knowledge of
HPV and the HPV vaccine, but had difficulty elaborating on details. Women were generally
aware of what HPV was and that it could cause cervical cancer. However, they were more
uncertain about other outcomes associated with HPV, such as genital warts or other HPV-related
cancers. This may be due to the heightened focus on the link between HPV and cervical cancer
through popular media campaigns rather than on outcomes with more sexual connotations
(Pisciotta, 2012). An additional area where women were lacking information was the mode of
transmission of HPV. In the interviews, women stated that HPV was transmitted sexually;
however, were generally unable to elaborate on modes of transmission (i.e., vaginal-penile, oral,
skin to skin). Previous research among young adult women has also documented the lack of
knowledge regarding routes of HPV transmission (Sandfort & Pleasant, 2009). If women are
unaware of these modes of transmission, they may have the false belief that protected sex with a
condom alone may prevent HPV, therefore underestimating their risk for acquiring the virus.
Of most concern were the misperceptions women have about the timing and target
population for the HPV vaccine. A subset of the vaccinated and unvaccinated women both
reported that HPV vaccination should occur after onset of sexual activity. Similarly,
approximately 7% of the NHIS sample reported that they did not need the vaccine because they
were not sexually active. This is contrary to the evidence supporting that the vaccine is most
effective prior to exposure to HPV and onset of sexual activity (Markowitz et al., 2014).
Moreover, it perpetuates the public’s focus on the connection of this vaccination with sexual
activity of adolescents and young adults (Zimet, Rosberger, Fisher, Perez, & Stupiansky, 2013).
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Additionally, despite the introduction and approval of a 9-valent vaccine immediately prior to the
commencement of data collection (Food and Drug Administration, 2015; Petrosky et al., 2015),
none of the participants described this change in vaccine availability. It is anticipated that health
messages surrounding the HPV vaccine will become increasingly complicated with options of a
quadrivalent and 9-valent vaccine.
Despite many of these misperceptions about HPV and the HPV vaccine, women reported
hearing about the HPV vaccine from a variety of sources, such as healthcare providers, family
members, partners, TV, and the Internet. Among these sources, women stated that they trusted
their healthcare provider the most for information about HPV and the vaccine. It is important to
identify the agent most trusted as previous research has indicated the more valued the
information source, the more likely the woman may be to prioritize that specific information
(Redmond et al., 2010; Worsley, 1989). Moreover, it is evident from the literature how valuable
a provider recommendation for the HPV vaccine can be, especially for young adult women
(Rosenthal et al., 2011).
Women also reported that they would prefer to learn more information in the future about
HPV and the vaccine from a healthcare provider and the Internet. Internet sources, while easily
accessible by this population, may also produce negative and mixed messages about the HPV
vaccine (Ruiz & Barnett, 2015). Other modes of information were less consistently cited as
sources of HPV vaccination information, including the television and radio. Identifying the
information-seeking preferences of this demographic can inform the agents or modes used in
future health interventions.

Motivation
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Motivating factors for HPV vaccination, which included attitudes, social influences, and
risk perceptions, were explored. Significant differences in motivations were observed for
attitudes about the HPV vaccine between vaccinated and unvaccinated women. Additionally, risk
perception varied based on relationship status, as previously described.

Attitudes
Overall, women reported positive attitudes about vaccines generally, stating that they
protected the population and personal health from diseases. Surrogate markers for attitudes about
other vaccines were measured in the NHIS sample; specifically women who had received a flu
shot in the last 12 months or received the Hepatitis B vaccine were more likely to be interested in
the HPV vaccine. This is supported by previous research as well (Anhang Price et al., 2011; Jain
et al., 2009; Laz et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013).
Yet, women in the interview sample differed in attitudes about the HPV vaccine based on
vaccination status. Women who were vaccinated had more favorable opinions about the HPV
vaccine compared to women who were unvaccinated. This may reflect true differences in
attitudes impacting vaccine behavior, or may be indicative of changes in attitudes after engaging
in the behavior. Higher perceived importance and positive attitudes about the HPV vaccine have
been cited as being associated with vaccination or intent for vaccination among young adult
women (Bendik et al., 2011; Bennett et al., 2012; Dillard, 2011; Ratanasiripong et al., 2013;
Rosenthal et al., 2011; Schaefer Ziemer & Hoffman, 2013). However, similar retrospective
adjustments have been reported in the literature for risk perceptions and recall bias (Brewer et
al., 2007). Thus, the differences in attitudes about the HPV vaccine between vaccination groups
may be attributed to experience with the vaccine. Women who were unvaccinated cited more
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often that side effects were a negative aspect about the vaccine; however, these women were
unable to describe these side effects in any detail. This is congruent with the NHIS sample,
which estimated that 12% of unvaccinated young adult women were worried about the safety of
the HPV vaccine. In contrast, women who had received the vaccine were able to describe any
side effects experienced, such as pain at the injection site, which is reported in the literature as a
common side effect with this vaccine (Reiter, Brewer, Gottlieb, McRee, & Smith, 2009a).
An explanation for the disparity observed between the attitudes about vaccines generally
and the attitudes about the HPV vaccine may be attributed to women classifying the HPV
vaccine as a separate type of vaccine. For instance, women stated it is not similar to required
vaccines, such as the MMR vaccine, but is more important than completely optional vaccines,
such as the influenza vaccine. Analogous perceptions have been reported by providers who
administer adolescent vaccines; specifically, that the HPV vaccine is more burdensome to
discuss with patients compared to other required vaccines (e.g., Tdap and meningococcal)
(Gilkey et al., 2015).

Social Motivation
There were no major differences between social motivators for HPV vaccination across
vaccination status and relationship status. The key motivator was/is a healthcare provider.
Previous literature repeatedly emphasizes the importance of a healthcare provider
recommendation for HPV vaccination initiation (Daley, Vamos, et al., 2010; Klosky et al., 2015;
Licht et al., 2010; Marchand et al., 2012; Rosenthal et al., 2011; Zimet et al., 2010); however,
this study also elicited the salience of a trusting or established relationship with a healthcare
provider. This confirms findings from Joseph et al. (2014) that a diverse sample of young adult
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women reported trust in a provider was important for HPV vaccine decision-making; however,
while it significantly predicted intent for vaccination, it was not statistically significant for
receipt of the HPV vaccine. Moreover, in this study, some women reported that providers
reassured them that the vaccine was best for them, and personalized it to their particular
circumstances. While this may appear as a facilitator to HPV vaccination, it can also negatively
affect HPV decision-making for this particular population. Women in college may not wish to
establish care with a new provider and prefer returning “home” to see a provider they have a
relationship with. Thus, while in college, women may not see a trusted provider due to logistics
and thus do not receive this recommendation during the catch-up years for HPV vaccination.
Additional influential others included friends, family members, and spouses. Previous
literature studying young adult college women has found peer norms impactful for HPV
vaccination (Hopfer & Clippard, 2011); however, in this study, peers were less important than
other agents. Peers were only seen as significant if they could share their experiences with HPV
vaccination as a model that it was safe and acceptable. Family members, specifically mothers,
were also important in encouraging or discouraging vaccination, which is previously found in the
literature (Cohen & Head, 2013; Hopfer & Clippard, 2011). However, this study found that
mothers’ roles in the HPV vaccination process were more salient during adolescence compared
to young adulthood. Moreover, women reflected that their mothers were one of the primary
barriers to vaccination in adolescence. In comparison, the NHIS sample found that a family
member or spouse against the HPV vaccine was a primary reason for non-vaccination in less
than 2% of the sample. Therefore, these agents may not necessarily be barriers to vaccination,
but rather facilitators.
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The final group examined as social motivators were partners. Interestingly, women
reported that these were not significant agents in HPV vaccination decision-making, in fact,
partners tended to be indifferent. Moreover, women reported that they thought their partners
should be vaccinated as well, while some women stated it was important to receive the vaccine
to protect their partner’s health. Both of these statements are consistent with previous literature
(Harper, Alexander, et al., 2014; Patel et al., 2013). This coincides with the notion that sexual
health prevention practices are often relegated to women’s health. Women often take on the
sexual and reproductive health prevention behaviors (e.g., birth control pills) to keep the
heterosexual partnership safe. This may also be the product of societal norms of masculine
hegemony resulting in men believing they do not need protection (Evans, Frank, Oliffe, &
Gregory, 2011). Perhaps this is a consequence of the feminization of the HPV vaccine, which
ultimately over-identified the vaccine as a women’s rather than men’s health behavior (Daley,
Buhi, Vamos, et al., 2012).
Previous literature among university women has indicated that attitudes toward HPV
vaccination and perceptions of social support predicted intention of HPV vaccination (Fisher,
Kohut, Salisbury, & Salvadori, 2013), which is supported by this study. However, one factor that
is understudied in the current literature emerged, the idea that HPV vaccination is a personal
decision. Women repeatedly mentioned that while outside information or people were
influential, women ultimately wanted to make the decision on their own with all the available
information. In other words, women were deciding if the vaccine was right for them. This
personalization of the vaccine for individual use has implications for future health messages
targeted at this newly autonomous group of young adults. Women desire to know that the HPV
vaccine is best for their health given their medical and social history. This contradicts the
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literature that reports social norms from peers and family members being influential for HPV
vaccine decision-making (Allen et al., 2009; Bennett et al., 2012; Hopfer & Clippard, 2011;
Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013). While these multiple spheres of
influence may be significant, women wish to reconcile the overwhelming amounts information
and perspectives with their own beliefs and judgement.

Reasons for Non-Vaccination as an Adolescent
Since the HPV vaccine has been available for females since 2006 and this study’s sample
comprised females 18 to 26 years old, women were questioned about the reasons they did not
receive the HPV vaccine as an adolescent, as these factors may influence current HPV
vaccination behavior. Major reasons were lack of awareness of the HPV vaccine and parental
beliefs about the HPV vaccine. For many of these women, lack of awareness perpetuated until
young adulthood. Similarly, approximately 30% of the NHIS 2010 sample of women had not
heard of the HPV vaccine. However, parental influence, while significant in adolescence, does
not have the same weight in young adulthood. This provides evidence to the statement that
young adulthood is a period of autonomous decision-making for sexual and reproductive health.
Furthermore it emphasizes the need to continue to target women in the catch-up range for HPV
vaccination, since their parents’ beliefs may have been an obstacle to vaccination at an earlier
age.

Reasons for (Non-) Vaccination as a Young Adult
Vaccination decision-making in young adulthood revealed that parental beliefs were no
longer primary drivers in this process. In examining the primary reasons for non-vaccination
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among unvaccinated women, two key themes emerged: (1) lack of awareness of the vaccine, and
(2) perceptions of low risk for HPV. As previously stated, the perceptions related to risk of HPV
varied based on relationship status groups, which impacted reasoning for not needing the vaccine
at that time. The lack of awareness of the HPV vaccine was a significant barrier to vaccination
among this sample, while similarly it affected interested in HPV vaccination in the NHIS sample.
These two barriers were also previously identified in the literature as contributing to low uptake
of the HPV vaccine (Anhang Price et al., 2011; Cohen & Head, 2013; Gelman et al., 2013;
Hodge et al., 2011; Hopfer & Clippard, 2011; Joseph et al., 2014; Laz et al., 2013;
Ratanasiripong et al., 2013; Schaefer Ziemer & Hoffman, 2013; Schmidt & Parsons, 2014).
In contrast, women who were vaccinated cited a variety of reasons for getting the HPV
vaccine as a young adult. These cues to action, while quite heterogeneous, could be simplified to
addressing the primary barriers: lack of awareness and perceptions of low risk for HPV. For
some women, a recommendation from another individual or awareness generally contributed to
uptake of the vaccine. For others, it was the realization of the actual risk for HPV in their
lifetime, which stemmed from HPV diagnosis, family history of cancer, becoming sexually
active, or other changes in relationship status.

Consequences
Similar to the findings from the informational needs, the majority of women focused on
cervical cancer as the primary consequence to HPV. Again, this may be attributed to popular
media and health messages’ focus on this connection (Pisciotta, 2012). Women repeatedly
mentioned cervical cancer to be the most severe outcome, while genital warts were seen as
inconvenient and aesthetically displeasing. Correspondingly, previous studies have found that the
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perceived severity of cervical cancer predicted HPV vaccination (Bendik et al., 2011; Krakow et
al., 2015). Findings from the knowledge survey confirm that women were less aware of HPV’s
connection to genital warts (60%) compared to cervical cancer (94%).
An additional consequence reported by a smaller proportion of the sample was the
emotional responses to an HPV diagnosis. Previous literature has reported on emotional
responses expressed by women who are HPV positive, including anger, self-blame, fear, and
stigma (Daley, Perrin, et al., 2010; Perrin et al., 2006). This consequence may be even more
salient in women compared to men since women have screening tests throughout their adult lives
to identify the presence of HPV (US Preventive Services Task Force, 2014a), whereas a
comparable test is not approved for use among men. Therefore, women may experience these
emotional responses on a greater scale due to increased testing. Yet, Daley, Buhi, Marhefka, et
al. (2012) found in a natural history study of HPV infection in men, that men who tested positive
for HPV experienced more negative emotional responses compared to HPV negative men. The
only instance where the emotional responses to HPV may be similar across sexes is with the
presence of genital warts, which may cause shame and affect self-esteem (Jeynes, Chung, &
Challenor, 2009), or potentially oropharyngeal cancer.

Behavioral Skills
Vaccinated and unvaccinated women had similar procedural knowledge for obtaining the
HPV vaccine. This is reassuring to confirm that unvaccinated women are aware of the process
for accessing, financing, and following up with the HPV vaccine. Additionally, women reported
similar facilitators to vaccination, including ease of logistics, cost/insurance, and healthcare
provider established or trusted. Yet, unvaccinated women desired additional information prior to
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vaccination. Another facilitator described was a fewer number of shots for the vaccine series.
This is reassuring as current research is evaluating the efficacy of a two-dose rather than threedose vaccine (Markowitz et al., 2014), which may ease the vaccination process for women.
In contrast, unvaccinated women reported more barriers to vaccination, such as cost and
insurance. However, the frequency of barriers reported in this group may be inflated compared to
vaccinated women due addressing a hypothetical situation, whereas vaccinated women recalled
the situation. Some of the barriers described by unvaccinated women were stated in reference to
women generally, not necessarily personally experienced barriers. In the NHIS sample of
unvaccinated women, the cost of the vaccine as a reason for non-vaccination was only cited by
3% of the sample. Yet, the presence of cost and lack of insurance coverage as a barrier to
vaccination is congruent with previous literature among this population (Anhang Price et al.,
2011; Dempsey et al., 2011; Ford, 2011; Head & Cohen, 2012; Hodge et al., 2011; Jain et al.,
2009; Joseph et al., 2014; Laz et al., 2013; Lindley et al., 2013; Rahman et al., 2015; Tiro et al.,
2012; Wei et al., 2013; Zimet et al., 2010).

Macro Factors
The macro factors assessed in this study were healthcare interaction, economic factors
(i.e., insurance coverage and poverty level), and social and cultural factors.

Healthcare Interaction
The interview sample reported high levels of healthcare interaction; visiting a
gynecologist or general practice physician approximately once a year. This indicates that access
to a healthcare provider is not an issue; rather these women have many clinical opportunities to
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discuss the HPV vaccine with providers. In fact, women mentioned needing to go to a healthcare
appointment for annual exams for preventive screening, such as Pap tests, as well as getting birth
control refills. Florida data from 2008-2009 indicate that approximately 24% of women reported
using short-acting reversible methods of contraception, such as pills, injectable, patches, and 5%
using long-acting reversible methods, such as intrauterine devices, and implants (Hernandez,
Sappenfield, Clark, & Thompson, 2012), all of which requires some level of healthcare
interaction. These simultaneous sexual and reproductive health behaviors may offer the
opportunity for increased vaccination among catch-up young adult women. However, one barrier
reported among college women was the desired to return to a familiar or trusted healthcare
provider “back home.” This may reduce the number of annual visits in the catch-up period for
some women since the logistics are less feasible. Efforts are needed to understand how to engage
college women with health services available in a university setting, which would ultimately
decrease logistical barriers for vaccine uptake.

Economic
Additionally, most women in the sample reported having some form of insurance
coverage, which may also contribute to the high healthcare interaction for this sample. Insurance
has been found to be a significant barrier in the literature (Anhang Price et al., 2011; Dempsey et
al., 2011; Ford, 2011; Hodge et al., 2011; Jain et al., 2009; Laz et al., 2013; Lindley et al., 2013;
Rahman et al., 2015; Tiro et al., 2012; Wei et al., 2013; Zimet et al., 2010), because without
insurance, there is a high out-of-pocket cost for the HPV vaccine (American Cancer Society,
2014b; Planned Parenthood, 2014). In contrast, insurance coverage was not a significant
predictor of HPV vaccine interest in the NHIS sample. In addition, certain economic factors may
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contribute to HPV vaccination in young adult women. In the NHIS sample, being less than 100%
of the poverty ratio was a significant predictor for interest HPV vaccination. This may be
attributed to the impending changes in Medicaid Eligibility across the United States at the time
of the survey (2010), which would create a national Medicaid minimum eligibility of 133% of
the federal poverty level (Centers for Medicare and Medicaid, n.d.). Additionally, young adults
were permitted to stay on their parent’s insurance coverage until age 26, as of 2010 ("Patient
Protection and Affordable Care Act," 2010). Previous research has reported that low income or
being below the federal poverty level was associated with non-vaccination among young adult
women (Chao et al., 2010; Jain et al., 2009; Laz et al., 2013; Rahman et al., 2013; Wei et al.,
2013). With the changing healthcare landscape and availability of health coverage for young
adults, it is anticipated that insurance coverage for this demographic will increase (Claxton,
Levitt, Brodie, Garfield, & Damico, 2014; Rudowitz, Snyder, Smith, Gifford, & Ellis, 2014).

Social and Cultural Factors
One of the more nebulous factors reported by women were the social and cultural factors
impacting HPV vaccination. These may be more difficult for participants to recall since they are
in the periphery of their influence. The most prominent theme that emerged throughout the
interviews was the discussion of the anti-vaccination movement. As a result, the discussion about
vaccines became politicized with participants stating they were “pro-vaccine” or did not
understand people who were “anti-vaccine.” The social context of this movement is necessary to
consider for this health behavior as public commentary and figures (e.g., celebrities) can have an
influence on a preventive behavior (Bean, 2011; Hoffman & Tan, 2015).
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Some women described media messages about the HPV vaccine that they have seen. The
majority were characterized as negative or mixed/incomplete messages. Similarly, a content
analysis of web media has revealed the majority of the HPV vaccine webpages also have a
negative spin (Ruiz & Barnett, 2015). Moreover, popular media, such as the television show
Girls on HBO, may provide unfocused or problematic messages about HPV and HPV
vaccination (Rogers, 2015). Overall, the women reported a level of skepticism of the messages
seen. While mass media campaigns or other sources of media may be used as a tool to reach a
broad audience, this may not necessarily be the best option to target young adult women.
Finally, the NHIS sample revealed that region of the United States impacted interest in
HPV vaccination. While previous literature has indicated that the South region has lower uptake
in the HPV vaccine (Rahman et al., 2013; Schmidt & Parsons, 2014), this analysis found that
women living in the Midwest were less likely than women living in the South to be interested in
the HPV vaccine.

Strengths and Limitations
For any research project, the strengths and limitations of the study design must be
evaluated in context of the results reported. For this study, these were be assessed by phase of
the study due to the mixed method design.

Phase I – Validity and Reliability
Utilizing the NHIS 2010 dataset for a secondary data analysis had advantages to achieve
this research aim. First, the survey used a nationally-representative sample based on the
population characteristics from the U.S. Census. The analysis procedures incorporated the
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primary sampling units, strata and clustering variables to appropriately weight the survey data
according to the complex sampling design. Thus, the external validity of this sample could
extend to the larger United States population of unvaccinated women 18 to 26 years of age.
Despite the benefits of conducting a secondary data analysis (e.g., feasibility,
generalizability), there were limitations. First, given that this was a cross-sectional survey, there
was the concern for issues with self-report for responses, specifically for HPV vaccination, one
of the sub-setting variables used to develop the samples for analysis. Previous studies have
estimated the reliability of self-report of HPV vaccination. One study has shown that the
sensitivity for recall among adolescent girls 13 to 17 years to only be 54%, and for mothers of
those girls 76%. Alternatively, the specificity was 100% (Stupiansky, Zimet, Cummings,
Fortenberry, & Shew, 2012). A study conducted among women 18 to 26 years old reported that
there was 94.5% agreement between recall and electronic medical records for the first dose of the
HPV vaccine series (Kharbanda et al., 2013). The remaining variables included in the analysis
were also self-reported and may have suffered from recall bias by the individual. Moreover, the
reliability of these survey questions was not reported on publically available reports from the
National Center for Health Statistics. However, the questions are periodically revised by experts
in health statistics and health content areas (Centers for Disease Control and Prevention &
National Center for Health Statistics, 2012). Also, because these data were from a secondary
source, the analysis was limited to the population who had the option to respond to the
psychosocial questions about the HPV vaccine, which were women un-interested in the vaccine.
As a result, a comparison of vaccinated to un-vaccinated women was not within the scope of this
analysis.
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An additional limitation of this dataset was the response rate. While participants were
drawn from a random sample, nearly 40% refused to participate. In 2009, the nonresponse bias
for the sample adult and sample child files were assessed. In the sample adult file, nonrespondents were more likely to be younger and Hispanic, but have a similar health status. As a
result of this analysis, an adjustment was made and implemented in the 2010 NHIS file weights
to account for nonresponse bias associated with geographic area, sex, age, and race/ethnicity
(Moriarity, 2009). Another issue faced was the large amount of missing data for the income
variable in the NHIS 2010 dataset. To address this issue, the NHIS has developed imputed values
for income based on demographic and health-related variables (Division of Health Interview
Statistics & National Center for Health Statistics, 2011b). As a result, multiple imputation was
used in the analysis to estimate income’s impact on HPV vaccine intention.
An additional limitation of using secondary, cross-sectional data was the ability to assess
causality between the exposure and outcome. While women may report no interest in the HPV
vaccine while in a particular relationship status, this only infers an association between
relationship status and HPV vaccination interest. Additional qualitative research elucidated
women’s specific decision-making for HPV non-vaccination.
The statistical analysis methods also must be considered. This study used logistic
regression to estimate the odds ratio. While this is the most commonly used methodology for
measuring the strength of association in cross-sectional data (Szklo & Nieto, 2007b), this
particular analysis was limited by the fact that the outcome variable of interest may not be rare
(i.e., ~35%) (Schmidt & Parsons, 2014). The odds ratio asymptotically approaches the relative
risk with small probabilities; however, when an event is not rare (>10%), then the odds ratio will
overestimate the relative risk (Szklo & Nieto, 2007a). To assist in this overestimation of the
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relative risk, an ad hoc adjustment of the odds ratio was used to derive a closer estimate of the
relative risk by accounting for the prevalence (Zhang & Yu, 1998).
The final statistical consideration was the use of survey-weighting procedures and the
availability of Exact tests in the statistical software program. The primary reasons for noninterest in HPV vaccination compared to relationship status revealed multiple cells with
frequencies less than five. While chi square tests are not equipped to handle small cell numbers
(Rosner, 2006), Fishers Exact test is not available in SAS 9.4 with survey-weighting procedures
(SAS Institute Inc., 2015). As a result, smaller categories were combined into an “other”
category to permit the use of a chi square test. This ultimately resulted in a reduction in the
variability of responses for reason for non-vaccination.

Phase II - Trustworthiness of Data
Qualitative methodology does not have the traditional methods for assessment of validity
and reliability. Rather data can be assessed for trustworthiness, the truth value of the findings,
using the following criteria: credibility, dependability, confirmability, and transferability (Ulin,
Robinson, & Tolley, 2005) In this context, the credibility of the interpretations of the data was
assessed by looking for negative cases for emerging hypotheses in the data, as well as seeking
explanations for inconsistencies in the data from outside sources (e.g., Phase I results).
Dependability refers to the ability to replicate the process for obtaining the results, which was
documented throughout the research process and reported in dissemination pieces. Due to the
subjective nature of data analysis, it was important for the researcher to be reflexive throughout
the project. This occurred through writing memos during the interview and analysis processes, as
well as debriefing with committee members and colleagues. Additionally, having a second coder
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establish the reliability of the coding process (kappa = 0.88) improved the dependability of the
analysis process. Confirmability of the results was achieved by utilizing an audit trail for all
research processes (e.g., raw data, data analysis process, memos). Finally, transferability is the
degree to which the results can be applied or transferred to groups of people beyond this project.
Results are more likely to be transferable when utilizing a theoretical framework to guide the
research, making it more likely to be adaptable to other populations (Ulin et al., 2005). To assist
in the transferability of the results, the IMB Model was used as a guiding theoretical framework.
To assist in the evaluation of the transferability of the results, the characteristics of the final
sample was assessed to allow for comparison with other types of populations (Denscombe,
2010). The student population at the University of South Florida is more racially/ethnically
diverse than most universities in the United States. Data from the NCHA 2013-14 surveys
indicate that USF had more black and Hispanic respondents (11.3% and 21.1%, respectively)
compared to the reference group (6.6% and 13.9%, respectively). Furthermore, these racial and
ethnic groups have increased at the University of South Florida from 2011 to 2014 (University
of South Florida, n.d.-a). Among the eligible sample completing the initial survey, 19% of
respondents were Hispanic and 19% were black. It may be that these results are only transferable
to similar college populations and not representative of women 18 to 26 years in the general
population. Moreover, the data from the knowledge questions will most likely be different in this
college population compared to a general population since one study found that knowledge about
the HPV vaccine was strongly associated with college educational attainment (Kennedy et al.,
2011).
Using qualitative methods to answer the proposed research question was an appropriate
scientific approach. The research question asked “why” and “how”, which qualitative
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methodology permits a greater level of detail and depth compared to quantitative methodology
(Hennink et al., 2011b). Additionally, this approach was an extension of what has been
previously documented using survey-based research indicating that married or monogamous
women are less likely to be vaccinated (Anhang Price et al., 2011; Bernat et al., 2013; Ford,
2011; Joseph et al., 2014; Laz et al., 2013; Liddon, Hood, et al., 2012; Liddon, Leichliter, et al.,
2012; Lindley et al., 2013; Rahman et al., 2013; Schmidt & Parsons, 2014; Wei et al., 2013;
Williams et al., 2013; Zimet et al., 2010). This form of data collection was suitable for
investigating how people make decisions, their personal beliefs and perceptions, motivations for
behavior, and for sensitive issues (Hennink et al., 2011a). Furthermore, this design of having two
segments for the sample allowed for a description of the variability of HPV informational needs,
motivations, and behavioral skills across these groups, rather than quantifying the variation,
which is typical of quantitative research.
An additional benefit of conducting in-depth interviews was the less-restrictive form of
data collection. The open-ended nature allowed for participants to add additional information
that may have not been explicitly asked for, thus permitting the generation of new findings. The
iterative process of qualitative data analysis allowed for adjustments to interview guide material
throughout the study to account for emergent findings (Hennink et al., 2011b). These
characteristics are typically not attributes of quantitative methodologies. Additionally, this study
design permitted women to self-identify their relationship status without any specific criteria.
Through the in-depth interview, descriptions about length of time, monogamy, and sexual
behavior were gathered to provide context to these relationship status categories, which may be
beneficial for future studies.
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While the knowledge scale was not the main focus of this research phase, the study
benefited from utilizing an HPV knowledge scale that had high reliability with an intraclass
correlation coefficient equivalent to α = 0.92. Moreover, this knowledge scale has been
previously applied among a college sample of women, confirming the content validity of the
scale (Daley, Vamos, et al., 2010).
This methodology was the most appropriate for the research question; however, there are
limitations that must be considered. Firstly, a major criticism of qualitative data analysis is the
subjectivity of the process, that is argued to affect the internal validity of the findings (Hennink
et al., 2011b). In order to make any potential subjectivity transparent, I engaged in reflexivity,
which is self-reflection on the research throughout the research project (Hennink et al., 2011b).
By documenting the potential biases I have as a researcher, this helped me be more aware of any
subjective bias introduced in the study. For example, I am a public health, female researcher who
perceives vaccination as a benefit to the public’s health. Also, I have received the HPV vaccine,
underscoring my personal preference for this vaccination. During interviews, participants
sometimes asked my personal opinion about the HPV vaccine; however, I asked that we wait
until the end of the interview to discuss information about me. This was an attempt to not allow
my beliefs to influence the participants’ perceptions of the HPV vaccine.
The mode of the interview administration via telephone may have impacted the social
desirability bias of the data collected. Compared to questionnaires, telephone interviewing has
been found to underestimate severity of health status due to respondents reporting better health
outcomes (Brewer, Hallman, Fiedler, & Kipen, 2004). However, a comparison of perceived risk
for cancer was compared for interview administered telephone surveys and mailed surveys
found there was no difference between these modes of data collection (Persoskie, Leyva, &
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Ferrer, 2014). To ameliorate the effect of social desirability bias on the data collection process,
the researcher attempted to establish rapport with the participants. This was implemented by
demonstrating gratitude to the participant for their time and honesty of their answers. Moreover,
the more sensitive questions regarding HPV risk were layered in the middle of the interview to
allow time for the participant to be more comfortable with the interviewer.
An additional potential source of bias that may have been present in this study is
sampling bias. Recruitment materials (Appendix A) stated the purpose of this study was to “…
investigat[e] the knowledge, attitudes and opinions of young adult women about HPV
vaccination.” As a result, women included in the sample may have had more of an interest or
more knowledge of the HPV vaccine compared to non-participants. Additionally, recruitment in
this phase was stratified only by vaccination status and relationship status in order to assess the
variability in HPV vaccine decision-making among these groups. This stratification alone may
prevent equivalent comparisons of known risk factors or associated sociodemographic factors for
HPV vaccination (e.g., age, sexual orientation), which may slightly bias these results.
Findings from the qualitative data indicated that there may have been recall bias for
women who already received the HPV vaccine. Certain constructs, such as attitudes about the
HPV vaccine and barriers to vaccination, may have been adjusted for women after receiving the
HPV vaccine compared to unvaccinated women. While the research design advertised that
women could be eligible to participate if they received the first dose of the vaccine within the
last six months, it became clear during the interview process that many women did not accurately
recall this length of time. Once the study concluded, it was determined that overall the
vaccinated women received at least one of the three doses for the vaccine in the last year, rather
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than the first dose in the last six months. Conducting the follow-up interviews after the survey
was permitted the elucidation of this difference.
One interesting finding in two of the interviews was women reporting that the HPV
vaccine was required for admittance to the university or living in residence halls. These women
were probed to describe the vaccine and the purpose of the vaccine to ensure it was the HPV
vaccine they were referencing. Additionally, these women were asked to clarify if it was the
HPV vaccine and not the meningococcal vaccine, which is often required for living on campus.
Everything stated by the participants indicated that they received the HPV vaccine with the
exception that it was required, which was incorrect. During the analysis, the USF Student Health
Services webpage was reviewed to determine if any confusion could occur for students. While
the webpage clearly delineates those vaccines required for documentation (e.g., MMR, Hepatitis
B, and Meningitis if living on campus), it does provide information on the HPV vaccine in
addition to these other vaccines (University of South Florida, n.d.-b). Future work should
examine how college entry policies could impact HPV vaccination behavior for catch-up groups.
The goal of Phase II was to compare the informational needs, motivations, and behavioral
skills for HPV vaccination among young adult women across relationship status groups and
vaccination status groups in congruence with the research questions proposed (Table 2). While
conducting these comparisons, it was evident that women who were married/living with a partner
or in a long-term monogamous relationship shared similar factors for HPV vaccination. Thus,
these two sampling groups were consolidated into one group for the analysis. It was
hypothesized that the single and dating, and single only groups would also be similar; however,
it was evident that these two sampling groups were distinct in their factors contributing to HPV
vaccination. As a result there were uneven numbers in the sampling categories for the data
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analysis. However, this study underscored the importance of finer categorizations of relationship
status for scientific study. Previous research has stratified samples by sexual activity (active or
never active) (Hopfer & Clippard, 2011); yet this oversimplification removes the heterogeneity
present within these groups as evidenced by this study.

Implications
This research study established that relationship status plays an integral role in HPV
vaccine decision-making for young adult women. Primarily, it identified that women’s risk
perceptions regarding HPV were moderated by their relationship status; specifically, women in
long-term relationships were less likely to see themselves at risk for HPV due to monogamy. A
potential mechanism to address this discrepancy between actual and perceived risk is the use of
health literacy. Health literacy is the process of finding, understanding, evaluating,
communicating and using health information to make informed health decisions (Coleman et al.,
2011). Returning to the IMB Model, women in this study were found to have adequate levels of
knowledge regarding HPV and HPV vaccination, such as identifying HPV as sexually
transmitted, the potential ways to prevent HPV, and that a vaccine does exist. Moreover, the
women also reported having the behavioral skills necessary to perform the behavior, such as
procedural knowledge and facilitators. The high level of healthcare interaction and insurance
coverage also facilitates the ability of these women to have opportunities for vaccination.
However, the motivations for vaccination served as obstacles, specifically risk perceptions.
Therefore, the missing step in the health literacy process is the accurate evaluation of this health
information regarding risk for HPV and how it applies to women’s personal health (Coleman et
al., 2011).
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A key social motivator identified by women was the healthcare provider. While previous
literature reports that a healthcare provider recommendation is an essential step in the HPV
vaccination process (Rosenthal et al., 2011), this study expanded these findings by emphasizing
the importance of provider reassurance that the vaccine is best for the individual. Healthcare
providers can be agents in the health literacy process to assist women in evaluating the true risk
for HPV, not only based on current relationship status, but also future risk for HPV. Currently,
US Preventive Services Task Force recommends sexually transmitted infection behavioral
counseling for sexually active adolescents and adults. This comprises providing essential health
information about STIs and transmission, assessing individual risk for STIs, and skill building
(e.g., condoms, communication, and goal-setting) (US Preventive Services Task Force, 2014b).
While this type of behavioral counseling is recommended generally for all STIs, specific health
messages are required for HPV, as well as for the HPV vaccine, for women not already
vaccinated. These messages can assist women in understanding individual risk for HPV in the
context of relationship status and potential future risk.
While healthcare providers are integral to the health literacy process for young adult
women and HPV vaccination, an assessment regarding current provider practices and HPV
vaccination should occur. Previous research has reported that providers have biases regarding
prioritization of HPV vaccination and young adult female patients’ relationship statuses (Zimet
et al., 2011); however, these were based on hypothetical scenarios. As such, it may be necessary
for healthcare providers to be recipients, in addition to agents, of health literacy to equip them
with the skills needed to assist patients in the evaluation process for the HPV vaccine (Vamos,
2011). Moreover, research with healthcare providers could identify the tools or methods that
would facilitate this process with patients, for example, patient decision-making aids,
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informational brochures, Internet websites, brief motivational interviewing or eHealth
technology. Previous research reported that providers rely on secondary sources (e.g., handouts)
to facilitate HPV vaccine discussions and also preferred to follow professional organization
recommendations (Vadaparampil et al., 2013). Integrating previous findings with formative
consumer-based research can inform the development of resources that would be acceptable and
feasible for providers in a clinic setting.
Ultimately tailoring health messages to young adult women’s specific risk misperceptions
about HPV can promote patient-centered, individualized care to reassure women about the HPV
vaccine. This connects with the women’s reported desire for personal decision-making about
HPV vaccination. By reinforcing the health literacy process, women will ultimately be able to
make an informed decision based on all evidence. The findings from this mixed-methods study
provide the formative research to inform future intervention development. In fact, this study
design aligns with the elicitation phase of the IMB Model intervention development sequence
(Fisher & Fisher, 2002). These findings can be used in future research in three specific manners:
(1) develop a quantitative instrument guided by the IMB Model to assess risk perceptions and
relationship status as a barrier to HPV vaccination among a larger sample and more diverse
population (e.g., community sample, 4-year college sample, 2-year college sample); (2) develop
health messages from the qualitative responses from women regarding their risk perceptions for
HPV and perceived need for the vaccine; and (3) evaluate developed health messages in multiple
settings. The proposed quantitative survey should include a measure of sexual behaviors to
compare actual and perceived risk for HPV. It can also be utilized to evaluate future
interventions. Findings from future research with the target population and healthcare providers
can inform the development of theory-based interventions using IMB Model and Intervention
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Mapping methodologies (Bartholomew et al., 1998; Fisher & Fisher, 2002) (Figure 10). In
addition to planning and preparing for future research endeavors, a dissemination plan has been
developed to share these results with scientific and community audiences (Appendix C).

Figure 10: Proposed Future Research to Improve HPV Vaccination

Additionally, this proposed future research aligns with a number of public health
priorities, including Healthy People 2020 objectives to: (1) Improve the health literacy of the
population; (2) Increase the proportion of patients whose doctor recommends personalize health
information resources to help them manage their health; (3) increase the proportion of persons
who report that their health care providers always involved them in decisions about their health
care as much as they wanted; (4) reduce the proportion of females with HPV infection; (5)
reduce invasive uterine cervical cancer cases; and (6) reduce the death rate from cancer of the
uterine cervix (Healthy People 2020, 2015a, 2015b, 2015c, 2015d).
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A final issue to address is the need for continued targeted efforts to improve HPV
vaccination rates among young adult women in the United States. The two major barriers
identified for HPV vaccination as an adolescent were unawareness of the vaccine and parental
refusal. As unvaccinated adolescents transition into young adulthood, they should be given the
opportunity to make individual health decisions to prevent HPV and HPV-related diseases,
outside the prevue of their parents’ beliefs. Future research aimed at improving HPV vaccination
among young adult women aligns with the Centers for Disease Control and Prevention call for
additional research to increase HPV vaccine coverage by engaging patients and providers to
eliminate missed clinical opportunities (Markowitz et al., 2014). Thus, young adults should not
be discounted from continued research on HPV vaccination.

Conclusion
This study found that relationship status impacts HPV vaccine decision-making and
reasons for non-vaccination among young adult women. Specifically, it operates by modifying
risk perceptions for HPV and perceived need for the HPV vaccine, which serve as barriers to
vaccination. Young adult women have the knowledge and behavioral skills necessary to access
and understand the importance of HPV vaccination, as well as the reinforcing macro factors in
place. However, women are unable to accurately perceive their individual risk for HPV, resulting
in impaired motivation for vaccination. A potential mechanism to address this issue is the use of
health literacy. Future research should integrate health literacy techniques with healthcare
providers serving this population to assist in the evaluation process for risk of HPV among
young adult women. This will facilitate shared decision-making and patient-provider
communication surrounding the HPV vaccine.
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If current trends in HPV vaccination continue in the United States, there will continue to
be a substantial proportion of women who are in the catch-up range of 18 to 26 years old, yet are
not vaccinated. Continued research is needed to target this specific group of unvaccinated
women who have the opportunity to make autonomous sexual and reproductive health decisions.
By promoting HPV vaccination among young adult women, it will ultimately reduce the
morbidity and mortality of HPV-related diseases, including genital warts and HPV-related
cancers.
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APPENDIX A: PHASE II RECRUITMENT EMAIL LANGUAGE

IRB #
Study Title: HPV Vaccination among Young Adult Women
PI: Erika Thompson, MPH
Volunteers Needed for Research Study
Description: We are investigating the knowledge, attitudes and opinions of young adult women
about HPV vaccination. Your participation would take about 5 minutes to complete an initial
online survey. You would then be contacted to schedule a follow-up 30 minute telephone or
Skype interview at a time that is convenient for you.
Who Can Participate?
 female,
 age 18 to 26 years,
 student at the University of South Florida, and
 meets one of these criteria:
o has not received any HPV vaccine shots
o has received the first HPV vaccine shot within the last 6 months
Incentives for Participation: Participants who schedule and complete the telephone/Skype
interview will receive a $10 gift card.
How to Participate? Start the process by clicking on this link to complete the initial short
survey.
HYPERLINK FOR SURVEY
To learn more, contact the Principal Investigator, Erika Thompson at XXX-XXX-XXXX or at
ethomps1@health.usf.edu.
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APPENDIX B: PHASE II INSTRUMENTS

Eligibility Survey
Thank you for your interest in the HPV Vaccination among Young Adult Women study. To
determine if you are eligible to participate, please complete the following questions.
1. What is your gender?
a. Female
b. Male
c. Transgender
d. Other
2. What is your current age? ______
3. A vaccine to prevent the human papilloma virus or HPV infection is available and is
called the cervical cancer or genital warts vaccine, HPV shot, Gardasil or Cervarix. Have
you EVER received an HPV vaccine shot?
a. No (Continue to Question 6)
b. Yes (Continue to question 4)
c. Don’t know (End survey)
4. Did you receive your first HPV vaccine shot in the last 6 months?
a. No (End survey)
b. Yes (Continue to question 5)
c. Don’t know (End survey)
5. (Question 4 = Yes) Thinking back to when you received your first dose of the HPV
vaccine, please identify your relationship status at that time:
a. Married or living with a partner
b. Single, but in a long-term monogamous relationship
c. Single and dating
d. Singe, but not in a relationship or dating
6. (Question 3 = No) Please identify your current relationship status:
a. Married or living with a partner
b. Single, but in a long-term monogamous relationship
c. Single and dating
d. Singe, but not in a relationship or dating
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Informed Consent
Informed Consent to Participate in Research
Information to Consider Before Taking Part in this Research Study
IRB Study #

You are being asked to take part in a research study. Research studies include only people who
choose to take part. This document is called an informed consent form. Please read this
information carefully and take your time making your decision. Ask the researcher or study staff
to discuss this consent form with you, please ask him/her to explain any words or information
you do not clearly understand. We encourage you to talk with your family and friends before
you decide to take part in this research study. The nature of the study, risks, inconveniences,
discomforts, and other important information about the study are listed below.
We are asking you to take part in a research study called:
HPV Vaccination among Young Adult Women
The person who is in charge of this research study is Erika Thompson. This person is called the
Principal Investigator. However, other research staff may be involved and can act on behalf of
the person in charge. Erika Thompson is being guided in this research by Dr. Ellen Daley. If you
have any questions about this research please contact Erika Thompson at
ethomps1@health.usf.edu (XXX-XXX-XXXX) or Dr. Ellen Daley at email address.

The research will be conducted via an online survey and a follow-up telephone or Skype
interview.

Purpose of the study
The purpose of this study is to assess and understand the information needs, motivations, and
skills required for HPV vaccination among college females. You are being asked to participate
because you are enrolled at the University of South Florida and met the eligibility criteria.
Study Procedures


If you take part in this study, you will be asked to spend approximately 5-minutes
answering questions about your knowledge of HPV and HPV vaccination. There are no
right or wrong answers to any of the questions. Your responses will be averaged with the
responses of other participants. All responses will remain anonymous and individual
responses will not be identified.
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No identifiable information, including your name or email address, will be associated
with your responses. However, you will be asked to report information on your age,
gender, race/ethnicity, relationship status, and sexual orientation. In order to schedule a
follow-up interview, you will be asked to provide your name, email, and telephone
number. These items will not be connected to any of the information you share.


You will only complete the survey once. There will only be a follow-up interview.
This research is being conducted at the University of South Florida, during March to
April 2015.

Total Number of Participants
About 48 individuals will take part in this study at USF.
Alternatives
You do not have to participate in this research study.
Benefits
We are unsure if you will receive any benefits by taking part in this research study.
Risks or Discomfort
This research is considered to be minimal risk. That means that the risks associated with this
study are the same as what you face every day. There are no known additional risks to those
who take part in this study.
Compensation
You will receive a $10 gift card for participating in the survey and interview for this study.
Cost
There will be no additional costs to you as a result of being in this study. However, routine
medical care for your condition (care you would have received whether or not you were in this
study) will be charged to you or your insurance company. You may wish to contact your
insurance company to discuss this further.
Conflict of Interest Statement
While we are conducting the research study, we cannot let you see or copy the research
information we have about you. After the research is completed, you have a right to see the
information about you, as allowed by USF policies.
Privacy and Confidentiality
We will keep your study records private and confidential. Certain people may need to see your
study records. By law, anyone who looks at your records must keep them completely
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confidential. The only people who will be allowed to see these records are:


The research team, including the Principal Investigator, Co-Investigators, study advisors,
and all other research staff.



Certain government and university people who need to know more about the study. For
example, individuals who provide oversight on this study may need to look at your
records. This is done to make sure that we are doing the study in the right way. They also
need to make sure that we are protecting your rights and your safety.



The USF Institutional Review Board (IRB) and its related staff who have oversight
responsibilities for this study, staff in the USF Office of Research and Innovation, USF
Division of Research Integrity and Compliance, and other USF offices who oversee this
research.



It is possible that unauthorized individuals could gain access to your responses.
Confidentiality will be maintained to the degree permitted by the technology used. No
guarantees can be made regarding the interception of data sent via the Internet. However,
your participation in this online survey involves risks similar to a person’s everyday use
of the Internet. If you complete and submit an anonymous survey and later request your
data be withdrawn, this may not be possible as the researcher may not be unable to
extract anonymous data from the database.

We may publish what we learn from this study. If we do, we will not include your name. We
will not publish anything that would let people know who you are.
Voluntary Participation / Withdrawal
You should only take part in this study if you want to volunteer. You should not feel that there is
any pressure to take part in the study. You are free to participate in this research or withdraw at
any time. The decision to participate or not to participate in the study will not affect your student
status (e.g., course grades, etc).
New information about the study
During the course of this study, we may find more information that could be important to you.
This includes information that, once learned, might cause you to change your mind about being
in the study. We will notify you as soon as possible if such information becomes available.
You can get the answers to your questions, concerns, or complaints
If you have questions about your rights as a participant in this study, general questions, or have
complaints, concerns or issues you want to discuss with someone outside the research, call the
USF IRB at (813) 974-5638.

By completing the survey, you are agreeing to participate in research.
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Demographic Questions
Thank you for agreeing to participate in this study. All of your responses will be confidential.
Please complete the following questions.
1. Which category(ies) best describes your race? (Check all that apply)
a. American Indian/Alaskan Native
b. Asian
c. Native Hawaiian/Pacific Islander
d. Black or African American
e. White or Caucasian
f. Other: _____________
2. Are you Hispanic or Latina?
a. Yes
b. No
3. Are you an international student?
a. Yes
b. No
4. What is your primary source of health insurance?
a. Private
b. School-sponsored
c. Medicaid
d. Other: _____________
e. Don’t have insurance
f. Not sure if I have insurance
5. What sexual orientation do you most identify with? (Check one)
a. Bisexual
b. Homosexual
c. Heterosexual
d. Unsure
e. Other:___________

207

Knowledge Questions
For each of the following questions, please answer True or False as a response. If you are unsure,
you can select Unsure. Please do not use any outside resources to assist you in answering these
questions.
1. There are many types of HPV (T)
2. Antibiotics can cure HPV (F)
3. Only men can get HPV (F)
4. Using a condom decreases the chance of HPV transmission (T)
5. There is a vaccine for women that prevents certain types of HPV (T)
6. You can have HPV without knowing it (T)
7. HPV can be cured (F)
8. Some types of HPV cause cervical cancer (T)
9. HPV can cause HIV/AIDS (F)
10. You can always tell when someone else have HPV (F)
11. HPV can cause abnormal Pap smears in women (T)
12. HPV can cause herpes (F)
13. HPV can affect a woman’s ability to get pregnant (F)
14. HPV is a virus (T)
15. HPV can cause genital warts (T)
16. HPV is spread on toilet seats (F)
17. Only women can get HPV (F)
18. HPV is a sexually transmitted infection (T)
19. Transmission of HPV can occur through sexual contact with another person (T)
20. HPV can be passed to a newborn at birth (T)
21. Even if you do not see a wart, you can transmit HPV (T)
22. HPV is a bacterial infection (F)
23. Most HPV infections clear up within a short time (T)

24. Where have you heard about the HPV vaccine? (Check all that apply)
a. Healthcare provider
b. Family
c. Friends/Peers
d. Partner/Spouse
e. Radio
f. Television
g. Internet
h. Other source: __________________
i. I have not heard about the HPV vaccine until today
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Interview Guide
Hello, my name is Erika Thompson, and I am a researcher and doctoral candidate at the
University of South Florida. May I please speak to ___________.
Thank you for completing the initial survey for this study and agreeing to participate in this
interview. This interview should only take about 30 to 40 minutes. As you may recall, you
consented to this interview when you initially completed the survey. Your participation is
completely voluntary and we can stop the interview at any time. Everything you state will be
confidential and not linked to your name or any other identifiers. Finally, there is no right or
wrong answer to each of these questions. I just ask that you answer the questions as honestly as
you can.
Would you mind if I audio-recorded our conversation?
So to start, what do you think about the HPV vaccine?
Construct
Information:
Knowledge

Sub-Group
All

Interview Question
What are some of the things you know about HPV?
[Probe: Transmission
Probe: Outcomes – cancer, genital warts, herpes, HIV
Probe: Curability and length of infection]
Added after pilot testing
What are some of the things you know about the HPV
vaccine?
[Probe: Who can get it?
Probe: When should you get it?
Probe: Any negative effect associated with it?]
Added after pilot testing
[People mention __[insert from knowledge
questionnaire]____ about HPV (HPV vaccine). What do you
think about this statement? Why?] Removed after pilot testing
[I see you mentioned on your survey that you heard of the
HPV vaccine from _____________. Is there one of these
sources that your trust the most?] Added after pilot testing

[If you wanted to receive more information about the HPV
vaccine, where would you want to get it from?] Added after
pilot testing
Human papillomavirus or HPV is a sexually transmitted infection. The HPV vaccine can protect
females and males against types of HPV that can cause genital warts and cancers, such as
cervical cancer. The vaccine includes three doses or three shots provided over the course of six
months typically.
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Motivation:
Personal

Unvaccinated

How do you feel about vaccines in general?
Probe: How important do you think they are? Why?
How do you feel about the HPV vaccine?
Probe: How important do you think it is? Why?
What are some good things about getting the vaccine? Why?
What are some bad things about getting the vaccine? Why?
What are the reasons for not getting HPV vaccinated?

Vaccinated

Why didn’t you get the vaccine when you were younger?
How do you feel about vaccines in general?
Probe: How important do you think they are? Why?
How do you feel about the HPV vaccine?
Probe: How important do you think it is? Why?
What are some good things about getting the vaccine? Why?
What are some bad things about getting the vaccine? Why?
What are some of the reasons why you decided to get the
vaccine now?

Motivation:
Social

Unvaccinated

Why didn’t you get the vaccine when you were younger?
Which people in your life do you think would impact your
decision to get the vaccine?
Probe: How would they impact your decision? (Positive or
negative)
Probe: Parents, peers, partners, providers?
Based on your response to the initial survey, I see that you are
in a [relationship category]. Can you talk a little bit about your
current relationship status?
Probe: Length of time?
Probe: Mutually monogamous? (if applicable)
Probe: Future together? (if applicable)
How does your current relationship status impact your
decision to be HPV vaccinated? Why?

Vaccinated

How do you think it might change if your relationship status
changes in the future?
Which people in your life do you think impacted your
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decision to get the vaccine?
Probe: How did they impact your decision? (Positive or
negative)
Probe: Parents, peers, partners, providers?
Based on your response to the initial survey, I see that you
were in a [relationship category] at the time you were
vaccinated. Can you talk a little bit about your relationship
status at that time?
Probe: Length of time? Still in this relationship?
Probe: Mutually monogamous? (if applicable)
Probe: Future together? (if applicable)

Motivation:
Perceived
Vulnerability

Unvaccinated

How did your relationship status at that time impact your
decision to be HPV vaccinated? Why?
What do you think your risk of HPV is, without the vaccine?
Probe: What influences this risk?
Probe: Does your relationship status impact this risk?
Do you think your risk would change if you got the vaccine?
Probe: How so?

Vaccinated

What do you think are the consequences of getting HPV?
Probe: How serious is the condition?; How severe is the
condition?; How significant is the condition?
What do you think your risk of HPV is, without the vaccine?
Probe: What influences this risk?
Probe: Did your relationship status impact this risk?
Do you think your risk has changed now that you got the
vaccine?
Probe: How so?
What do you think are the consequences of getting HPV?
Probe: How serious is the condition?; How severe is the
condition?; How significant is the condition?

Behavioral
skills

Unvaccinated

Walk me through the steps you would need to do to get the
HPV vaccine.
Probe: access, communicate, complete
What would make it easy to get the vaccine?
What would make it difficult to get the vaccine?
Probe: How confident do you feel to overcome these
barriers?
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Vaccinated

Walk me through the steps you took to get the HPV vaccine.
Probe: access, communicate, complete
What made it easy to get the vaccine?

Macro factors

All

What made it difficult to get the vaccine?
Probe: How confident did you feel to overcome these
barriers?
How frequently do you visit your healthcare provider?
Probe: How often did you go in the last year?
You have mentioned [list here] barriers and facilitators to
HPV vaccination, are there any other social or cultural factors
that impact your opinion or ability to get the vaccine?
Probe: Distrust government or pharmaceuticals
Probe: Media messages
Probe: Vaccine culture
Insurance status question in demographics section.

Is there anything else you would like to share with me about HPV or HPV vaccination?
Thank you for your participation and contribution to this research.
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APPENDIX C: DISSEMINATION PLAN
1. Manuscripts
Brief Title
IMB Model Findings

Target Journals
(Impact Factor)
American Journal of
Public Health (4.552)
Vaccine (3.624)

Risk Perceptions

Health Education and
Behavior (2.229)
American Journal of
Public Health (4.552)
American Journal of
Preventive Medicine
(4.527)

NHIS 2010 Analysis

HPV Knowledge and
Information

Women’s Health
Issues (2.330)
Sexually Transmitted
Diseases (2.594)

Health Education and
Behavior (Impact
Factor 2.229)

Description
The purpose is to compare the information,
motivation, behavioral skills, and macro factors
for HPV vaccination between vaccinated and
unvaccinated women. Methods will be from
Phase II of the dissertation.

The purpose is to describe how relationship
status impacts risk perceptions and perceived
need of the HPV vaccine. Methods will be from
Phase II of the dissertation.

The focus on this paper is to describe the
differences in primary reasons for nonvaccination by relationship status. This
manuscript will likely be a Brief Report.
The purpose of this paper is to compare how
knowledge items are measured for the
quantitative and qualitative components of
Phase II.

Women’s Health
Issues (2.330)
2. Conference Abstracts
Brief Title
IMB Model Findings

Risk Perceptions

Conference
American Academy
of Health Behavior
2016
Due: Sept 19 2015
Society for the

Description
The purpose is to compare the information,
motivation, behavioral skills, and macro factors
for HPV vaccination between vaccinated and
unvaccinated women. Methods will be from
Phase II of the dissertation.
The purpose is to describe how relationship
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Scientific Study of
Sexuality 2015

NHIS 2010 Analysis

Due: Sept 1 2015
American Public
Health Association
2016

HPV Knowledge and
Information

Due: Feb 2016
American Public
Health Association
2016

HPV Vaccine
Attitudes

Due: Feb 2016
American Public
Health Association
2016
Due: Feb 2016

status impacts risk perceptions and perceived
need of the HPV vaccine. Methods will be from
Phase II of the dissertation.
The focus on this abstract is to describe the
differences in primary reasons for nonvaccination by relationship status. This
manuscript will likely be a Brief Report.
The purpose of this abstract is to compare how
knowledge items are measured for the
quantitative and qualitative components of
Phase II.
The purpose of this abstract is to describe how
women frame the HPV vaccine as a separate
vaccine from required and optional
vaccinations, as well as reconcile these attitudes
with the anti-vaccination movement.

3. Community Reports
An executive summary of the findings from this dissertation will be drafted and shared with the
USF Student Health Services staff. This report will translate the research into implications for
practice.
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